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Zusammenfassung
B-Zellen sind bisher hauptsächlich für ihre Funktion als Antikörper-produzierende Zellen in der humoralen 
Immunantwort bekannt. In letzter Zeit jedoch stehen die Antikörper-unabhängigen Funktionen von B-Zellen 
im Fokus des Interesses. Hier leistet die Antigenpräsentation durch B-Zellen nicht nur einen entscheidenden 
Beitrag zur Induktion von schützenden Immunantworten, sondern ist im Gegensatz dazu auch beteiligt an 
schädigenden Immunreaktionen wie Autoimmunerkrankungen. Antigenpräsentation durch B-Zellen ist ge-
kennzeichnet durch die Fähigkeit, B-Zell-Rezeptor-abhängig und -unabhängig Antigene aufzunehmen, zu 
prozessieren und über MHC-Klasse-II Komplexe zu präsentieren. Während einer Immunantwort interagieren 
T-Helferzellen über die Expression von CD40-Ligand (CD40L) mit B-Zellen, welche daraufhin aktiviert wer-
den, proliferieren und sich differenzieren. 
Diese CD40-aktivierten B-Zellen (CD40-B) sind professionelle Antigen-präsentierende Zellen, vergleichbar 
mit dendritischen Zellen (DC) und weisen ebenso eine hohe Expression an ko-stimulatorischen und MHC-
Molekülen auf. Desweiteren sind CD40-B Zellen nicht nur in der Lage naive CD4+ und CD8+ T-Zellen zu primen, 
vielmehr induzieren sie auch sekundäre Gedächtnis-T-Zellantworten in vitro. Außerdem exprimieren sie voll-
ständig die „lymph node homing triad“ (CD62L, CCR7/CXCR4 und LFA-1) und induzieren T-Zell-Chemotaxis 
in vitro. Kürzlich konnten wir zudem zeigen, dass murine CD40-B Zellen (mCD40B) spezifisch in sekundäre 
lymphoide Organe einwandern. Im Unterschied zu dendritischen Zellen jedoch sind CD40-aktivierte B-Zellen 
in nahezu unbegrenzter Anzahl mit einer Reinheit von über 95 % für Vakzinierungen verfügbar. Somit kön-
nen mit CD40-B als zellulärem Adjuvans hohe Impf-Dosen und -Frequenzen realisiert werden, die als äußert 
wichtig erachtet werden um eine Tumorkontrolle zu erreichen. Allerdings waren B-Zell-basierte Adjuvantien, 
die in vivo in Tiermodellen getestet wurden, bisher meist nicht in der Lage funktionelle und schützende zyto-
toxische T-Zellantworten zu induzieren. 
Im Rahmen dieser Arbeit stelle ich die Entwicklung eines wirksamen mCD40B-Zell-basierten Maus-Vakzi-
nierungsmodells vor. Dieses Model ist durchaus geeignet um in vivo zu untersuchen, wie mCD40B-Zellen 
präventive anti-Tumorantworten induzieren.
So etablierten wir ein System zur Stimulation von murinen B-Zellen, das auf einer wirksamen 
B-Zellaktivierung durch Ko-Kultivierung mit membranständigem CD40L und Interleukin-4 basiert. 
Mithilfe dieser Technik ist es möglich hoch-aktivierte mCD40B-Zellen bis zu fünffach und mit einer Reinheit 
von über 90 % innerhalb von 14 Tagen anzureichern. Wir identifizierten geeignete mCD40B Subpopulatio-
nen, die funktionell näher charakterisiert wurden. Obwohl ihre Fähigkeit zur T-Zellstimulation in vitro der von 
murinen dendritischen Zellen unterlegen war, konnten wir zeigen, dass Antigen-beladene mCD40B-Zellen in 
vivo effektiv spezifische zytotoxische T-Zellantworten gegen virales und Modell- Peptidantigen induzieren. 
Wir konnten die Injektionsroute, die Zelldosis und die Anzahl der Impfwiederholungen als jene Parameter 
identifizieren, die einen gewichtigen Einfluss auf die Induktion der T-Zellantwort durch mCD40B-Zellen 
haben. Unter Berücksichtigung dieser Parameter im Vakzinierungsalgorithmus konnte in der vorliegenden 
Arbeit gezeigt werden, dass mCD40B-Zellen in vivo eine Zytolyse von Antigen-spezifischen Zielzellen indu-
zieren, die vergleichbar ist mit der von murinen dendritischen Zellen. Schließlich wurde der Vakzinierungsal-
gorithmus  unter Verwendung von Tumorantigen-beladenen mCD40B-Zellen erfolgreich in einer präventiven 
Impfung gegen das B16-Melanom angewandt.  Zusammenfassend weisen hoch-aktivierte mCD40B-Zellen 
in der Tat Antigen-präsentierende Eigenschaften auf, die hinreichend sind um eine schützende Immunität 
gegen das B16-Melanom zu induzieren.
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Abstract
B cells have mainly been recognized for their antibody-secreting function in humoral immune re-
sponses. Lately, the focus of interest has moved to the antibody-independent functions of B cells. 
In that context, it has become clear that antigen presentation by B cells is critically involved in 
both physiologic immune responses as well as pathologic immune reaction such as autoimmune 
diseases. Antigen presentation by B cells is characterised by their ability to take-up, process and 
present antigen via MHC-II in a B cell receptor dependent and independent fashion. Furthermore, 
during immune responses armed helper T cells interact with B cells by expression of CD40 Ligand 
(CD40L), which thereby become activated and in turn start to proliferate and differentiate. 
CD40-activated B cells (CD40-B) are professional antigen-presenting cells comparable to dendritic 
cells (DC) exhibiting a high expression of costimulatory and MHC molecules. CD40-B cells were 
shown to not only prime naïve CD4+ and CD8+ T cells efficiently, but also expand memory T cells in 
vitro. Furthermore they express the full lymph node homing triad (CD62L, CCR7/CXCR4 and LFA-
1) and were shown to induce T-cell chemotaxis in vitro. Recently, we demonstrated that murine 
CD40B cells (mCD40B) specifically migrate to secondary lymphoid organs in vivo. Importantly, 
these cells are available at virtually unlimited amounts at a purity > 95% for high-dose, high-
frequency vaccination considered crucial for the control of cancer. However, most B cell-based 
vaccines tested so far failed to induce functional and protective cytotoxic T lymphocyte (CTL) re-
sponses in animal models in vivo.
Within this work I present the successful development of a functional murine mCD40B-based 
vaccination model. This model is indeed suitable to study the ability of mCD40B cells to induce 
protective anti-tumour responses in vivo. 
We established a murine B-cell stimulation system based on potent B-cell activation maintained 
by co-cultivation with membrane-bound CD40 ligand and interleukin-4. By using this technique 
highly activated mCD40Bs expand more than 5-fold with purity above 90% within 14 days. Hence, 
we identified appropriate mCD40B subsets and further characterised them on a functional level. 
Despite their T-cell stimulatory capacity in vitro being inferior to murine dendritic cell (mDC) sub-
sets, we demonstrated that vaccination with antigen-loaded mCD40B effectively induces spe-
cific CTL responses against viral and model peptide antigen in vivo. We clearly identified injec-
tion route, cell dose and vaccination repetitions as parameters exerting dominant influence on 
the effective induction of specific T cell responses by mCD40B. Incorporating these parameters 
into the vaccination algorithm, I showed that mCD40B induce in vivo cytolysis of antigen-specific 
target cells comparable to mDC. Finally, by using tumour antigen-loaded mCD40B we success-
fully transferred our vaccination algorithm to preventive immunization against B16 melanoma. 
In summary, highly activated mCD40B cells indeed exhibit antigen-presenting capacity sufficient 
to induce protective anti-tumour immunity in B16 melanoma.
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List of Abbreviations
Table 1: List of Abbreviations
Acronym Expansion
aa amino acid
aAPC artificial antigen-presenting cell
ADCC antibody-dependent cell-mediated cytolysis
AIDS Acquired immunodeficiency syndrome
APC antigen-presenting cell
β-ME β-Mercaptoethanol
BCR B-cell receptor
BSA bovine serum albumin
CAR chimeric antigen receptor
CD40-B CD40-activated B cell
CD40L CD40 ligand
CDC complement-mediated cytotoxicity
cDNA complementary DNA
CEA carcinoembryonic antigen
CLP common lymphoid progenitor
CTL cytotoxic T cell
CpG-ODN oligodeoxynucleotides with non-methylated cytosine-guanine motifs
CR2/1 complement receptor 2/1
CRPC castrate-resistant prostate cancer
CsA Cyclosporin A
CVCTWG Cancer Vaccine Clinical Trial Working Group
DC dendritic cell
DMSO dimethyl sulfoxide
EBNA-1 Epstein-Barr virus nuclear antigen 1
ECM extracellular matrix
FACS Fluorescence Activated Cell Sorting
FasL Fas ligand
FBS foetal bovine serum
FcR Fc-Receptor
FO follicular
GC germinal centre
GM-CSF granulocyte/macrophage colony-stimulating factor
H&E hematoxylin and eosin
HEV high endothelial venules
HGFR haematopoietic growth factor receptor
HPV human papillomavirus
HSC hematopoietic stem cell
III
Acronym Expansion
HTL helper T cells
IFA Incomplete Freund´s Adjuvant
IFN interferon
Ig immunoglobulin
IL interleukin
ip intraperitoneal
iv intravenous
LPS lipopolysaccharide
LT lymphotoxine
MFI mean fluorescence intensity
MHC major histocompatibility complex
MLR Mixed Lymphocyte Reaction
NC negative control
NEAA non-essential amino acid
NK natural killer cell
NKT natural killer T cell
mCD40B murine CD40-activated B cell
mDC murine dendritic cell
mRNA messenger ribonucleic acid
MZ marginal zone
PAP phosphatase antigen
PC positive control
PBS  phosphate-buffered saline
PGE-2 prostaglandin E2
PMA Phorbol 12-Myristate 13-Acetate
PSA prostate-specific antigen 
RAG recombination activating gene
RT Room temperature
sc subcutaneous
SD standard deviations
SLO secondary lymphoid organ
TAA tumour-associated antigen
TAP Transporter associated with antigen processing
TCR T-cell receptor
TGF transforming growth factor
TNF tumour necrosis factor
TLR Toll-like receptor
Treg regulatory T cell
TRP tyrosinase-related protein
TSA tumour-specific antigen
VEGF vascular endothelial growth factor
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INTRODUCTION
1
1. INTRODUCTION
This study wants to contribute to the current understanding of B-cell function other than in hu-
moral immune responses. In particular, the role of murine CD40-activated B cells (CD40-B) as 
model of professional antigen-presenting cells alternative to dendritic cells (DC) is analysed. 
In order to establish how the immunological characteristics of CD40-B cells affect the induction of 
specific T cell responses against cancer, the basic principles of cancer immunology are discussed in 
detail (section 1.1.). Due to their immune-stimulatory capacity CD40-B cells are recognized as cel-
lular adjuvant. Therefore, current concepts of targeted cancer immunotherapy are subsequently 
summarized (section 1.2.). Thereafter, I set up how the model of CD40-CD40 ligand interaction 
equips B cells with antigen-presenting function and report on the current knowledge in this re-
gard (section 1.3.). Finally, the key questions and aims leading to the present study are identified 
(section 1.4.). 
1.1. Basic Principles of Cancer Immunology
By definition immunology deals with the complex defence system that protects an organism 
differentiating self from foreign and neutralizing pathogenic organisms or substances. To date 
a growing body of knowledge about the complex interactions of immunological active organs, 
tissues, cells and signalling molecules comprising the immune system exists. Our understanding 
is based on the principles of innate and adaptive immunity and their cellular players inducing cel-
lular and humoral immune responses.  
1.1.1.   Overview of the Immune system
On the one hand cells of the innate immune system build the first line of defence. Macrophages 
equipped with specialized receptors recognize pathogen and hence induce phagocytosis of patho-
gens and release of cytokines and chemokines like tumour necrosis factor-α (TNF-α) and inter-
leukin-12 (IL-12) which drive inflammation and the attraction of further leukocytes (Mantovani A. 
and Sica A., 2010 1; Ma X., 2001 2). Furthermore macrophages are activated through interferon-γ 
(IFN-γ) and CD40 ligand (CD40L) by armed CD4+ helper T cells triggering production of toxic nitro-
gen or oxygen intermediates, thereby exhibiting direct antimicrobial activity (Dedon P.C. and Tan-
nenbaum S.R., 2004 3). Macrophage-derived cytokines or release of IFNs activates natural killer 
(NK) cells which recognize transformed cells lacking MHC molecules. Their cytotoxic activity is 
tightly regulated by stimulatory and inhibitory receptors and induced by release of lytic granules. 
On the other hand NK cells and macrophages recognize immunoglobulin G (IgG) -coated path-
ogens by binding to their Fcγ-receptors leading to antibody-dependent cell-mediated cytolysis 
(ADCC) or phagocytosis of infected cells (Herberman et al., 1986 4). In ADCC apoptosis of infected 
cells is induced via release of perforin and granzymes. 
Natural killer T cells (NKT) are considered as specialized CD4+ T cell subset and a remainder of an 
evolutionary primitive form of the immune system. They co-express a characteristic NK receptor 
(NK1.1) and a T-cell receptor. NKT cells recognize antigens presented by the MHC-like molecule 
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CD1 expressed by most of the antigen-presenting cells. Upon CD1-antigen recognition they im-
mediately start secretion of IFN-γ or IL-4 thereby probably polarizing type 1 or 2 T-cell responses 
(Berzins et al., 2011 5).
On the other hand T cells are the principal effectors of the adaptive immune responses, mainly 
mediated by CD8+ cytotoxic T cells (CTL) and CD4+ helper T cells (HTL). Professional antigen-pre-
senting cells (APCs) take up antigen directly in the blood-stream or in tissue and migrate to lymph 
nodes or spleen where they present it to T cells. This interaction drives the initiation of antigen-
specific adaptive immune responses. In order to activate naïve T cells two signals are necessary: 
First, antigen presentation via MHC molecule on APC recognized by a specific T-cell receptor (TCR) 
on the T cell; and second, costimulation via B7 receptors (CD80 and CD86) on activated APC and 
CD28 on armed T cell (Bretscher P.A., 1999 6; Bevan M.J., 2004 7). 
1.1.1.1.   CD8+ cytotoxic T cells
As the potent effectors of adaptive immune responses CD8+ T cells are able to recognize and elim-
inate cells presenting 8-10 amino acid long peptides arising from proteasomal degradation of 
intracellular proteins bound to MHC-I (Klein et al., 2000 8). Naïve CD8+ T cells become initially 
activated (“primed”) when antigen presented by activated APC is recognized via MHC-I. Then CD8+ 
T cells rapidly expand and differentiate into effector T cells which migrate to the periphery. There 
they function by production of cytokines such as IFN-γ as well as the apoptosis inducing effector 
molecules perforin and granzyme B. Additional up-regulation of Fas ligand (FasL) on CTLs medi-
ates direct cytolysis of target cells. Furthermore memory T cells are established which respond 
faster and develop more efficiently into effector cells upon re-exposure of antigen (Weninger et 
al., 2002 9). Co-stimulatory agents and cytokines therefore represent key strategies for the modu-
lation of tumour-directed T cell responses.
1.1.1.2.   CD4+ helper T cells
CD4+ helper T cells (HTL) recognize 10-34 amino acid long peptides from exogenous proteins, en-
docytosed and digested intracellularly in endosome-lysosome compartments and presented on 
MHC-class II molecules (MHC-II)(Klein et al., 2000 8). Cytokine release during initial stage of im-
mune response drives the differentiation of HTL into two major classes:
Type 1 cytokine-secreting CD4+ helper T cells (T
h
1 cells) provide essential help for activation and 
expansion of CD8+ T-cell responses. T
h
1 cells develop in the presence of IL-12 and are character-
ized by secretion IFN-γ and TNF-β favouring cellular immune responses. They activate APCs mainly 
through engagement of CD40 ligand expressed on CD4+ T cells and CD40 on APCs (Bourgeois et 
al., 2002 10). These CD40-activated APCs in turn up-regulate MHC and co-stimulatory molecules 
and are able to directly drive CD8+ T cell responses (Lanzavecchia A., 1998 11). Upon activation by 
IL-4 and IL-6 T
h
2 cells secrete IL-10 and transforming growth factor-β (TGF-β) thereby effectively 
activating B cells in humoral responses and inhibiting T
h
1 driven cellular responses. Furthermore 
antigen nature has an influence on type of HTL-response induced: Whereas a strong interaction 
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and high density of antigen tend to promote T
h
1-like response, weak interaction or low density 
predominantly causes T
h
2-like responses (Fishman M.A. and Perelson A.S., 1999 12).
1.1.1.3.   Immunological Tolerance
The absence of an immune response to a particular set of self-antigens shows that the immune 
system does discriminate between self and non-self. There are two mechanism involved in the 
development of immunological tolerance.
In thymus-dependent central tolerance developing T cells are selected for their recognition pat-
tern (positive selection) and affinity (negative selection), mainly resulting in a T-cell repertoire 
recognizing self MHC molecules complexed to foreign peptides (Hogquist et al., 2005 13). But also 
auto-reactive T cells that escape thymic deletion recognizing cryptic or subdominant epitopes of 
self-antigens can develop (Farris et al., 2000 14).  
In peripheral tolerance absent costimulatory signal results in incomplete activation of APCs due to 
deficient expression of B7 receptors (CD80, CD86). Thus, T cells specific for certain tissue antigens 
not selected for in thymus become insufficiently activated and are then tolerized by antigen rec-
ognition and do not induce autoimmune responses (Albert et al., 2001 15). 
Figure 1:  Central and 
peripheral tolerance 
mechanisms
The upper panel shows 
thymic central toler-
ance mechanisms due 
to negative and positive 
selection of self-reactive 
thymocytes giving rise to 
CD4+ and CD8+ effector 
T cells and - depicted in 
the lower panel - regu-
latory T cells which are 
the key mediators of 
peripheral tolerance 
(adopted from Gregersen 
et al., 2006 16).
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Recently, the involvement of regulatory T cells (Treg), which are capable of suppressing T-cell re-
sponses through direct contact with APCs or through production of anti-inflammatory cytokines, 
in the induction of tolerance has been recognized (Nomura et al., 2005 17; Shevach E. M., 2009 
18).
1.1.1.4.   Lymphopoiesis and Humoral Function of B cells
Diverse roles of B cells in immune responses have been discovered with functions in the innate 
and adaptive branches of the immune system as well as interacting with many other cell types. 
A short overview of the main B-cell developmental stages and immunological functions will be 
described in the next section. 
B cells develop in the bone marrow in continuous developmental stages from hematopoietic stem 
cells (HSC) to common lymphoid progenitors (CLP), pro B cells and pre B cells. These stages are 
characterized by immunoglobulin gene rearrangement providing diversity of the B-cell antigen 
receptor (BCR) repertoire as well as by changes in gene expression and surface phenotype (Os-
mond et al., 1990 19; Hardy et al., 1991 20; Hardy R.R., 2003 21). Furthermore, dysfunctional or 
auto-reactive B cells recognising self-antigens are eliminated by receptor editing (Melchers et al., 
1995 22; Hardy et al., 2000 23). Immature B cells then leave bone marrow and enter the spleen 
where transitional (T1 and T2) are followed by mature B cell stages giving rise to naïve functional 
B cells. Past this step in maturation when expression of IgM isotype is accompanied by IgD on the 
surface of B cells, engagement of the BCR by an antigen leads to terminal differentiation (Osmond 
et al., 1998 24; Rolink et al., 1999 25). Three subsets of naïve B cells are generally distinguished 
due to their location: marginal zone (MZ), follicular (FO) and B-1 B cells. 
B-1 B cells locate mainly in the pleural and peritoneal cavities (Kantor et al., 1993 26). Because 
of their mainly foetal origin B-1 B cells may represent a separate lineage from MZ and FO B cells 
(Martin F. and Kearney J.F. 2001 27; Allman et al., 2004 28).  B-1 B cells are involved in very early 
stages of thymus-independent immune responses against particulate bacterial antigens, like li-
popolysaccharide (LPS) and other Toll-like receptor (TLR) -ligands. Upon BCR-signalling they can, 
together with MZ B cells, differentiate into short-lived IgM-producing plasmablasts responsible 
for the majority of “natural” IgM in the serum (Martin F. and Kearney J.F. 2000 29; Hardy R.R and 
Hayakawa K., 2001 30). 
Marginal zone B cells are located to the marginal sinus in the spleen which borders the red and the 
white pulp and do not re-circulate after differentiation (Martin F and Kearney J.F. 2002 31). Due to 
their location MZ B cells like MZ macrophages are able to respond early after infection as they are 
into close contact with blood-borne antigens and pathogens, thereby linking innate and adaptive 
immunity (Kraal G., 1992 32). Following stimulation of BCR and TLRs or TLRs alone, they migrate to 
the T-B border of the lymphoid follicle where they can present antigen to CD4+ T cells (Attanavan-
ich K. and Kearney J.F., 2004 33). Upon migration into the red pulp these MZ B cells will differenti-
ate into plasma cells secreting large amounts of IgM (Martin et al., 2001 34). Alternatively, after a 
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combinatorial encounter of antigen and complement along with subsequent engagement of BCR 
and complement receptor CR2/1 (CD21/CD35) MZ B cells are able to transfer antigen to follicular 
DC leading to downstream T-cell activation (Whipple et al., 2004 35; Ferguson et al., 2004 36). As 
largely B-1 and MZ B cells do not form germinal centres and therefore do not undergo somatic 
hypermutation simply low-affinity plasma cells are formed. This is in contrast to functional roles 
of follicular B cells. 
Follicular B cells make up the biggest B cell population re-circulating through blood and lymph 
to B cell follicles of lymph nodes, spleen and Peyer´s patches mediating humoral B cell functions 
(Allman D. and Pillai S., 2008 37). Herein, interaction of cognate antigen with specific BCR will 
lead to cross-linking of BCR and BCR-dependent signal transduction, initiating receptor-mediated 
endocytosis of the antigen, antigen processing in endosomes and its presentation onto MHC-II 
molecules (Lanzavecchia A., 1990 38). Upon antigen-encounter B cells change their chemokine-
receptor profile and migrate to the B-T boarder where activated CD4+ T cells with corresponding 
TCR can bind to the MHC-antigen complex. Clustering of T and B cells after cognate antigen-rec-
ognition is also referred to as “immunological synapse” describing the highly organized spatial 
and temporal processes of signal transduction upon antigen-recognition (Grakoui et al., 1999 39; 
Pereira et al., 2010 40). Upon building of the “primary focus” some activated B cells differentiate 
into plasmablasts with initiation of antibody synthesis and further into short-lived plasma cells 
producing large amounts of secreted IgM antibody (Jacob et al., 1991 41). Furthermore some acti-
vated B cells migrate to lymphoid follicles and form germinal centres (GC) there (Thorbecke et al., 
1993 42; Carter R.H. and Myers R., 2008 43). Here activated B cells built the light and dark zones 
composed of strongly proliferating centroblasts as well as centrocytes undergoing somatic hyper-
mutation, affinity maturation and isotype switching resulting in long-lived plasma cells produc-
ing affinity-matured antibody (mainly IgG, with some IgE and IgA), and memory B cells (Coico et 
al., 1983 44; Ziegner et al., 1994 45). These are released from the GC, thus providing a more effec-
tive subsequent secondary immune response. Upon cognate antigen re-exposure memory B cells 
react more quickly and start producing large amounts of high-affinity antibodies that neutralize 
their antigen upon binding. Furthermore antibodies trigger complement-mediated cytotoxicity 
(CDC), enable lysis of coated pathogens by ADCC and mediate apoptosis by disrupting oncogenic 
signals. (Rolink A. and Melchers F., 1991 46; Rajewsky K., 1992 47; Mackay C.R., 1993 48). 
1.1.1.5.   Antigen Presentation by Dendritic cells
An immune response will only be generated when antigen is presented by an activated APC, such 
as dendritic cell, macrophage or B cell (Cassell et al., 1994 49; Askew et al., 1995 50; Banchereau 
et al., 1998 51). This happens in secondary lymphoid organs (SLO) like spleen, lymph nodes, ton-
sils and Peyer´s patches where the organ architecture brings antigen and APC into close contact 
with T cells. It is accepted that DCs play a critical role in inducing primary T-cell responses, thus 
permitting establishment of immunological memory (Steinman R.M., 1991 52; Hart D.N.J., 1997 
53; Banchereau et al., 2005 54; Palucka et al., 2011 55). 
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After the first report on dendritic cells by Steinman and Cohn with a round, branching morphol-
ogy (Steinman et al., 1973 56) different subtypes arising from CD34+ bone marrow progenitors 
have been identified: (A) CD11c+ myeloid DC give rise to Langerhans cells localized in epidermis, 
interstitial DC  localized within other tissue than skin and (B) CD11c- lymphoid DC  resulting in 
plasmacytoid DC and (C) follicular DC assumedly derived from mesenchymal progenitors with 
different phenotype as well as innate and adaptive immune functions (Shortman et al., 2002 57; 
Steinman et al., 2010 58). Progenitor DCs develop in the bone marrow and migrate through the 
blood into peripheral tissues where they encounter antigen. There immature DCs develop and 
efficiently capture antigen by several uptake mechanisms such as phagocytosis, macropinocy-
tosis and receptor-mediated endocytosis. Upon antigen processing DC mature by means of in-
flammatory stimuli and CD40-CD40L interaction and migrate through the afferent lymphatics 
to the draining lymphoid organs where they present antigen to T cells. Thereby cellular immune 
responses are induced involving both CD4+ helper T cells (T
h
1) and CD8+ cytotoxic T cells. Further-
more, besides inducing cellular immunity DCs elicit humoral immune responses by activation of 
naïve and memory B cells. Finally DC are also able to activate cells of the innate branch of immu-
nity, such as NK cells and NKT cells as well as non-antigen specific macrophages and eosinophils 
(Banchereau et al., 1998 51 and 2000 59; Steinman R.M., 2008 60). Hence, “nature´s adjuvant” 
dendritic cells drive all arms of the immune system and have therefore been intensively studied 
for use in vaccination against cancer. 
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1.1.2.   Cancer Immunosurveillance
Already at the beginning of the 19th century Paul Ehrlich suggested that the immune system could 
recognize and eliminate neoplastic cells (Ehrlich P., 1909 61). 50 years later Burnet and Thomas 
formulated the “cancer immunosurveillance hypothesis” which stated that a cellular immune re-
action might protect from neoplastic disease (Thomas L., 1959 62 and 1982 63; Burnet F.M., 1970 
64 and 1971 65). Due to a lack of direct experimental evidence this hypothesis remained highly 
controversial. Only during the last 15 years researchers have been able to show that the immune 
system indeed plays a vital role in the control of neoplastic growth.
Based on tumour formation experiments in mice in the 90s three fundamental mechanisms of 
anti-tumour immunity were discovered: First, the contribution of endogenously expressed cy-
tokine IFN-γ to protection against growth of tumours (Kaplan et al., 1998 66; Street et al., 2001 
67). Second, perforin-mediated cytotoxicity of effector lymphocytes was shown to control tumour 
development (van den Broek et al., 1996 68; Street et al., 2001 67). And third, by using immune-
deficient RAG-2 knockout mice lacking mature lymphocytes their protective role against tumour 
formation was demonstrated (Shankaran et al., 2001 69). 
Further pieces of evidence for immune surveillance derive from observations made in humans. 
On the one hand an increased incidence of oncogenic virus infections and B-cell lymphomas in 
transplant patients treated with immunosuppressive drugs and AIDS patients was found (Grulich 
et al., 2007 70). On the other hand a number of bacterial infections were shown to be cancer-
associated and several cancer-causing viruses have been identified (Mager D.L., 2006 71; Sarid R. 
and Gao S.-J., 2011 72).
1.1.3.   Cancer Immunoediting
To describe the complex interactions that occur between a developing tumour and the immune 
system the “cancer immunosurveillance” hypothesis was extended from a simple  host-protective 
role of the immune system to a more complex process in which the tumour is imprinted by its im-
munological environment, termed “cancer immunoediting” (Dunn et al., 2002 73 and 2004 74,75). 
This process can lead to three possible outcomes. (A) Either the tumour is completely eliminated 
by the innate and adaptive arms of the immune system (elimination phase), or (B) in case of elimi-
nation failure a dynamic equilibrium between tumour and immune system (equilibrium phase) is 
kept, when due to selection pressure through heterogeneity and genetic instability tumour cells 
can sustain immune attack. (C) The third phase is reached when these unstable, mutated tumour 
cells become resistant to immune detection (escape phase) and malignant disease develops.
In the light of these findings Hanahan and Weinberg added immune surveillance to their defini-
tion of the “Hallmarks of cancer” (Hanahan et al., 2000 76 and 2011 77). Furthermore, recently the 
involvement of the tumour microenvironment to the tumour-formation process has been identi-
fied. Herein various cell types located in the tumour microenvironment build up tumour stroma 
where a cross-talk of immune and inflammatory cells, blood and lymph vessels and nerves takes 
place. Fibroblasts secreting growth factors and chemokines support angiogenesis, and altered ex-
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tracellular matrix (ECM) provides additional oncogenic signals enhancing cancer-cell proliferation 
and invasion (Liotta et al., 2001 78).
1.1.4.   Tumour-mediated Immune Escape
Mechanisms underlying tumour evasion are in focus of interest to break tolerance to tumour an-
tigens and to induce anti-tumour responses. Several tolerance mechanisms by which tumours 
evade destruction by the immune system (immune-escape) have been discovered. 
Active tolerance mechanisms induced by the tumour (figure 2) include the down-regulation of 
MHC-molecules or the tumour-antigen itself leading to impaired T-cell recognition (Ferrone et 
al., 1995 79). Secretion of immunosuppressive anti-inflammatory cytokines such as TGF-β, IL-10 
and expression of co-inhibitory molecules such as apoptosis-inducing Fas-Ligand were shown to 
induce apoptosis of tumour-reactive T cells and immune evasion (Chen et al., 1994 80, Walker et 
al., 1998 81; Teicher et al., 2007 82). 
Figure 2:  Tumour-mediated immune evasion
Tumour cells may escape immune recognition through (A) direct deletion by engagement of death-
inducing ligands, (B) direct tolerization by secretion of immunosuppressive cytokines, (C) sup-
pression of tumour-reactive T cells by Treg, (D) spatial separation and / or (E) tolerization of T cells 
by cross-presentation of tumour-derived antigens (adopted from Mapara et al., 2004 83).
At last, for the successful treatment of cancer the key step is to prime T lymphocytes resulting in 
the induction of an effective immune response finally leading to tumour destruction.
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1.2. Targeted Cancer Immunotherapy
Already in the 1890s William Coley pioneered the field of immunotherapy. He supposed a causal 
link between streptococcal infection and tumour regression in some of his patients, leading him 
to the first documented attempts to treat cancer with mixed bacterial vaccines, so-called Coley´s 
toxins (Coley W.B., 1893 84). Later it´s use was replaced by the promising advent of chemotherapy 
and radiation therapy. Given that cancer resists conventional surgery and nonsurgical treatment 
options and still remains major cause of death worldwide, the development of novel prophylac-
tic and therapeutic strategies is required. More than one century of growing body of knowledge 
about the complex cellular and molecular interplay between immune system and tumour and 
the identification of tumour-associated antigens (TAA) have led to the development of targeted 
cellular immunotherapeutic strategies to face malignant tumour (reviewed in Baxevanis et al., 
2009 85). 
1.2.1.   Tumour Antigens
The link between specific immune responses and targeted cancer immunotherapy was estab-
lished with the first identification of tumour antigens recognized by CD8+ cytotoxic T cells in hu-
man melanoma (van der Bruggen et al., 1991 86). During the last 20 years a large array of im-
munogenic tumour antigens has been identified and characterised (van der Bruggen et al., 2011 
87). Furthermore to support and accelerate the development of therapeutically effective cancer 
vaccines the American National Cancer Institute (NCI) has developed a priority ranking of 75 can-
cer vaccine target antigens through defining and weighting relevant or ‘ideal’ cancer antigen cri-
teria as the following (in descending order): therapeutic function, immunogenicity, oncogenic-
ity, specificity, expression level and percent antigen-positive cells, stem cell expression, number 
of patients with antigen-positive cancers, number of antigenic epitopes and cellular location of 
expression (Cheever et al., 2009 88). Basically, two primary groups can be distinguished: tumour-
specific antigens and tumour-associated antigens (Graziano et al., 2005 89). 
1.2.1.1.   Tumour-specific antigens
Tumour-specific antigens (TSA) result from modification in genes of tumour cells that may be 
implicated with tumoural transformation (Carbone et al., 2005 90). They arise from genetic altera-
tions like point-mutations, deletions or chromosomal translocations (Bielas et al., 2006 91). Since 
they are unique for an individual patient their usefulness for standard immunotherapy is limited, 
because most are highly patient-specific and therefore manufacture of such a vaccine would be 
labour-intensive and costly (Sensi et al. 2006 92). Then again, shared tumour-specific antigens 
have been isolated found among several tumours of patients which are derived from oncogenes 
and tumour suppressor genes. For example, oncogenic ras being mutated in 30-40% of all color-
ectal carcinomas, and the most prominent tumour suppressor p53 being mutated in 60-70 % 
of all cancers (Bos et al., 1989 93 and Chiba et al., 1990 94, respectively). Other tumour-specific 
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antigens are virus-associated proteins, like the oncoproteins E6 and E7 from the human papillo-
mavirus (HPV) expressed in cervical cancer, or like EBNA-1, the Epstein-Barr virus nuclear antigen 
expressed by Burkitt´s lymphoma and nasopharyngeal carcinoma cells (zur Hausen H., 2002 95; 
Hislop et al., 2007 96). Being foreign and therefore highly immunogenic viral oncoproteins do not 
bear the risk to induce tolerance or autoimmunity reactions after vaccination.
1.2.1.2.   Tumour-associated antigens
Tumour-associated antigens are tumour-antigens expressed differently by cancer cells and most 
normal cells. Herein, the first group consists of proteins encoded by genes usually expressed ex-
clusively in primitive germs cells of the testes. Because these cells do not express MHC molecules, 
antigenic peptides should not be presented to T cells. In cancer cells those germ line genes can 
be aberrantly activated (Caballero et al., 2009 97). Therefore such antigens can be considered as 
strictly tumour-specific. The genes encoding such antigens have also been named cancer-testis 
genes including for example the melanoma-antigen family (MAGE) of proteins.
The second group contains differentiation antigens only expressed in certain types of tissue in 
embryogenesis or in particular stages of differentiation. Examples are Melan-A, gp100, tyrosinase 
and tyrosinase-related proteins 1 and 2 (TRP-1 and TRP-2) which are expressed by both healthy 
melanocytes and melanoma cells. Therefore, their use as targets for cancer immunotherapy may 
result in auto-immunity towards the corresponding normal tissue. Other well-known group mem-
bers are prostate-specific antigen (PSA) in prostate carcinoma and carcinoembryonic antigen-re-
lated cell adhesion molecule (CEA) in gut carcinoma. 
The third group of tumour-associated antigens is characterised by expression in normal tissue and 
overexpression in tumour cells for example due to gene amplification. Prominent group members 
are HER2/neu and telomerase, which are overexpressed in several tumour entities. As those anti-
gens are expressed in normal tissue only at very low level a minimal amount of peptide is required 
to elicit a T-cell response and auto-immunity should not be induced (van der Bruggen et al., 2011 
87). 
Besides identifying immunogenic tumour antigens as targets for cancer immunotherapy and 
choosing the right platform in which to deliver these, it is essential to break self-tolerance and 
minimize contrary tumour-escape mechanisms. Two basic immunotherapeutic approaches for 
the manipulation of the immune system to regain effective anti-tumouricidal properties can be 
distinguished.
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1.2.2.   Passive Immunotherapy
On the one hand, passive strategies aim at stimulating the patient´s immune system through 
adoptive transfer of anti-tumour antibodies, antibody-derivatives or cytolytic effector cells, like 
T cells, NK cells or NKT cells (Rosenberg et al., 1986 98; Wu et al., 2003 99; Motohashi et al., 2006 
100; An Z. et al., 2011 101; Chhabra A., 2011 102). There are several monoclonal antibodies that 
have been approved by the US Food and Drug Administration (FDA) for the use in human. For 
example antibodies like Herceptin directed against specific antigens aberrantly expressed on tu-
mour cells (ErbB2 in breast cancer) lead to the destruction target cells by CDC and ADCC. Further 
monoclonal antibodies block the action of inhibitory receptors (e.g. anti-CTLA-4 and anti-PD-1) or 
trigger activation of effector lymphocytes (e.g. anti-4-1-BB). Moreover other lethal principles are 
coupled to antibodies, like toxins, radionuclides or enzymes (Zarour H.M. and Ferrone S, 2011 103). 
In adoptive T cell transfer tumour-specific T cells are re-infused into the lympho-depleted patient 
to induce anti-tumour immunity. They derive from patients enriched ex vivo by either multiple in 
vitro stimulations with tumour antigen or by genetic engineering to introduce tumour antigen-
specific TCR (Baxevanis C.N. and Papamichail M., 2004 104; June C.H., 2007 105).  Furthermore 
chimeric antigen receptors (CAR) represent a promising technology where genetic constructs are 
introduced into lymphocytes containing an antigen-recognizing antibody linked to a T-cell sig-
nalling domain. Thereby T cell specificity and effector activity are redirected against target cells 
recently showing positive results in early clinical studies (Porter et al., 2011 106; Kalos et al., 2011 
107). 
1.2.3.   Active Immunotherapy
On the other hand, active immunotherapeutic approaches aim at induction of live-long immunity 
through eliciting a specific in vivo anti-tumour response by vaccination (Dougan et al., 2009 108). 
Herein, the adaptive immune system is specifically activated through the induction of cellular im-
mune responses, for example by CD8+ and CD4+ T cell recognition of peptides presented by MHC 
class I and II, respectively. Peptides may be presented to T cells after processing of intracellular 
antigens or after APCs engulf extracellular antigens, process them, and present peptides on the 
host´s endogenous MHC molecules via cross-presentation. Different treatment modalities includ-
ing the injection of inactivated autologous cancer cells, as well as the injection of tumour antigen, 
protein, peptide, or nucleic acid delivered alone, cellularly or genetically, with or without adjuvant 
are possible.
Strategies comprise non-cellular vaccines with purified tumour-antigen or synthetic peptide as 
well as vaccines containing autologous tumour lysates or irradiated tumour cells. However these 
approaches involve the combination with adjuvants. Such agents composed of aluminium-salts or 
oily emulsions augment the immune response to an antigen unspecifically, for example through 
tissue irritation and attraction of immune cells or through prolonging the time of antigen release 
(depot-effect). 
Other cellular vaccination strategies directly use the immunological properties of APCs to induce 
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tumour-specific T cells - the main advantage being selective with only little toxicity (Ribas et al., 
2003 109; Berzofsky et al., 2004 110; Rosenberg 2004 111; Hinz et al., 2006 112). Most effort is un-
dertaken using dendritic cells as APCs in various settings. As an alternative artificial APCs (aAPC) or 
B cells are investigated (Schultze et al., 1997 113 and 2004 114; Banchereau et al., 2005 54; Mason 
et al., 2008 115; Butler et al., 2010 116). Strategies with APCs loaded with TAA aim at inducing 
effective cellular and antibody-mediated responses specific for antigens selectively expressed by 
the tumour and at avoiding unintended tissue damage as seen by other conventional approaches 
such as chemotherapy (Grabbe et al., 1995 117; Ward et al., 2003 118; Banchereau et al., 2005 54).
To this end challenges to be met have been identified as finding immunogenic tumour antigens, 
overcoming tolerance and generating professional antigen-presenting cells that effectively acti-
vate T-cell immunity.
1.2.4.   Dendritic cell Vaccination
In mice vaccinations with bone-marrow-derived ex vivo matured antigen-loaded DCs have already 
been shown to induce protective and therapeutic anti-tumour immunity (Mayordomo et al., 1995 
119; Zitvogel et al., 1996 120; Gilboa et al., 1998 121). Several strategies to select immunogenic, 
tumour-specific antigen targets and to deliver the antigens to DCs have been explored. Thus tu-
mour antigens are isolated from cDNA-libraries or from peptides eluted from the tumour cell sur-
face and DC are loaded by simply incubation with antigen (“pulsing”) in forms of peptides or pro-
teins (Parkhurst et el., 1996 122; Li et al., 2002 123), by transfecting with mRNA or plasmid DNA 
(Boczkowski et al., 1996 124) or by transducing with viral vectors (Ribas et al., 2002 125). Further 
DC vaccination strategies include  tumour-DC fusions, loading DC with dying tumour cells (Albert 
et al., 1998 126; Berard et al., 2000 127) and enhancing the immune-stimulatory context in which 
the vaccines are delivered, for example by targeting DCs in vivo with antibodies specific for DC 
surface molecules like DEC205 or DC-SIGN (Gilboa E., 1999 128; Fong et al., 2000 129). 
In order to further improve DC-based immunotherapeutic approaches processes exploited by tu-
mours to down-regulate effective immune responses elicited by DC vaccines are investigated; for 
example the targeting of endogenous DCs in tumour-bearing patients by tumour-derived fac-
tors like IL-10, TGF-β, VEGF (vascular endothelial growth factor), IL-6 and PGE-2 (prostaglandin E2) 
leading to a subsequent delay in maturation and impaired development of effector T-cell func-
tions (Almand et al., 2001 130; Inaba et al., 2003 131, Pinzon-Charry et al., 2005 132). 
With the discovery of methods to generate human autologous DCs ex vivo for example by differ-
entiating CD34+ progenitors with granulocyte/macrophage colony-stimulating factor (GM-CSF) 
and interleukin-4 into immature DC and maturing them or terminally differentiating them by 
triggering toll-like receptors for example with CpG-ODN or PolyIC and tumour-necrosis factor re-
ceptors (TNF-R) with LPS, tumour-necrosis factor-α (TNF-α) or CD40 ligation, clinical studies using 
DC as vaccines were facilitated (Caux et al., 1992 133; Romani et al., 1994 134; Sallusto et al., 
1994 135). These revealed the importance of the maturation status of DCs and the importance of 
the particular subset of DCs being targeted.  It was demonstrated that antigen-presentation by 
immature DC subsets induces undesired antigen-specific tolerance mechanisms impeding effec-
13INTRODUCTION
tive anti-tumour responses. Moreover different DC-maturation programs elicited by treatment 
with various cytokine combinations also result in differential effects on T-cell function (figure 3). 
So by generation of different DC subsets distinct types of immune responses can be induced, for 
example favourable induction of tumour-specific CD8+ T cells, T
h
1 polarization and limited induc-
tion of Treg as well as a deleterious T
h
2 directed T-cell response, T-cell anergy, T-cell deletion and 
the development of Treg further limiting DC application (Steinman et al., 2003 136; Mailliard et 
al., 2004 137; Liu et al., 2009 138). 
Figure 3:  Dendritic cell activation stimuli and subsequent type of T-cell response
Activation of DCs by immunogenic, inflammatory or tolerogenic stimuli leads to 
their maturation and subsequent release of distinct cytokine patterns. Depend-
ing on the signal the type of the elicited adaptive immune response will be determined. 
TSLP: thymic stroma lymphopoietin (adopted from Palucka et al., 2011 139).
Another challenge regarding the quality of immune responses elicited by DCs is represented by 
their capacity to migrate to the T cell-rich areas of secondary lymphoid organs, to closely interact 
with T cells  and thereby influence the homing properties of the effector cells (Morse et al., 1999 
140; Verdijk et al., 2008 141). Thus besides DC subset, maturation status, dose and frequency of 
vaccinations, the injection route (intravenous vs. non-intravenous routes: subcutaneous, intra-
dermal, intralymphatic, intranodal) is considered an important variable that has to be adjusted 
to improve immunotherapy (Mullins et al., 2003 142 and Palucka et al., 2005 143, Draube et al., 
2011 144). As intralymphatic and intranodal injections are technically challenging and still only 
less than 4 % of the administered DC reach the regional lymph nodes, intradermal and intrave-
nous injections are preferred in clinical studies (Ridolfi et al., 2004 145; Quillien et al., 2005 146), 
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whereas in mice subcutaneous injection is effective in both targeting DC to draining lymph nodes 
and inducing immune responses (Eggert et al., 1999 147; Okada et al., 2001 148).
Nevertheless, recently the first autologous DC-based therapeutic cancer vaccine, Sipuleucel-T 
(PROVENGE) based on ex vivo generated DC activated with a recombinant PAP-GM-CSF fusion 
protein (PA2024) used to target prostate acid phosphatase antigen (PAP) on prostate cancer cells 
has been approved by the US Food and Drug Administration (FDA) prolonging the median survival 
of men with advanced castrate-resistant prostate cancer (CRPC) by 4.1 months (Cheever M.A. and 
Higano C.S., 2011 150). On the other hand strategies targeting DC in vivo are pushed forward re-
cently. While GVAX® consisting of two prostate cancer cell lines transfected with GM-CSF failed 
to exceed standard therapy in the phase III study, other strategies aiming at immune activation 
by targeting costimulatory molecules like B7.1, ICAM-1 and Lfa-3 (targeted in PROSTVAC®) seem 
to be promising (Galsky et al., 2011 151; Heery et al., 2011 152). Furthermore, anti-CTLA-4 mono-
clonal antibody Ipilimumab blocking immune inhibitory pathway leading to T-cell inactivation, 
has shown to be effective in immunotherapeutic treatment of metastatic melanoma (Cameron et 
al., 2011 153). Thus, combinatorial strategies with immunomodulatory agents and DCs together 
with conventional strategies like radiation and chemotherapy are considered to provide new ther-
apeutic approaches and improve the therapeutic efficacy of vaccination strategies against cancer 
(Palucka et al., 2010 154 ; Le et al., 2010 155). An overview of DC-based therapeutic vaccination 
strategies is given in figure 4.
During the last decade few hundred clinical trials have been performed using DCs as cellular ad-
juvants in cancer immunotherapy with low induction of clinical responses. In 2005 the Cancer 
Vaccine Clinical Trial Working Group (CVCTWG) of experts from academia, biotech and pharma-
ceutical industry as well as regulatory bodies from Europe and America elaborated a clinical devel-
opment paradigm for cancer vaccines and related biologics addressing end points for clinical trials, 
trial designs and statistical methods, technical and developmental challenges as well as com-
bination therapy to set up a guideline meeting the specific requirements of therapeutic cancer 
vaccines (Hoos et al., 2007 149). The major feasibility hurdles have been identified as the reliable 
production of functioning DC preparations as it is difficult to quality control the levels of antigens 
being processed and presented by DC. Furthermore ensuring the proper maturation status and 
the appropriate DC subset are critical for ensuring that DCs are capable of migrating into second-
ary lymphoid organs to prime T cells. DC vaccinations are costly in terms of labour and money as 
autologous DC preparations have to be generated individually for each patient. 
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Figure 4:  Therapeutic vaccination strategies with DC
1) Antigen-based vaccination randomly targeting DC in vivo. 2) Ex vivo-generation of an-
tigen-loaded DC infused back to the patient. 3) Specific DC-targeting in vivo and 4) op-
timized combinatorial DC approaches (adopted from Palucka et al., 2011 139).
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1.3. B cells as Antigen-Presenting cells
Besides their role as producers of antibody in humoral immune responses B cells are increasingly 
recognized as antigen-presenting cells which play a crucial role in the initiation of T cell responses. 
Even though dendritic cells are thought to be the most important APCs, it has become clear that 
antigen-presentation by B cells plays an important role under certain circumstances. Compared 
to DCs B cells are less efficient at capturing antigens by either adsorption, or pinocytosis, or Fc-
Receptor (FcR)-mediated up-take (Chesnut et al., 1982 156; Grey et al., 1982 157; Batista F.D. and 
Neuberger M.S., 1998 158; Rodriguez-Pinto D., 2005 159). Despite the fact that lymph-borne solu-
ble antigens enter the lymph node via the afferent lymph vessels at the subcapsular sinus and dif-
fuse directly into the follicle where the B cells reside (Pape et a., 2007 160), antigen-presentation 
to B cells is usually thought to be mediated through cross-presentation by other professional APCs 
that take up antigens unspecifically through generic receptors, for example subcapsular-sinus 
macrophages in the lymph nodes and follicular DCs (FDCs) in lymph nodes and spleen (Wykes et 
al., 1998 161; Qi et al., 2006 162; Carrasco Y. and Batista F., 2007 163; Phan et al., 2007 164). 
In contrast, specific BCR-mediated antigen up-take processing of antigen in the endosomal com-
partment leads to an export of MHC class II-peptide complexes to the B-cell surface. As men-
tioned before sufficient T cell activation occurs when naïve T cells receive two signals from APCs: 
signal 1) recognition of the MHC-peptide complex by TCR and signal 2) engagement of the cos-
timulatory molecules CD80 (B7-1) and CD86 (B7-2) on APCs via interaction with CD28 on T cells 
(Bretscher P.A., 1999 6). However, the expression of co-stimulatory molecules on APCs needs to 
be induced first and in turn is triggered by the reciprocal interaction of CD40L (CD154, gp39) ex-
pressed on activated T cells with CD40 receptor expressed on APCs, such as B cells (van Kooten C. 
and Banchereau J, 2000 165).
1.3.1.   CD40-CD40L Interaction
The well recognized model of CD40-CD40L interaction has been extensively investigated on 
molecular and functional levels and shown to regulate diverse cell-mediated immune func-
tions (Banchereau et al., 1994 166; Foy et al., 1996 167; Grewal I.S. and Flavell R.A., 1996 168; 
van Kooten C. and Banchereau J., 1996 169; Noelle R.J., 1996 170; Mackey et al., 1998 171): 
CD40 is a cell surface receptor that belongs to the TNF-receptor family. First identified in 1985 on 
B cells, engagement of CD40 receptor on B cells was shown to play an important role in B-cell sur-
vival and proliferation, GC and memory B-cell formation, and immunoglobulin isotype switching, 
functions which are abrogated in patients suffering from hyper-IgM syndrome due to defects in 
CD40-CD40L interaction. CD40-activation of B cells exhibits directly effects on cytokine produc-
tion as well as on expression of adhesion, costimulatory and MHC class I and II molecules. CD40 
was demonstrated to be also critical for the maturation of DCs, and CD40 expression on endothe-
lial cells, fibroblasts and epithelial cells was shown to be involved in inflammatory responses, au-
toimmunity and tolerance induction. Thus CD40-CD40L interaction is playing a more general role 
in cellular immune regulation. 
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The CD40L homotrimer is transiently expressed on mature CD4+, CD8+ and γδ T cells and its liga-
tion through cross-linked CD40 enhances cytokine production of T cells. Furthermore, different 
CD40L mRNA species have been identified in monocytes, DCs, B cells, NK cells and further more. 
CD40 and CD40L have also been described in soluble forms enabling a cytokine-like action at dis-
tant sites and CD40-CD40L interactions can result in bidirectional stimulatory signalling of B and 
T cells. Thus, besides its role in humoral immunity CD40-CD40L interaction has also been investi-
gated for its essential role in the initiation of antigen-specific T-cell responses. There is no doubt 
that CD40-CD40L interaction is essential for effective in vivo priming, expansion and maturation 
of CD4+ T cells into effector cells (Grewal et al., 1995 172; van Essen et al., 1995 173; Grewal I.S. 
and Flavell R.A., 1996 174; Scaria et al., 1997 175). Furthermore this interaction plays an impor-
tant role for the establishment of memory CTL and for providing CD4-dependent help for cross-
priming of CD8+ cytotoxic T cells (Borrow et al., 1996 176; Bennett et al., 1997 177; Bennett et al., 
1998 178; Schoenberger et al., 1998 179; Bourgeois C. and Tanchot C., 2003 180). 
Pharmacologic manipulation of the CD40-CD40L pathway seems a promising tool in the treat-
ment of different immunological diseases. On the one hand a specific interference of uncontrolled 
immune reactions, like inflammation, autoimmunity and allo-graft rejection can be achieved by 
using blocking anti-CD40L antibodies (Larsen et al., 1996 181; Kirk et al., 1997 182; Kirk et al., 
2001 183; Pearson et al., 2002 184; Grammer et al., 2003 185; Sidiropoulos P.I. and Boumpas D.T., 
2004 186). On the other hand the amplification of CD40-CD40L interactions via agonistic CD40-
antibodies results in direct anti-proliferative anti-tumour effects by binding to CD40 expressed 
on tumour cells or mediates cellular immunity required for effective tumour protection (Mackey 
et al., 1998 187; Diehl et al., 1999 188; Tong A.W. and Stone M.J., 2003 189; Watanabe et al., 2003 
190; Eliopoulos A.G. and Lawrence S.Y., 2004 191; Vonderheide et al., 2007 192). Thus, triggering 
CD40 on APCs displays an attractive approach to manipulate their capacity to prime and expand 
antigen-specific CD4+ and CD8+ T cells. 
1.3.2.   CD40-activated B cells 
Based on the observation that long-term human B cell lines could be established by triggering 
CD40 and IL-4 (Banchereau et al., 1991 193 and 194) the group of Lee M. Nadler first reported that 
CD40-activated human B cells can serve as an alternative source of highly efficient APC to induce 
allogeneic CD4+ and CD8+ T cell responses and to generate autologous tumour-antigen specific 
T cells in vitro, comparable to dendritic cells (Schultze et al., 1997 113). Furthermore, upon CD40 
ligation and IL-4 signalling these B cells strongly expand from small amounts of peripheral blood, 
up-regulate co-stimulatory, MHC as well as adhesion molecules, and show increased antigen pres-
entation capacity in vitro, which was confirmed by Lapointe et al. in 2003 (Lapointe et al., 2003 
195). Thus, in addition to implementing CD40-stimulated B lymphocytes in the context of tu-
mour-antigen discovery (SEREX) and the ex vivo generation of T cells for adoptive immunotherapy 
(Kondo et al., 2002 196; Fujiwara et al., 2005 197; Ivanov et al., 2005 198) the clinical application 
of CD40-activated B cells as antigen-presenting cells in therapeutic vaccination strategies appears 
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promising (von Bergwelt-Baildon et al., 2002 199; Coughlin et al., 2004 200; Yoon et al., 2005 201; 
Van den Bosch et al., 2005 202; Shen et al., 2008 203; Wu et al., 2010 204). 
To this aim, diverse ex vivo strategies to manipulate CD40-CD40L interactions in order to activate 
B-lymphocytes and evaluate their potential as APC in cellular therapies have been developed (re-
viewed in Néron et al., 2011 205). Besides triggering CD40 with agonistic monoclonal anti-CD40 
antibodies, usage of recombinant soluble CD40L proteins, soluble CD40L membrane fractions as 
well as CD40L expressing feeder cell lines have been tested alone or in combination with other 
stimuli and an impact of signal strength (cross-linking) and nature (soluble vs. membrane bound) 
on B-cell activation has been proposed (Fanslow et al., 1994 206; Néron et al., 2005 207). Further-
more different antigen-loading strategies have been tested showing that CD40-activated B cells 
can be pulsed with peptide, protein, tumour lysates, transfected with DNA or RNA, or transduced 
with viral vectors (Kondo et al., 2002 196; von Bergwelt-Baildon et al., 2002 199; Lapointe et al., 
2003 195; Coughlin et al., 2004 200; Ahmadi et al., 2008 208). 
Several studies have proven that antigen-presenting activated B cells induce effective expansion 
of antigen-specific CD4+ and CD8+ T cells in vitro, however also CD4+ or CD8+ and CD25+FoxP3+ Treg 
can be expanded with resting or suboptimally activated B cells emphasising the need for the ap-
plication of optimal activated B cell formulations in the right setting (Tu et al., 2007 209; Zheng 
et al., 2009 210; Zheng et al., 2010 211). In addition, the capacity of activated B cells to migrate 
in vivo and home to secondary lymphoid organs has been under examination by us and others 
(unpublished data N. Klein-Gonzáles; Guo et al., 2009 212). We could show that human CD40-
activated B cells express the full lymph node homing triad of CD62L, CCR7/CXCR4 and LFA-1, and 
induce T-cell chemotaxis, requirements necessary for successful T-cell interaction (von Bergwelt-
Baildon et al., 2006 213). Furthermore when properly activated GFP-labelled CD40-B cells were 
injected intravenously (iv) into recipient mice, we were able to find significant amounts in periph-
eral lymph nodes and spleen. There, CD40-B cells localized in the B cell zones of the splenic white 
pulp and in the B/T boundary close to the T cell zone in spleen and lymph nodes. In contrast, when 
administered subcutaneously the number of CD40-B cells found in SLO was significantly lower 
than when injected iv (unpublished data N. Klein-Gonzáles). 
Finally, very few in studies have been conducted so far investigating the in vivo antigen-presenting 
capacity of CD40-activated B cells and their participation in anti-tumour immunity. In 2004 Ritch-
ie et al. showed that mice immunized with B cells activated with membrane fractions containing 
CD40 ligand and loaded with the MHC-I binding peptide LCMV
33-41
 [KAVYNFATM] injected iv could 
induce a delay in tumour growth of the LCMV-transfected tumour cell line LL-LCMV in a preventive 
setting. Furthermore, this effect was not only due to cross-dressing of antigen from CD40-B cells 
to other antigen-presenting cells but also through direct APC mechanisms (Ritchie et al., 2004 
214). Still, the contribution of B cells as antigen-presenting cells to induction of antigen-specific 
T- cell responses is discussed controversially. 
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1.4. Purpose of this study
While we have detailed knowledge about the antibody-dependent functions of B cells, compara-
tively little is known about the antibody-independent functions, such as antigen presentation and 
their contribution to the induction of primary immune responses in vivo. In order to elicit a func-
tional immune response, antigen-presentation to and co-stimulation of T cells are prerequisites 
of professional APCs – which have shown to be fulfilled by properly activated B cells in vitro, too. 
In order to study antigen-presentation by B cells in vivo this study aimed at the development of a 
murine model which enabled the examination of antigen-presentation by activated B cells.
The first step was to develop a cell culture system for the generation of murine CD40-activated B 
cells (mCD40B) based on murine CD40-ligand expressing feeder cells (tmuCD40L HeLa), in order 
to test whether the strength and nature of the applied CD40 stimulus and cultivation conditions 
were able to drive B cells through their differentiation program to generate suitable stimulators of 
immune responses. Second, mCD40B cultivation conditions were optimized on the basis of yield, 
purity and cell activation status and the immune stimulatory efficacy of mCD40B compared to 
state-of-the-art murine dendritic cells (mDCs) was evaluated in vitro. With the intention to find 
the main parameters impacting the strength of the elicited immune-response in vivo a murine 
vaccination model was developed based on the loading of mCD40B with foreign antigen by means 
of peptide-pulsing. Furthermore, the specific immune response elicited by mCD40B loaded with 
peptide was characterised phenotypically and functionally by assessing cytokine secretion and 
by measuring cytotoxic potential against target cells, respectively. Finally, as a proof-of-principle 
and to investigate whether vaccination with mCD40B is able to overcome immune evasion and to 
prime T cells, antigen-presentation by mCD40B was studied in a murine melanoma model.
Taken together, this work therefore investigates antigen presentation by B cells particularly in the 
context of tumour immunotherapy with the aim to provide further insights into the mechanisms 
of the APC function of B cells and their therapeutic manipulation.
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2. MATERIAL & METHODS
2.1. Chemicals
For preparation of buffers and solutions chemicals of analytically purity were used exclusively.
Table 2: Chemicals
Name Manufacturer
Acetic Acid Roth
β-Mercaptoethanol (β-ME) Sigma
Bovine Serum Albumin (BSA) Sigma
5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester  
(5(6)-CFDA, SE; CFSE) - mixed isomers
Invitrogen
Cyclosporin A (CsA) Sigma
CpG-ODN D-SLIM Mologen
Dimethyl sulfoxide (DMSO) Sigma
Ethanol Roth
Ethylenediaminetetraacetic acid (EDTA) Sigma
Foetal Bovine Serum (FBS) (Lot 5SB0018) Lonza
VLE-FBS (very low endotoxin) (Lot 6SB0007) Lonza
Gentamicin PAA
Golgi Stop (Monensin) BD
Hydrochloric Acid (HCl) Roth
Hygromycin PAA
Ionomycin Sigma
Isopropanol Roth
LPS (derived from E.coli 055:B5) Sigma-Aldrich
Pancoll Mouse (density 1.086 g/mL) PAN Biotech
Paraformaldehyde (PFA) Sigma
Phorbol 12-Myristate 13-Acetate (PMA) Sigma
Sodium Azide (NaN3) Sigma
Sodium Chloride (NaCl) Roth
Sodium Hydroxide (NaOH) Roth
Trypan Blue Stain 0.4 % Gibco
Trypsin-EDTA Gibco
22MATERIAL & METHODS
2.1.1.   Antibodies
Table 3: Anti-Mouse Antibodies
Antigen [clone] Species / Ig class Labelling Manufacturer
B220 (CD45R) Rat IgG2a, κ FITC BD Pharmingen
CD3e Hamster IgG1, κ APC-Cy7 BD Pharmingen
CD4 Rat IgG2a, κ PE-Cy7 BD Pharmingen
CD8a Rat IgG2a, κ PerCP BD Pharmingen
CD11b Rat IgG2b, κ APC BD Pharmingen
CD11c Hamster IgG1, λ2 PE BD Pharmingen
CD16/CD32 Rat IgG2b, κ unlabelled BD Pharmingen
CD19 Rat IgG2a, κ PE-Cy7 BD Pharmingen
CD25 Rat IgG2b, κ APC BD Pharmingen
CD25 Rat IgG1, κ PE Immunotools
CD40 [HM40-3] Hamster IgM, κ unlabelled BD Pharmingen
CD69 Hamster IgG PE Caltag Laboratories
CD80 Hamster IgG2a, κ FITC BD Pharmingen
CD83 Rat IgG1, κ APC BD Pharmingen
CD86 Rat IgG2a, κ PE BD Pharmingen
CD154 (CD40L) Hamster IgG3, κ PE BD Pharmingen
H-2Db (MHC-I) Mouse IgG2b, κ PE BD Pharmingen
I-Ab (MHC-II) Mouse IgG2a, κ FITC BD Pharmingen
IFN-γ Rat IgG1, κ PE BD Pharmingen
Vβ 5.1, 5.2 TCR Mouse IgG1, κ PE BD Pharmingen
Table 4: Isotype Controls
Species / Ig class Labelling Manufacturer
Rat IgG1, κ APC-Cy7 BD Pharmingen
Hamster IgG1, λ2 PE BD Pharmingen
Rat IgG 2a FITC Caltag
Rat IgG 2a PE Caltag
Rat IgG 2a PE-Cy7 Caltag
Rat IgG 2b, κ APC BD Pharmingen
Table 5: Secondary anti-Mouse Antibodies and Streptavidin Conjugates
Antigen [clone] Species / Ig class Labelling Manufacturer
B220 (CD45R) Rat IgG2a, κ Biotin BD Pharmingen
CD3e Hamster IgG1, κ Biotin BD Pharmingen
CD19 Rat IgG2a, κ Biotin BD Pharmingen
CD34 [RAM34] Rat IgG2a, κ Biotin eBioscience
Streptavidin PE BD Pharmingen
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2.1.2.   Peptides
Table 6: MHC class I Peptides
Name (amino acid position) Purity
Peptide sequence 
(N‐terminal‐>C‐terminal) Manufacturer
LCMV (aa33-41) > 98 % KAVYNFATM Thermo Scientific
OVA (aa257-264) > 97 % SIINFEKL Thermo Scientific
TRP-2 (aa180-188) > 99 % SVYDFFVWL Thermo Scientific
2.1.3.   Recombinant Cytokines
Table 7: Recombinant Cytokines
Cytokine Species  (Specific Activity U/mg) Manufacturer
GM-CSF Mouse ( 5 x 10e5) Immunotools
Interleukin-4 Mouse ( 5 x 10e5) Immunotools
2.1.4.   Buffers & Solutions
Table 8: Buffers and solutions
Name Composition / Manufacturer
Bone marrow Isolation Buffer 1 
1x PBS 
1 % VLE-FBS 
1mM EDTA 
Buffer 2
1x PBS
1 mM EDTA
Buffer 3
1x PBS
5 % VLE-FBS
1 mM EDTA
Cell Fix 1x BD Biosciences
Cell WASH BD Biosciences
Dulbecco´s PBS 1x PAA
EasySep Purification buffer
1x PBS
2 % FBS
1 mM EDTA
Erylysis Buffer 1
0.2 % NaCl
pH 7.4
Buffer 2
1.6 % NaCl
pH 7.4
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Name Composition / Manufacturer
FACS Flow BD Biosciences
FACS Staining buffer 
1xPBS
2 % FBS
0.1 % Sodium Azide 
pH 7.4
HEPES Buffer 1 mM PAA
MEM NEAA 1x Gibco
2.1.5.   cell culture media
Table 9: Feeder cell Standard medium
Medium (Manufacturer) Composition and Supplementation
RPMI 1640 (Gibco)
10 % FBS (Lot 5SB0018)
300 µg/mL L-Glutamine 
10 mM HEPES
15 µg/mL Gentamicin
Table 10: Feeder cell Selection medium
Medium (Manufacturer) Composition and Supplementation
RPMI 1640 (Gibco)
10 % FBS (Lot 5SB0018)
300 µg/mL L-Glutamine 
10 mM HEPES
15 µg/mL Gentamicin
0.2 mg/mL Hygromycin B
Table 11: mCD40B Washing medium
Medium (Manufacturer) Composition and Supplementation
DMEM (Gibco)
580 µg/mL L-Glutamine 
4.5 mg/mL Glucose
10 mM HEPES
15 µg/mL Gentamicin
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Table 12: mCD40B Standard medium
Medium (Manufacturer) Composition and Supplementation
DMEM (Gibco)
10 % FBS (Lot 5SB0018)
580 µg/mL L-Glutamine 
4.5 mg/mL Glucose
10 mM HEPES
0.1 mM MEM NEAA
1 U/mL IL-4
100 µM/mL β-Mercaptoethanol
0.63 µg/mL Cyclosporin A
15 µg/mL Gentamicin
Table 13: mDC Standard medium
Medium (Manufacturer) Composition and Supplementation
VLE-RPMI 1640 (Biochrom)
5 % VLE-FBS (Lot 6SB0007)
L-Glutamin
50 µM/mL β-Mercaptoethanol
15 µg/mL Gentamicin
Table 14: Serum-free Medium for Peptide Pulsing
Medium (Manufacturer) Composition and Supplementation
AIM V (Gibco)
L-Glutamin
50 µg/mL Streptomycin Sulfate
10 µg/mL Gentamicin Sulfate
Table 15: B16 Tumour Medium
Medium (Manufacturer) Composition and Supplementation
DMEM (Gibco)
10 % FBS (Lot 5SB0018)
L-Glutamin
4.5 g/L Glucose
100 µM/mL β-Mercaptoethanol
50 µg/mL Streptomycin Sulfate
10 µg/mL Gentamicin Sulfate
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2.1.6.   Kits
Table 16: Kits
Name Manufacturer
Cytofix/Cytoperm Plus Kit (554715) BD Biosciences
Easy Sep Mouse CD19 Positive Selection Kit (18754) Stemcell Technologies
Easy Sep Mouse T Cell Enrichment Kit (19751)
Negative Selection
Stemcell Technologies
Easy Sep Mouse Biotin Selection Kit (18556) Stemcell Technologies
2.1.7.   Cell Lines
Table 17: Cell Lines
Name Supplier
HeLa DSMZ
tmuCD40L HeLa Prof. Dr. C. Wendtner
B16.F10 ATCC
2.1.8.   Tools & Instrumentation
Table 18: Tools and Instrumentation
Tool / Instrument Manufacturer
Aristoplan Microscope Leitz
BAHR-DIGIMESS 150A4 (Digital Caliper) TSB-shop
BioBeam 8000 Gamma-Service Medical GmbH
FACS Canto Becton Dickinson
Freezing Chamber Nalgene NUNC
Kofferdam Punch Pliers Ainsworth B. Braun Melsungen AG
Mouse Restraining device G&B Kunststofftechnik
Purple EasySep Magnet StemCell Technologies
Televal 31 Microscope fitted with
EOS 350D Digital Camera 
Zeiss 
Canon
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2.1.9.   Consumables
Table 19: Consumables
Name Manufacturer
cell scraper 25 cm Sarstedt
cell strainer 70, 100 µM BD Falcon
cryo tube 1.0, 1.8 mL Sarstedt
dish 6-, 12- well (flat bottom) NUNC
dish 96-well (round bottom) NUNC
FACS tube 5 mL BD Falcon
bottle top filter 0.22 µm BD Falcon
Minisart filter 0.2 µm Sartorius Stedim Biotech
needle 20 G (0.90 x 70 mm) B. Braun Melsungen AG
needle 26 G (0.45 x 12 mm) BD Medical
petri dish (60 x 15 mm) Sarstedt
pipette tip 5, 10, 25 mL Sarstedt
pipette tip 10, 200, 1000 µL Sarstedt
reaction tube 0.5, 1.0, 1.5, 15, 50 mL Sarstedt
surgical blade Scalpel No. 22 Feather Safety Razor Co.
syringe Injekt-H 1 mL B. Braun Melsungen AG
syringe Discradit II 2, 5, 10, 20 mL BD Medical
tissue culture flask 75, 175 cm2 Sarstedt
2.2. Cell Culture
2.2.1.   Counting of cells – Trypan Blue Exclusion Test
Cells were counted using a Neubauer counting chamber and an aliquot 10x diluted and stained in 
Trypan Blue Stain 0.4 % to differentiate viable from non-viable cells. 10 µl of stained aliquot were 
applied to the counting chamber and bright, unstained cells were counted viable. Using a light 
optical microscope with 20 fold magnification four corner quadrants of the Neubauer chamber 
were counted completely. One big quadrant has a volume of 0.1 µl. The average cell number per 
quadrant was multiplied by 10e4 giving the amount of cells present in 1 ml of cell suspension. The 
total cell number was calculated by including the dilution factor and the total volume. The rela-
tive growth of cultures during whole cultivation period was assessed by calculating the relative 
increase between two passages.
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2.2.2.   Cryopreservation and Thawing of cells
Cells were suspended at a density of 5-10 x 10e6 cells/mL in cold freezing medium (90 % FCS and 
10 % DMSO (v/v)) on ice. Cell suspension was aliquoted into cryo tubes, tubes placed in an iso-
propanol freezing chamber and slowly frozen at -80 °C. 24-72 h later, tubes were transferred into 
liquid nitrogen for long-term storage.
Frozen cells were quickly removed from nitrogen and rapidly thawed in a water bath at 37 °C until 
a small ice clump was left in the vial. Then, cells were transferred dropwise into excess of medium 
and spun down (200 g, 5 min) to remove DMSO. Finally, cells were suspended in the appropriate 
medium or solution for further passaging.
2.2.3.   Trypsinization of Adherent Cells
Old medium was removed and adherent cells washed with 10 mL of 1x PBS. After removal of PBS 
cells were detached by adding 4 (6) mL of 1x Trypsin-EDTA in a 75 (175) cm2 flask and incubated 
for 10-15 min at 37 °C. Detachment of cells was facilitated by gentle tapping at the flask. In order 
to stop trypsin digestion 10 mL of FBS containing medium was added to the cells. Then, cells were 
harvested, washed twice with 1x PBS in excess (265 g, 7 min) and suspended in Standard Medium. 
2.2.3.1.   Assessment of Cell Morphology by Microscopy
To assess morphology of cell subsets, cultures were completely screened, a representative section 
was chosen and photographed with a 5x magnification using an inverted phase Zeiss Televal 31 
microscope fitted with a Canon EOS 350D digital camera.
2.2.4.   Cell Lines
2.2.4.1.   Passaging of tmuCD40L HeLa cell line
tmuCD40L HeLa cell line is an adherent human epithelial cell line, which should never become 
completely confluent. Therefore cell passaging was done twice per week and cultivated for not 
longer than 6 weeks. Then a new aliquot stored in liquid nitrogen was thawed. 
For regularly passaging adherent tmuCD40L HeLa cells were trypsinized (see section 2.2.3.) and 
suspended in 10 mL of Feeder cell Standard medium in order to determine the cell number (see 
section 2.2.1.). Finally, 2.5 x 10e6 cells were disseminated in a 75 cm2 flask in 10 mL Feeder cell 
Selection medium and incubated at 37 °C and 5 % CO
2
.
For generation of murine CD40-activated B (mCD40B) cells the remaining tmuCD40L HeLa cells 
were lethally irradiated 3 times with 26 Gy (total: 78 Gy) and subsequently plated on a sterile 
6-well plate at a concentration of 0.4 x 10e6 cells/well in 2 ml Feeder cell Standard medium and 
incubated at 37 °C at 5 % CO
2
. After 4 to 24 h of incubation tmuCD40L HeLa cells were checked for 
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adherence using microscope. Adherent feeder cells were used for B-cell stimulation.
tmuCD40L HeLa is a stable transfectant; its expression of CD40L was regularly tested by flow cy-
tometry using PE-conjugated anti-Mouse CD154 (CD40L) antibody.
2.2.4.2.   Passaging of B16.F10 melanocytes
B16.F10 is an adherent cell line derived from murine melanoma. In order to ensure genetic stabil-
ity of the cell line a new aliquot of B16.F10 cells was thawed every 4-6 weeks and monitored for 
brown pigmentation. Cells were kept in logarithmic growth phase by passaging them with ≤ 50 %
confluence twice per week. 
For regularly passaging cells were trypsinized according protocol (see section 2.2.3.) except 0.5 % 
trypsin/EDTA was used, and suspended in 10 mL of B16 Tumour Medium in order to determine the 
cell number (see section 2.2.1.). Finally, 1 x 10e6 (5 x 10e6) B16.F10 melanocytes were disseminat-
ed in a 75 (175) cm2 flask in 20 (30) mL of B16 Tumour Medium and incubated at 37 °C and 5 % CO
2
.
2.2.5.   Cell-subset Enrichment
2.2.5.1.   Purification of murine Lymphocytes from Blood
A maximum of 50 µL of blood was withdrawn from lateral tail veins. Therefore, mice were fixed 
in the Mouse Restraining device, target area was pre-warmed using a red light lamp, target area 
was sterilised with skin disinfectant and tail vein was cut using a surgical blade. Blood sample was 
collected in 1 mL tube containing heparin. Lymphocytes were purified from erythrocytes by lysis 
(see section 2.2.5.6.). 
2.2.5.2.   Purification of murine Lymphocytes from Lymph Nodes
In order to analyse lymphocytic cells from mesenteric or inguinal lymph nodes by FACS single-cell 
suspensions were prepared. Therefore, dissected organs were stored in mCD40B Washing Me-
dium on ice until further preparation. First, single-cell suspensions from lymph nodes were made 
by disintegration of lymph nodes by squashing them between two glass slides. Cellular fragments 
were washed down into a Petri dish on ice, minced with the back side of a syringe plunger and 
filtered through a 100 µm cell strainer that was wetted with 1 mL of mCD40B Washing medium. 
Past this step lymphocytes from lymph nodes were purified by density-gradient centrifugation 
using Pancoll Mouse (see section 2.2.5.3.). 
2.2.5.3.   Purification of murine Lymphocytes from Spleen
Murine lymphocytes were separated from whole splenocytes by density-gradient centrifuga-
tion using Pancoll Mouse. First, spleens from 8-12 weeks old C57BL/6 mice, BALB/c mice or OT-I 
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mice were minced by passing them through a 100 µm cell strainer that was wetted with 1 ml of 
mCD40B Washing medium. Second, the cell suspension was spun down at 265 g for 7 min. Third, 
splenocytes were suspended in 7-8 ml mCD40B Washing medium and layered on top of 5 ml pre-
warmed Pancoll Mouse in a 15 mL reaction tube. Fourth, cells were spun down at 450 g for 25 min 
without brake, at acceleration level 4 and at RT. Finally, the upper layer was removed and the 
lymphocyte-rich interphase was carefully collected with 20 G Needle and washed afterwards at 
least once with 1x PBS at 265 g for 10 min.
2.2.5.4.   Purification of murine CD3+ T cells
Murine CD3+ T cells were negatively enriched from whole spleen of 8-12 weeks old BALB/c mice 
using EasySep Mouse T cell enrichment Kit according manufacturer´s protocol. For that purpose 
spleens were minced by passing them through a 100 µm cell strainer that was wetted with 
1 mL EasySep Purification buffer. Cells were spun down at 200 g for 10 min and suspended at 
1 x 10e8 cells/mL in EasySep Purification buffer. 1 mL of cell suspension was filled into a sterile 5 mL 
FACS tube and supplemented with 50 µL rat serum. First, for negative selection 50 µL EasySep 
Mouse T cell Enrichment Cocktail was added to the suspension, mixed well by pipetting up and 
down and incubated for 15 min on ice. Second, 100 µL EasySep Biotin Selection Cocktail was added 
to the suspension, mixed well and incubated for 15 min on ice. Third, 50 µL of thoroughly mixed 
EasySep Magnetic Nanoparticles were added to the suspension and incubated for 15 min on ice. 
Finally, the cell suspension was adjusted to a total volume of 2.5 mL, mixed well by pipetting up 
and down and placed into the Purple EasySep Magnet for 5 min. Thereafter, the desired unlabelled 
CD3+ T cell fraction was collected by carefully picking up the magnet and pouring off supernatant 
into another sterile FACS tube leaving one remaining drop in the tube. Enrichment of CD3+ T cells 
by EasySep Mouse T cell Enrichment Kit yielded in purities of > 90 % CD3+ T cells as determined by 
flow cytometric analysis.
2.2.5.5.   Purification of murine CD34+ bone marrow progenitor cells
Murine CD34+ bone marrow progenitor cells were enriched from bone marrow of hind limbs of 
C57BL/6 or OT-I mice by positive selection with EasySep Biotin Selection Kit in combination with 
biotinylated anti-mouse CD34 antibody. 
A) Bone marrow Preparation:
Preparation of bone marrow was performed by sterile isolation of hind limbs. First, hind limbs 
were cut off above hip joint, foot pads were separated below ankle joint and femurs and lower 
legs divided. Then muscle tissue was removed and bones were saved for further preparation in 
Petri dish on ice until all remaining limbs were prepared.  Second, bone tips were cut off and bone 
marrow washed out from each side with 26 G needle by thoroughly rinsing 3 times with 4 mL cold 
Bone marrow Isolation Buffer 1 into a 50 mL tube containing the buffer reservoir. In order to free 
bone marrow cell suspension from bone fragments cell suspension was filtered through a 100 µm 
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cell strainer and spun down at 550 g for 5 min at 4 °C. Then supernatant was discarded and cell 
pellet suspended in 8 mL pre-warmed Buffer 2 by carefully pipetting up and down.
Third, bone marrow progenitors were further separated by density-gradient centrifugation at 450 g 
for 30 min at RT without break using Pancoll Mouse. Therefore 5 mL pre-warmed Pancoll Mouse 
was filled in 15 mL Falcon and cell suspension slowly layer on top. 
Finally, the upper layer was removed and the lymphocyte-rich interphase was carefully collected 
with 20 G Needle and washed twice with 20 mL cold Bone marrow Isolation Buffer 2 at 800 g for 
10 min at 4 °C. Then cell pellet was suspended in 1 mL cold Bone marrow Isolation Buffer 3 by 
pipetting it up and down. Finally cells were counted, spun down at 550 g for 5 min at 4 °C, su-
pernatant was removed completely and cells adjusted to 1 x 10e8 cells/mL in cold Bone marrow 
Isolation Buffer 3. 
B) Positive selection of CD34+ bone marrow progenitors with EasySep Mouse Biotin Isolation Kit:
First, 1 mL of the cell suspension containing 1 x 10e8 bone marrow cells was filled into a sterile 5 
mL FACS tube, blocked with 10 µL Fc-Receptor Block (CD16/CD32 antibody), labelled with 15 µL 
biotinylated anti-Mouse CD34 antibody (c = 0.5 mg/mL) and incubated for 15 min at RT. Cells were 
mixed during incubation by agitating the tube from time to time. Second, unbound antibody was 
removed by adding 10 mL cold Bone marrow Isolation Buffer 3, spinning down at 250 g for 7 min 
at 4 °C and completely pipetting off supernatant. Labelled cells were thoroughly suspended in 
700 µL cold Bone marrow Isolation Buffer 3 and filtered through a 70 µm cell strainer into a 5 mL 
FACS tube. Afterwards cell strainer was rinsed with 300 µL cold Bone marrow Isolation Buffer 3 
to free cell suspension from clumps. Third, 100 µL EasySep Biotin Selection Cocktail was added to 
the suspension mixed well and incubated for 15 min at RT. Cells were mixed during incubation 
by agitating the tube from time to time. Fourth, 50 µL of thoroughly mixed EasySep Magnetic 
Nanoparticles were added to the suspension and incubated for 10 min at RT. Cells were mixed 
during incubation by agitating the tube every 2 min. Then, the cell suspension was adjusted to a 
total volume of 2.5 mL, mixed well by pipetting up and down and placed into the Purple EasySep 
Magnet for 5 min. Thereafter, the desired labelled CD34+ bone marrow progenitor cell fraction 
was collected by carefully picking up the magnet, pouring off the supernatant one drop remaining 
in the tube, taking the tube out of the magnet and washing out the desired cell fraction 3 times 
with 1 mL Bone marrow Isolation Buffer 3 into a 15 mL tube. CD34+ cell fraction was collected by 
spinning down at 360 g for 7 min at 4 °C and suspending the cell pellet in 1 mL mDC Standard 
Medium. Enrichment of CD34+ bone marrow progenitor cells by EasySep Mouse Biotin Isolation 
Kit yielded in purities of 75-80 % CD34+ cells as determined by flow cytometric analysis.
2.2.5.6.   Lysis of Erythrocytes
In order to prepare splenocyte suspensions for lysis of erythrocytes cells from one spleen were 
spun down at 158 g for 5 min at 4 °C, thoroughly vortexed and stored on ice. Erythrocytes were 
removed by addition and quickly suspension of 5-10 mL Erylysis Buffer 1, being followed by ad-
dition of the same amount of Erylysis Buffer 2 and spinning down at 158 g for 5 min at 4 °C. The 
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supernatant containing the lysed erythrocytes was removed, cells filtered through 100 µM cell 
strainer and washed with cold 1x PBS at 158 g for 5 min at 4 °C 1-3 times until the pellet appeared 
white. Otherwise lysis was repeated. 
2.2.6.   Generation of mCD40B cells 
For in vitro generation of mCD40B cell cultures murine lymphocytes from C57BL/6 or OT-I mice 
separated from whole splenocyte suspensions by density-gradient centrifugation were used (see 
section 2.2.5.3.). 
2.2.6.1.   Initiation of mCD40B cell cultivation (day 0)
First, lymphocytes were washed in excess of mCD40B Washing medium and counted (see sections 
2.2.5.3. and 2.2.1.). Second, portions of 30 x 10e6 cells appropriate for plating one 6-well plate 
were filled into 50 mL tubes and cell numbers were adjusted to 1.25 x 10e6 cells/mL by spinning 
down at 265 x g for 7 minutes at RT and suspending in mCD40B Standard medium.
In order to ensure sufficient costimulation mCD40B Standard Medium was supplemented with 
freshly solutions of murine interleukin-4, ß-Mercaptoethanol and Cyclosporin A immediately 
before use. If not marked differently 1 U/mL of interleukin-4, 100 µM ß-Mercaptoethanol and 
0.63 µg/mL Cyclosporin A were added to one mL of mCD40B Standard Medium. Finally, for co-cul-
tivation with tmuCD40L HeLa cells supernatant from the 6-well plates pre-incubated with feeder 
cells was removed and 4 mL of the lymphocyte suspension (c = 1.25 x 10e6 cells/mL) were gently 
added to each well of the 6-well plate. At last, the plate was incubated at 37 °C and 5 % CO
2
 until 
re-cultivation.
2.2.6.2.   Cultivation of mCD40B cells (day 3 and then twice a week)
Before harvesting mCD40Bs, cell cultures were checked for proper CD40-stimulation by forma-
tion of round cell clusters. mCD40B cell clusters were harvested by vigorously pipetting cell sus-
pension up and down with a 10 mL pipette and pooling suspensions in a 50 mL tube. Then, cell 
suspensions were spun down at 265 x g for 7 min and supernatant completely removed and re-
placed by 10 mL of mCD40B Washing medium. Viable cells were counted (see section 2.2.1.) and 
suspended at a concentration of 0.75 x 10e6 cells/mL in new mCD40B Standard Medium freshly 
supplemented with 1 U/mL of interleukin-4, 100 µM ß-Mercaptoethanol and 0.63 µg/mL Cyclo-
sporin A if not marked differently. For re-cultivation with tmuCD40L HeLa cells supernatant from 
the 6-well plates pre-incubated with feeder cells was removed and 4 mL of the lymphocyte sus-
pension (c = 0.75 x 10e6 cells/mL) were gently added to each well of the 6-well plate. Finally, the 
plate was incubated at 37 °C and 5 % CO
2
 until re-cultivation after 3-4 days (twice a week) or final 
cell harvest usually yielding in > 90 % pure CD19+ CD3- mCD40B cells with a high expression of 
MHC-molecules class I (H-2Db), II (I-Ab) and co-stimulatory molecules CD80, CD86 after a total 
cultivation period of 14 days. (mCD40B cells harvested after 7 days of cultivation are referred to as 
mCD40B d7, mCD40B from day 14 of cultivation as mCD40B d14.)
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2.2.7.   Generation of murine dendritic cells
For in vitro generation of mDC cultures CD34+ bone marrow progenitors enriched by using an-
ti-Mouse CD34 antibody and EasySep Mouse Biotin Isolation Kit were used (see section 2.2.5.5. 
A and B).
2.2.7.1.   Initiation of mDC cultivation (day 0)
Purified CD34+ bone marrow progenitors were cultivated at 0.25 x 10e6 cells/mL in mDC Standard 
Medium supplemented with freshly thawed murine GM-CSF(c = 500 U/mL). 2 mL of the cell sus-
pension was applied per well onto 12 well-plates and incubated at 37 °C and 5 % CO
2
.  
2.2.7.2.   Differentiation of mDC (days 2, 4 and 6)
On days 2, 4 and 6 of cultivation period 50 % of medium was exchanged. Therefore, 1 ml of the 
overlaying medium was carefully removed from each well with a 25 mL pipette and fresh mDC 
Standard Medium supplemented with 1000 U/mL murine GM-CSF was added with a 25 mL pi-
pette by letting 1 mL of medium run in very slowly without touching the bottom of the well.
2.2.7.3.   Maturation of mDC (from day 7 to day 8)
On day 7 of cultivation, for generation of immature mDC cell suspensions were left untouched. 
Then, on day 8 of culture immature mDC were harvested by using a cell scraper. For maturation 
of mDC cell suspensions of day 7 were treated by adding 10 ng/mL LPS (DC LPS) or 1 µg/mL anti-
Mouse CD40 antibody (DC aCD40Ab) and incubated at 37 °C at 5 % CO
2
 for 24 hours. 
Purity of mDC cultures was regularly determined by flow cytometric analysis of the CD11c+ CD11b+ 
and MHC-IIhigh (I-Ab) cell population. Mature mDC generated from bone marrow progenitors were 
usually > 90% pure CD11c+ CD11b+ MHC-IIhigh cells with high expression of co-stimulatory mol-
ecules CD80, CD86, and CD83.
2.3. Phenotypical and Functional Analyses
2.3.1.   Fluorescence Activated Cell Sorting (FACS)
Flow cytometry (FACS analysis) based on antibody-antigen reaction coupled to fluorescent dye 
was used to quantify the expression of surface and intracellular proteins of viable cells. Flow cy-
tometric analysis was performed using a FACS Canto equipped with BD FACSDiva software. Signal 
spill-over occurring between fluorescence channels were corrected by setting different compen-
sations for multiple colour analyses. Further analyses and interpretation was done using FlowJo 
software from Tree Star. Mean values of fluorescence intensity (MFI) were determined from gat-
34MATERIAL & METHODS
ing on specific cell subsets in histogram plots which were used to plot bar charts. Frequencies of 
specific cell subsets were determined by gating on specific cell subsets in dot plots. Mean values 
of frequencies were calculated to plot bar charts. 
2.3.1.1.   Surface staining
In order to assess phenotype of cell subsets cells were harvested, counted and 5 x 10e5 cells filled 
in a 5 mL FACS tube. Cells were washed once with 1.5 mL CellWASH by spinning down at 353 g for 
5 min at 4 °C. Then, supernatant was discarded completely and cells stained for 15 min at 4 °C in 
the dark in a volume of 50 µL FACS Staining buffer containing 1 µL of Fc-Block (CD16/CD32) and 
0.8 µL of further denoted antibodies. Afterwards, cells were washed again with 1.5 mL CellWASH 
and finally spun down at 353 g for 5 min at 4 °C. At last, supernatant was discarded and cells sus-
pended in either 200 µL of CellWASH or 200 µL Cell Fix when performing flow cytometric analysis 
on the same day or within the next week, respectively.
2.3.1.2.   Intracellular Cytokine Staining using Cytofix/Cytoperm Kit
Production of intracellular IFN-γ by specific antigen-experienced CD8+cytotoxic T cells was detect-
ed by flow cytometry analysis upon re-stimulation of purifed lymphocytes of vaccinated animals 
with the same peptide. Therefore, spleens from vaccinated mice or control animals were dissected 
and lymphocytes purified by density-gradient centrifugation (see section 2.2.5.3.). When neces-
sary lysis of erythrocytes was performed additionally (see section 2.2.5.6.). Cells were counted, 
suspended at 1 x 10e6 cells/mL in Feeder cell Standard Medium and handled on ice thereafter.
Stimulation with PMA and Ionomycin:
In vitro stimulation with PMA and Ionomycin served as positive control. 1 mL of cell suspension 
was filled into a sterile 5 mL FACS tube and stimulated with 10 ng/ml of PMA and 500 ng/ml of 
Ionomycin and incubated for 4 hours at 37 °C and 5 % CO
2
. 
Stimulation with peptide corresponding to immunization:
1 mL of cell suspension was filled into a sterile 5 mL FACS tube and stimulated with 10 µM of cor-
responding peptide and incubated for 4 hours at 37 °C and 5 % CO
2
. 
After 1 hour of stimulation with either PMA/Ionomycin or peptide or control incubation was in-
terrupted for addition of 0.66 µl Golgi-Stop per 1 x 106 cells. Then, cells were spun down at 353 g 
for 5 min at 4 °C and stained for expression of surface markers. Therefore, 2 µL of the follow-
ing antibodies were added: CD4-PE-Cy7, CD8-PerCP, CD25-APC and CD69-PE (see section 2.2.8.1.). 
Upon surface staining cells were washed with 3 mL of FACS buffer and supernatant discarded 
completely by stripping it off over a tissue. 
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Fixation and Permeabilization of cells using Cytofix / Cytoperm Kit:
In order to fix surface stains on cells during further staining procedure, cells were vortexed thor-
oughly and suspended in 250 µL of Cytofix/Cytoperm solution by pipetting up and down. Cells 
were fixed by incubation for 20 min on ice in the dark.  Then, fixed cells were washed with 3 mL of 
FACS buffer and suspended in 1 mL of FACS buffer for overnight storage at 4 °C in the refrigerator.
The next day fixed cells were spun down and supernatant discarded completely by stripping it off 
over a tissue. In order to permeabilize cells, they were vortexed thoroughly and suspended in 500 µL 
of 1x Perm/Wash solution by pipetting up and down. Cells were permeabilized by incubation for 
10 min on ice in the dark. Then permeabilized cells were spun down and supernatant discarded 
completely by stripping it off over a tissue.
Intracellular staining:
Intracellular staining of fixed and permeabilized cells was performed by thoroughly suspend-
ing cells in 200 µL of 1x Perm/Wash solution containing 0.25 µg of PE-labelled IFN-γ antibody 
or matched isotype control. Cells were incubated for 30 min on ice in the dark. Finally, cells were 
washed two times with 3 ml 1x Perm/Wash solution, suspended in 250 µl of 1x Perm/Wash so-
lution and analysed by flow cytometry immediately after. Frequencies of IFN-γ positive CD8+ T 
cells were determined by using FlowJo software and mean values calculated from animals treated 
identical. Bar charts were plotted from mean values of frequencies of IFN-γ positive CD8+ T cells re-
stimulated with peptide normalized to corresponding un-stimulated sample of the same animal.
2.3.2.   Mixed Lymphocyte Reaction (MLR)
In order to study the APC capacity of mCD40B and mDC antigen-unspecific allogeneic Mixed Lym-
phocyte Reactions were performed based on the induction of T-cell responses by TCR signalling 
through binding of alloantigen-MHC complex and T-cell activation through co-stimulation by 
APCs.
2.3.2.1.   CFSE-labelling of CD3+ T cells
Prior to MLR CD3+ T cells were purified from spleen of naïve BALB/c wild type mice (MHC haplotype 
d) (see section 2.2.5.4.) and stained with fluorescent proliferation marker CFSE. Therefore, CD3+ T 
cells were suspended in a 50 mL tube at 100 x 10e6 cells/mL in 1x PBS with 5 % FBS and stained 
by addition of 10 µM CFSE in PBS. Cells were mixed and stained uniformly by agitating the tube 
constantly for 5 min in the dark. To stop staining reaction 5 mL pure FBS were added and CFSE-
labelled T cells were spun down at 265 g for 5 min. Then, CFSE-labelled T cells were washed twice 
with Feeder Cell Standard Medium and separated in two fractions. One fraction was suspended at 
1 x 10e6 cells / mL and plated in triplicates of 100 µL for APC-to-T cell ratios 1:1, 1:10, 1:20, 1:50, 
1:100, the other one was suspended at 5 x 10e5 and plated in triplicates of 100 µL for the APC-
to-T cell ratio 3:1 onto a 96-well plate. One triplicate was plated with plain Feeder Cell Standard 
Medium for the APC-to-T cell ratio 0:1. 
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2.3.2.2.   Irradiation and serial dilution of APCs
To measure the dynamics of the allogeneic T-cell response T cells were cultivated together with 
DC LPS, DC aCD40Ab, mCD40B d14 or mCD40B d7 at the various APC-to-T cell ratios. Therefore, 
mCD40B and mDC from C57BL/6 wild type mice (MHC haplotype b) where generated suspended 
at 1 x 10e6 cells/mL in Feeder Cell Standard Medium and irradiated once with 26 Gy to stop them 
from proliferation. Upon irradiation serial dilution was performed for the indicated APC-to-T cell 
ratios and 100 µL plated onto T cells. Cells were kept at 37 °C and 5 % CO
2
 for 5 days.
2.3.2.3.   Flow cytometric analysis of T-cell divisions
CFSE segregated equally between daughter cells upon cell division, resulting in the sequential 
halving of cellular fluorescence intensity with each successive generation. When analyzed by 
flow cytometry, this sequential halving of fluorescence was visualized as distinct peaks in the 
histogram. After 5 days of co-cultivation cells were harvested and stained with the following an-
tibodies: CD3-APC-Cy7, CD4-PE-Cy7, CD8-PerCP, CD25-APC and CD69-PE (see section 2.3.1.1.). The 
frequencies of proliferating CD3+CD25+CFSElowCD4+ and CD3+CD25+CFSElowCD8+ T cell subsets was 
determined by flow cytometry immediately after. In order to plot bar charts mean values were 
calculated and normalized to intrinsic T cell activity as determined by APC-to-T cell ratio 0:1. 
2.4. In vivo Experiments
2.4.1.   Mouse strains
Table 20: Used Mouse Strains
Name Haplotype Supplier
BALB/c H2^d Harlan
C57BL/6N H2^b Charles River
OT-I H2^b PD Dr. med.  F. Tacke, PhD
2.4.2.   Breeding and Handling of mice
The experiments were performed in accordance with the national and European guidelines for 
laboratory animal keeping with permissions from the local government authorities (permission 
numbers 8.87-50-203.2-K 17, 16/05 and 8.87-51.04.20.09.369). Referring the German animal 
welfare law the animals were controlled regularly by the proper authorities.
Mice were offspring from breeding pairs originally obtained from suppliers see table 1.3.1. TCR-
transgenic OT-I mice were kindly provided by PD Dr. Frank Tacke (University Hospital Aachen, Ger-
many). OT-I mice were routinely monitored for expression of TCR-chain Vβ5 on CD3+CD8+ T cells 
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and expressed TCR-chain Vβ5 in more than 90 % of all CD3+CD8+ T cells. 
All mice were housed under specific pathogen-free conditions and used at 8 to 12 weeks of age. 
In order to dissect organs for further analysis or preparation of single-cell suspensions mice were 
sacrificed by cervical dislocation.
2.4.3.   Toxicity of mCD40B
2.4.3.1.   Cell transfer and schedule 
In order to assess secondary immunological effects of adoptive mCD40B cell transfer C57BL/6 
mice were challenged with pure mCD40B d14 suspended in 1x PBS. Generation of mCD40B cells 
was done from spleens of C57BL/6 mice (see section 2.2.6.) and cells routinely analysed by FACS. 
Highly activated > 90 % pure CD19+CD3- mCD40B cells were harvested and thoroughly washed 
in excess of 1x PBS for 3 times by spinning down at 265 g for 5 min at 4 °C. Cells were filtered 
through a 100 µm cell strainer and separated into two fractions. One fraction was suspended at 
1 x 10e7 cell/mL, the other one was suspended at 1 x 10e8 cells/mL and kept on ice until injec-
tion. To address long-term toxicity 1 x 10e6 mCD40B cells were injected two times a week for five 
weeks. Acute toxicity was assessed by injecting mice once with 1 x 10e7 mCD40B cells. Matched 
groups of mice received PBS buffer only serving as negative control. Injections of 100 µL were per-
formed in three different routes: intraperitoneal injection, intravenous injection into lateral vein 
and subcutaneous injection into the right flank. 
2.4.3.2.   Assessment of Behaviour and Weight
The following five weeks mice were observed for clinical symptoms and changes in behaviour 
such as reduced food and water intake, reduced activity, aggressiveness, difficulties of breathing 
and moving, increased body temperature and abnormal body posture. After five weeks of obser-
vation mice were sacrificed by cervical dislocation, weighed and organs dissected and stored in 
mCD40B Washing Medium on ice until further analysis. 
2.4.3.3.   Hematoxylin and Eosin staining procedure
Microscopy was performed at the former laboratory of PD Dr. Claudia Wickenhauser (Institute for 
Pathology, University Hospital of Cologne). H & E Staining was performed by the technician Silke 
Kummer.
For standard histo-chemical staining, paraffin-embedded tissues (heart, lung, liver, kidney and 
spleen) were sectioned (5 µm). First, samples were deparaffinized with xylene (Merck) twice, each 
10 min, and rehydrated in descending ethanol series (100, 100, 96, 70, 50), each 5 min. Second, 
samples were washed with distilled water. Third, samples were stained in Mayer’s hematoxylin 
solution (Merck) for 3 min. Fourth, samples were washed in running tap water and subsequently 
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washed with distilled water. Fifth, samples were counterstained with eosin 1 % (w/v) solution 
aqueous (Merck) for 3 min. Sixth, samples were dehydrated in ascending ethanol series, each 
5 min. Finally, samples were mounted in Pertex (Medite, Burgdorf, Germany).
2.4.3.4.   Histo-pathological analysis
Samples were analyzed with an Aristoplan Microscope under supervision of C. Wickenhauser. 
Histo-pathological analysis was performed by completely screening of three non-consecutive his-
tological sections of each organ. If present lymphocytic infiltrates were counted. For semi-quan-
titative analysis mean values of four independent experiments were calculated and assigned to 
one of three categories: o  no infiltrate, +  few lymphocytic infiltrates (1 ≤ x ≤ 3)  or ++  several 
lymphocytic infiltrates (4 ≤ x ≤ 8).
2.4.3.5.   Assessment of Lymphocytic subsets in Lymph nodes and 
Spleen
In order to assess the distribution of lymphocytic subsets in mesenteric and inguinal lymph nodes 
and spleen lymphocytes were enriched and stained for flow cytometric analysis (see sections 
2.2.5.2., 2.2.5.3. and 2.3.1.1.). 
Therefore, lymph nodes and spleen were dissected and single cell suspensions prepared. Aliquots 
of cells were stained with following antibodies: B220-FITC, CD3-APC-Cy7, CD4-PE-Cy7 and CD8-
PerCP or matched isotype controls and analysed by flow cytometry.
2.4.4.   Vaccination Strategies
2.4.4.1.   Immunization with Peptide-loaded Cell Subsets
In order to immunize C57BL/6 or OT-I mice with mCD40B or mDC subsets, cells subsets gener-
ated from syngeneic mice were exogenously loaded with indicated peptide. Therefore, freshly pre-
pared mCD40B or mDC subsets of given time points or thawed mCD40B subsets that had been co-
cultivated for at least one cultivation period of 3-4 days were harvested and washed three times 
with excess of 1x PBS by spinning down at 265 g for 5 min at 4 °C. Cell subsets were suspended in 
serum-free AIM V Medium at 1 x 10e6 cells/ml and filled in 50 mL tube. After addition of 10 µM 
peptide the cells were incubated for three hours at 37 °C and 5 % CO
2
. Before injection cells were 
washed three times with 20 mL of 1x PBS, filtered through a 100 µM cell strainer, suspended and 
slowly injected in 100 µL of 1x PBS. Irradiation of indicated mCD40B subsets was performed with 
26 Gy for one time.
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Table 21: Varying Parameters of Immunizations with mCD40B
Vaccination Parameter Varying Attribute
route of administration
intraperitoneal
intravenous (lateral vein)
subcutaneous (right flank)
cell dose in 100 µL
1 x 10e5
1 x 10e6
1 x 10e7
vaccination interval
day 0 – 7
day 0 – 7 – 14 
mCD40B formulation
mCD40B d7
mCD40B d14
irradiated mCD40B (mCD40B irr)
Peptide-pulsed mDC were injected subcutaneously into the right flank.
2.4.4.2.   Immunization with Incomplete Freund´s Adjuvant (IFA)
Immunizations with 100 µL of IFA/peptide emulsions served as positive control. Herein, the fi-
nal concentration of peptide per injection amounted to 20 µM. Immunomodulatory CpG-ODN 
(oligodeoxynucleotide with non-methylated cytosine-guanine motifs) with a double stem-loop 
structure (D-SLIM) were kindly provided by Mologen AG, Berlin. All solutions were always handled 
on ice.
In order to prepare the IFA/peptide emulsion sufficient for two injections 50 µL of peptide was 
mixed with 50 µg (17.5 µL) of CpG D-SLIM and adjusted to 250 µL by addition of 182.5 µL 1x PBS, 
first. Second, 250 µL of IFA were added to the peptide solution and an emulsion formed by strong 
vortexing for 3 min at 4 °C. Resulting IFA/peptide emulsion was set aside on ice. When result-
ing emulsion remained in phase syringes were drawn up and used for immunizations. Otherwise 
vortexing was repeated. Transfer of emulsion into syringes was carried out without attaching the 
needle to the syringe. This was done immediately prior to injection. Immunizations with IFA/pep-
tide emulsions were injected subcutaneously into the right flank on day 0 and day 7.
2.4.5.   In vivo Cytotoxicity Assay
The in vivo cytotoxicity assay aims at detection of in vivo killing of antigen-specific target cells 
by recognition through cognate CD8+ cytotoxic T cells induced by immunization. Hence, three to 
four days after the last vaccination mice were injected with CFSE-labelled target cells from naïve 
syngeneic mice loaded with peptide corresponding to immunization. 
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2.4.5.1.   Injection of Target cells
Target cell were prepared from single-cell suspension of spleens (see section 2.2.5.3.). When nec-
essary lysis of erythrocytes was performed additionally (see section 2.2.5.6.). Splenocytes were 
washed two times with 10 mL of 1x PBS by spinning down at 265 g for 5 min at 4 °C, suspended 
in 10 mL of 1x PBS and counted. In order to label with CFSE splenocyte suspension was adjusted 
to 100 x 10e6 cells/mL in 1x PBS + 5 % FBS and separated into two equal fractions. One fraction 
was labelled with low amount of CFSE (2 µM), one with high amount (20 µM) by adding CFSE and 
constantly agitating the tube for 5 min in the dark. To stop staining reaction 5 mL pure FBS were 
added and CFSE-labelled target fractions were spun down at 265 g for 5 min. Then, target cells 
were suspended in 10 mL of 1x PBS and counted. Cells were adjusted to 1 x 10e7 cells/mL in AIM-V 
Medium for peptide pulsing. The CFSE high fraction (20 µM) was pulsed with 10 µM of peptide 
corresponding to immunization, the CFSE low fraction (2 µM) left unpulsed. Upon incubation for 
one hour at 37 °C and 5 % CO
2
 both fractions were washed extensively with 20 mL of 1x PBS for 
three times, filtered through a 100 µm cell strainer, counted and suspended at 10 x 10e7 cells/mL 
in 1x PBS. Both fractions were mixed 1-to-1 and 100 µL drawn up per syringe for intraperitoneal 
injection.
2.4.5.2.   Detection of Specific Cytolysis by FACS
In order to analyse remaining CFSE-positive target cell fractions from spleens of immunized mice, 
mice were sacrificed 16-40 hours after target cell injection by cervical dislocation. Then, spleens 
were dissected, minced through a 100 µM cell strainer and suspended in mCD40B Washing Me-
dium. Cells were handled on ice and in the dark thereafter. Splenocytes were counted immediately 
after. For flow cytometric analysis 4 x 10e6 cells were filled in a FACS tube, washed, blocked with 4 
µL of Fc-Block (CD16/CD32) and labelled with 3 µL of the following antibodies:  CD3-APC-Cy7 and 
CD19-PE-Cy7 for 15 min on ice in the dark. Cells were analysed by FACS immediately. Frequencies 
of CFSE-positive fractions were determined by using FlowJo software. Unloaded CFSE low spleno-
cytes served as reference. Specific killing of the peptide-loaded CFSE high target cell fraction was 
determined by calculating the reciprocal value of the ratio of the frequencies of CFSE high and 
CFSE low fractions of immunized mice and PBS-injected naïve mice. In order to plot bar charts of 
specific lysis mean values of frequencies normalized to negative control were calculated.
2.4.6.   Tumour Formation
Vaccinations were performed according protocol section 2.4.4.1. with minor modifications. In 
order to examine the effect of preventive vaccinations with mCD40B on inducing anti-tumour 
responses, C57BL/6 mice were vaccinated with indicated doses of Trp-2-loaded mCD40B d14 in-
jected intraperitoneally for three times in a seven day interval. Alternatively, mice were vaccinated 
with indicated dose of DC LPS or DC aCD40Ab pulsed with Trp-2 peptide injected subcutaneously 
into the left flank. Administration of PBS alone (NC) or mCD40B left unpulsed (mCD40B d14-) in-
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jected intraperitoneally served as negative controls.
Seven days after the last vaccination B16.F10 tumour cells were prepared for inoculation. There-
fore, adherent B16.F10 cells were trypsinized (see section 2.2.4.2.), washed two times with 1x PBS 
in excess, filtered through a 100 µM cell strainer and counted. For tumour inoculation B16.F10 
cells were suspended at 1 x 10e7 cells/mL in 1x PBS and injected subcutaneously into the right 
flank. Tumour size was determined daily until day 13 after inoculation by measuring tumour di-
ameter in three dimensions using a vernier calliper. Tumour volume was calculated by multiplying 
single diameters [mm3]. In order to plot growth curves mean values of diameters were calculated. 
2.5. Statistics
Significant differences were calculated by the Student’s t -test for paired data. P-values of 
less than 0.05 were considered statistically significant and marked with asterisks: * p ≤ 0.05, 
** p ≤ 0.01, *** p ≤ 0.001. Mean values and standard deviations (SD) were calculated from at least 
3 experiments with at least three batches per group.
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3. RESULTS
3.1. Generation of murine CD40-activated B cells
To develop a model to study B cells as antigen-presenting cells in vivo an in vitro culture system 
to  generate murine CD40-activated B cells was established in close collaboration with Nela 
Klein-Gonzáles. 
This in vitro culture system is based on a cultivation technique initially developed by Dr. J. 
Banchereau in the early 90s, allowing the long-term growth of human B lymphocytes through en-
gagement of the CD40 receptor by monoclonal antibodies and IL-4 signalling (Banchereau et al., 
1991 194). Later, in the mid 90s Dr. L. M. Nadler and J. S. Schultze elaborated the system (Schultze 
et al., 1997 113) by co-culturing peripheral blood mononuclear cells with irradiated CD40L trans-
fected feeder cells (thuCD40L NIH3T3) in the presence of IL-4 and cyclosporin A. Thus > 80% pure 
CD19+ CD3- activated human B cells were generated. These strongly proliferating cells termed 
“human CD40-activated B cells” expressed high levels of co-stimulatory, MHC and adhesion mol-
ecules. Compared to dendritic cells CD40-Bs were likewise highly efficient alloantigen-presenting 
cells inducing significant T cell proliferation and IFN-γ production in vitro. 
3.1.1.   Establishment of effective murine CD40B culture conditions
In order to assess the function of mCD40B as antigen-presenting cells for adoptive immunothera-
py, we established the murine in vitro culture. From the human system we had learned that the 
key proliferation signals would be triggered by CD40 stimulus, IL-4 signalling and the selection 
of applicable additives and cell culture media (Liebig et al., 2009 215). C57BL/6 (MHC haplotype 
b) wild type mice were chosen as model strain as it is the most widely used mouse inbred strain, 
robust and easy to breed. With the spleen being the biggest lymphocyte reservoir in mouse lym-
phocytes were isolated from it by density gradient centrifugation with specific mouse Pancoll®. 
Purified lymphocytes were co-cultivated with irradiated murine CD40L expressing feeder cells 
(tmuCD40L HeLa) providing the CD40 signal. CD40 stimulus and additives, namely recombinant 
murine IL-4, ß -mercaptoethanol (ß-ME) and CsA were replenished every 3-4 days. 
Quantitative analysis of B-cell proliferation was performed by determining the number of viable 
cells in each culture using the trypan blue exclusion test and a light optical microscope. Purity was 
assessed by flow cytometric analysis of the CD19+ CD3- B cell subset in the cultures. To study the B 
cell activation status the expression levels of MHC (I-Ab and H-2Db) and co-stimulatory molecules 
(CD80 and CD86) were determined. Furthermore up-regulation of adhesion molecules resulting in 
the morphologic typical formation of homotypic cell clusters was photographically documented.
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3.1.1.1.   CD40 ligation
The B-cell stimulation system is based on the CD40 receptor – CD40-Ligand (CD40 – CD40L) in-
teraction. CD40 – CD40L interaction naturally occurs when activated CD4+ T cells recognize pep-
tide presented by MHC Class-II on B cells, leading to various effects on both interaction sides 
(Banchereau et al., 1994 166; Foy et al., 1996 167; Van Kooten et al., 1996 169). On the B cell´s 
side CD40-activation drives antigen-specific B cells through their differentiation program and pre-
vents the terminal differentiation of activated mature B cells into plasma cells and rescues them 
from apoptosis. In addition, CD40 activation directly up-regulates cytokine production (IL-6, IL-10, 
TNF-α, LT-a), expression of adhesion molecules and co-stimulatory receptors (ICAM, CD23, B7.1/
CD80, B7.2/CD86) and increases expression of MHC Class-I, MHC Class-II and TAP transporter by 
B lymphocytes. 
As no GMP-grade soluble CD40L with adequate activating and proliferating capacity has been 
available so far, CD40 activation of B cells was assured by using irradiated recombinant murine 
CD40 ligand expressing feeder cells (tmuCD40L HeLa) which were kindly provided by Dr. Clemens 
Wendtner (Mayr et al., 2006 216). HeLa wild type cells served as negative control. 
To avoid contamination with non-transfected cells expression of the murine CD40 ligand 
(muCD40L, CD154) on the transfectants was controlled by flow cytometry regularly. Viable HeLa 
wild type cells (figure 5A) showed no expression of the ligand (figure 5B) whereas tmuCD40L HeLa 
transfectants stably expressed CD154 (figures C and D, respectively). (Mean values of fluorescence 
intensity gated on viable (FSC vs. SSC) cells ± standard deviation (SD); 5B) HeLa wild type 0.38 ± 0.08, 
n=4, p < 0.001 and 1D) tmuCD40L HeLa 47.09 ± 8.82, n=8, p < 0.001).
Figure 5:  Phenotype of 
HeLa wild type cells (A, B) 
and tmuCD40L HeLa cells 
(C, D)
Phenotype of HeLa cells was 
regularly controlled by flow 
cytometry prior to using them 
as feeder cells for murine 
CD40B culture. (A and C) Vi-
able cells were identified by 
gating FSC vs. SSC. (B and D) 
Expression of CD40L (CD154) 
was determined in histogram 
overlays. Histograms in dark 
grey represent isotype con-
trols, thick black lines stain-
ing with specific antibody 
anti-mouse CD154-PE. 
(One representative FACS analysis is shown.)
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When splenocytes from C57/BL6 mice were co-cultivated with HeLa wild type cells no prolifera-
tion of B cells occurred (figure 6A) whereas murine CD40-activated B cells (mCD40B) proliferated 
intensively when grown on tmuCD40L HeLa cells (figure 6B). After 14 days of cultivation the rela-
tive growth rate of mCD40B was thereby increased on an average 2.6 fold ranging from 1.4 to 4.85 
(n=10). Similarly, when splenocytes were cultivated with tmuCD40L HeLa cells mCD40B formed 
homotypic cell clusters (figure 6D) whereas on Hela wild type cells the cluster formation was in-
hibited (figure 6C).
Figure 6:  Proliferation and cluster formation of mCD40B cells is dependent on muCD40L 
expression of HeLa cells  
(A and B) The number of viable mCD40B cells was determined every 3-4 days using the trypan blue exclu-
sion test. Until day 14 of culture the relative growth was assessed by calculating the relative increase be-
tween two passages of mCD40B cultures grown on HeLa wild type cells (A) or on tmuCD40L HeLa cells (B). 
(Growth curves of 10 independently grown mCD40B cultures are shown.)
(C and D) Photographs were taken at a 5 x magnification using a light optical micro-
scope fitted with a digital camera and formation of homotypic B-cell clusters docu-
mented using HeLa wild type cells (C) or tmuCD40L HeLa cells (D) as feeder cells. 
(One representative picture of at least 10 independent cultures is shown.)
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Flow cytometric analysis revealed that the splenocyte suspension initially consisted of 49.3 ± 5.7 % 
CD19+ B cells and 37 ± 8.2 % CD3+ T cells (mean value ± SD, n=5). During the course of 14 days the 
mean frequency of CD19+ B cells grown on tmuCD40L HeLa was highly increased to 89.1 ± 4.7 % 
and 92.7 ± 3.0 % whereas only a small proportion of CD3+ T cells of 6.9 ± 1.8 % and 2.8 ± 2 % 
remained in the culture on day 7 and day 14, respectively (figure 7A-C). Furthermore analysis of 
the activation status of CD19+ CD3- mCD40B over the course of the culture showed a consistent 
up-regulation of the expression levels of MHC molecules I-Ab and H-2Db (figure 7D, E). A similar 
effect was observed for the expression levels of co-stimulatory molecules CD80 and CD86 (figure 
7F, G) exclusively when B cells were cultivated with tmuCD40L HeLa cells. Therefore, tmuCD40L 
HeLa were used for generation of murine CD40 activated B cells. 
Figure 7:  High purity 
and activated phenotype 
of mCD40B grown on 
tmuCD40L HeLa 
Assessment of mCD40B 
cell phenotype grown on 
tmuCD40L HeLa cells dur-
ing time course was done by 
FACS analysis on day 0, day 
7 and day 14 of culture. B 
cell purity was determined 
by gating for the CD19+ 
CD3- population (A-C). 
Activation status was 
documented by analys-
ing the expression of 
MHC molecules Class-I 
(H-2Db) and Class-II (I-Ab) (D and E) and the expression of co-stimulatory molecules CD80, CD86 (F, 
G). Histograms shaded in dark gray represent the isotype controls; lines in light grey stand for spe-
cific antibody staining on day 0, line in dark grey on day 7 and black lines represent day 14. 
(One representative experiment out of 5 is shown.)
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3.1.1.2.   Interleukin-4 signalling
Second, the optimal interleukin-4 (IL-4) concentration applied to co-stimulate murine B cells was 
determined. IL-4 belongs to the haematopoietic growth factor receptor (HGFR) family and is nat-
urally produced by T
H
2 cells, thus providing efficient helper activity for B cells. IL-4 has a wide 
range of activating effects on B cells such as up-regulation of MHC Class-II expression, induction 
of proliferation and differentiation of activated B cells as well as regulation of immunoglobulin 
(Ig) isotype production (Mosmann et al., 1998 217). One common feature of cytokines is their 
activity at low concentrations. Due to this reason and following the human system for generation 
of CD40-activated B cells five different IL-4 concentrations [0, 0.2, 0.5, 1 and 2 U/mL] were tested 
in the murine system to find effective culture conditions. 
When splenocytes from C57/BL6 mice were cultivated with tmuCD40L HeLa cells and treated 
with 0, 0.2 and 0.5 U/mL IL-4 no proliferation of B cells during 14 days of culture occurred (figure 
8; black, red and green line, respectively), whereas an initial increase until day 7 of culture was 
found when murine CD40-activated B cells (mCD40B) were cultivated with 2 U/mL IL-4 (blue line). 
Best proliferation of mCD40B was obtained when cultivated with 1 U/mL IL-4 (yellow line). After 
14 days of culture the relative growth rate of mCD40B was thereby significantly increased 2.8 fold 
ranging from 1.7 to 4.4 (p ≤ 0.05, n = 8).
Figure 8:  mCD40B growth is dependent on IL-4 supplementation
Starting with C57BL/6 splenocytes 
on irradiated CD40L-expressing 
feeder cells tmuCD40L-HeLa 
mCD40B cells were grown in 5 differ-
ent concentrations of IL-4 depicted 
by different coloured lines: 
[0 U/mL] - black line  
[0.2 U/mL] - red line  
[0.5 U/mL] - green line   
[2 U/mL] - blue line  
[1 U/mL] - yellow line
(One representative experi-
ment of 8 is shown.)
Similarly, when splenocytes were cultivated with tmuCD40L HeLa cells with different concentra-
tions of IL-4, arrangement of homotypic cell clusters varied from few small clusters in cultures 
with no IL-4 (figure 9A) to frayed, dissociated clusters with the concentrations 0.2, 0.5 and 2 U/mL 
IL-4 (figures 9B, C and E, respectively). In contrast, big, round and circular clusters were observed in 
mCD40B cultures with 1 U/mL IL-4 (figure 9D). 
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9A B
Figure 9:  Cluster formation of mCD40B cells is dependent on IL-4 supplementation
Photographs were taken at a 5 x magnification. Formation of homotypic B-cell clusters varies upon 
IL-4 treatment: omission of IL-4 (A) and treatment with 0.2, 0.5, 1.0 and 2.0 U/mL IL-4 (B, C, D and E).
(One representative picture of at least 8 independent cultures is shown.)
Analysis of the proportions of CD19+ B cells and CD3+ T cells during culture on day 0, day 7 and day 
14 by flow cytometry revealed that varying concentrations of IL-4 [0, 0.2, 0.5, 1 and 2 U/mL] had no 
significant effect on purity of cultures. All cultures revealed a purity of the CD19+ CD3- population 
of ≥ 90 % independent from IL-4 treatment. (One representative test series of at least 8 is shown 
in figure 10A-K). Surprisingly, although omitting IL-4 addition during 14 days of culture a high 
number of enriched cells were CD19+ B cells (93.5 ± 2.4 %, n=8). 
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Figure 10:  Purity of 
mCD40B cells is inde-
pendent from treat-
ment with different  
wIL-4 concentrations
(A-K) Assessment of phe-
notype of mCD40B cells 
grown on tmuCD40L HeLa 
cells treated with different 
IL-4 concentrations was 
done by FACS analysis on 
day 0, day 7 and day 14 of 
culture. B cell purity was 
determined by gating for 
the CD19+ CD3- population.
(One representative experi-
ment out of 8 is shown.)
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Similarly examination of the activation status revealed a consistent up-regulation of MHC mol-
ecules I-Ab and H-Db, and co-stimulatory molecules CD80 and CD86 which was also independent 
from the concentration of IL-4. (One representative test series of at least 8 is shown in figure 11A-
D, 12A-D, 13A-D, 14A-D, 15A-D). 
As mCD40B cultures with 1 U/mL IL-4 had a significantly increased proliferation rate and formed 
big, encircled cell clusters this concentration was chosen for further mCD40B cultures. 
Figure 11:  Activation sta-
tus of mCD40B without 
IL-4 treatment
Phenotypical FACS analysis 
was performed assessing the 
expression of MHC molecules 
Class-I (H-2Db) and Class-II 
(I-Ab) and the expression of co-
stimulatory molecules CD80, 
CD86 on CD19+ CD3- mCD40B 
cells treated with different con-
centrations of IL-4:  
[0 U/mL] - (11A-D)  
[0.2 U/mL] - (12A-D)  
[0.5 U/mL] - (13A-D)  
[1 U/mL] - (14A-D)  
[2 U/mL] - (15A-D) 
Histograms shaded in dark gray represent the isotype controls; 
lines in light grey stand for specific antibody staining on day 
0, line in dark grey on day 7 and black lines represent day 14. 
(One representative experiment out of 8 is shown.)
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Figure 12:  Activation 
status of mCD40B with 
0.2 U/mL IL-4
Figure 13:  Activation 
status of mCD40B with 
0.5 U/mL IL-4
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Figure 14:  Activation 
status of mCD40B with 
1.0 U/mL IL-4
Figure 15:  Activation 
status of mCD40B with 
2.0 U/mL IL-4
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3.1.1.3.   ß - Mercaptoethanol supplementation
Third, the optimal concentration of ß-mercaptoethanol (ß-ME) was identified. ß-ME is preferen-
tially used as antioxidant in cell culture and is known to stimulate growth and differentiation of 
murine cells. Therefore four different concentrations [0, 50, 100 and 200 µM/mL] were tested.  
When mCD40B culture was conducted and ß-ME was omitted from the culture medium no du-
rable B-cell proliferation was observed (figure 16; black line). Treatment with 50 µM mL ß-ME 
resulted in a medium proliferation of B cells until day 11 decreasing after further cultivation (red 
line). Similarly, when mCD40B culture was supplemented with 200 µM/mL ß-ME an initial in-
crease until day 7 of culture was found which was not sustainable thereafter (yellow line). Best 
proliferation of mCD40B was obtained when cultivated with 100 µM/mL ß-ME (green line). Af-
ter 14 days of culture the relative growth rate of mCD40B was thereby significantly increased 
2.95 fold ranging from 1.9 to 3.7 (p ≤ 0.05, n = 8).
Figure 16:  Proliferation of mCD40B 
cultures is dependent on ß-ME 
supplementation
The number of viable mCD40B cells in mCD40B 
cultures treated with 4 different concentrations of 
ß-ME was determined until day 14 of culture: 
[0 µM/mL] - black line  
[50 µM/mL] - red line  
[100 µM/mL] - green line  
[200 µM/mL] - yellow line
(One representative of at least 8 experiments is shown.)
Cluster formation was prevented when omitting ß-ME from mCD40B culture medium (figure 17A) 
whereas few frayed and dissociated clusters were observed with 50 and 200 µM/mL ß-ME (figures 
17B and D, respectively). Most consistent clusters were found with supplementation of 100 µM/
mL culture medium (figure 17C).
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Figure 17:  Cluster formation of mCD40B cells is dependent on ß-ME supplementation
Photographs were taken at a 5x magnification and B-cell cluster formation documented after treatment 
with 4 different ß-ME concentrations:
[0 µM/mL] - (17A) [50 µM/mL] - (17B) [100 µM/mL] - (17C) [200 µM/mL] - (17D)
(One representative picture of at least 8 independent cultures is shown.)
Flow cytometric analysis of the proportions of CD19+ B cells and CD3+ T cells in mCD40B cultures 
with altering concentrations of ß-ME showed that leaving out ß-ME or supplementing culture 
with 200 µM / mL resulted in lower CD19+ proportions (85.3 ± 3.6 % and 87.1 ± 2.7 %, respectively, 
n = 8). In cultures  with 50 or 100 µM /mL ß-ME significantly higher proportions of CD19+ mCD40B 
cells were found after 14 days (97.1 ± 1.3 % and 97.4 ± 1.5 %, respectively, p ≤ 0.01, n = 8). (One 
representative test series of at least 8 is shown in figure 18 A-I; see also next page).
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Figure 18:  Purity of mCD40B cells is reliant on ß-ME 
supplementation
Assessment of the proportion of CD19+ CD3- B cells in mCD40B cul-
tures supplemented with 4 different concentrations of ß-ME on day 
0, day 7 and day 14 of culture by  flow cytometry:  
[0 µM/mL] - (18A-C)  
[50 µM/mL] - (18D, E)  
[100 µM/mL] - (18F, G)  
[200 µM/mL] - (18 H,I)
(One representative experiment out of 8 is shown.)
Dependent upon ß-ME supplementation the expression of MHC molecules and co-stimulatory 
molecules varies. The activation status of mCD40B cultivated without ß-ME or with 200 µM / mL 
was intrinsically lower for MHC molecules I-Ab and H-2Db as well as CD80 and CD86 whereas sup-
plementation with 50 or 100 µM/mL revealed no significant difference. One representative test 
series of at least 8 is shown in figures 19 - 22. 
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Figure 19:  Activation status of mCD40B without ß-ME
Phenotypical FACS analysis was performed assessing the expres-
sion of MHC molecules Class-I (H-2Db) and Class-II (I-Ab) and the 
expression of co-stimulatory molecules CD80, CD86 on CD19+ 
CD3- mCD40B cells treated with different concentrations of ß-ME: 
[0 µM/mL] - (19A-D)  
[50 µM/mL] - (20A-D)  
[100 µM/mL] - (21A-D)  
[200 µM/mL] – (22A-D)
Histograms shaded in dark gray represent the isotype controls; 
lines in light grey stand for specific antibody staining on day 0, 
line in dark grey on day 7 and black lines represent day 14. 
(One representative experiment out of 8 is shown.)
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Figure 20:  Activation 
status of mCD40B with 
50 µM/mL ß-ME 
Figure 21:  Activation 
status of mCD40B with 
100 µM/mL ß-ME
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58RESULTS
Figure 22:  Activation 
status of mCD40B with 
200 µM/mL ß-ME
Due to improved proliferation and consistent clustering 100 µM/mL ß-ME was applied in further 
mCD40B cultures.
3.1.1.4.   Cell culture media
To further optimize mCD40B culture conditions different media for optimal cell nutrition were 
tested. Dulbecco´s modified Eagle´s medium (DMEM) is the most frequently used classical basal 
medium suitable for a wide spectrum of mammalian cells. In particular primary and secondary 
murine cells and highly proliferating cell cultures are fed with this medium containing vitamins, 
amino acids and high glucose concentration. 
Iscove´s Modified Dulbecco´s Medium (IMDM) is a completely defined variant of DMEM, includ-
ing additional vitamins, amino acids, sodium pyruvate and HEPES buffer to especially support the 
growth of murine B-lymphocytes and rapidly proliferating high-density cell cultures.
DMEM-Ham´s F12 is a 1:1 mixture of DMEM and Ham´s F12 of which the latter was designed for 
cultivation of mammalian primary cells and murine L-cells containing increased concentrations 
of amino acids, vitamins and micronutricients as well as a additional buffering system for higher 
osmotic stability. 
Murine splenocytes cultivated on tmuCD40L HeLa cells were grown in each of the three media 
supplemented with 1 U/mL IL-4 and 100 µM/mL ß-ME as defined before. Cultivation with IMDM 
and DMEM-Ham´s F12 media induced comparably low growth rates ranging from 1.0 to 2.8 and 
from 1.3 to 2.2, respectively (figure 23, red and black lines). In contrast performing mCD40B cul-
ture with DMEM medium resulted in constantly strong proliferation rates ranging from 2.4 to 5.2 
until day 14 of culture (green line). 
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Figure 23:  Proliferation of mCD40B is reli-
ant on cell culture media
Proliferation of mCD40B cells is dependent on the 
selection of cell culture medium: cultivation in 
DMEM medium (green line), IMDM medium (red 
line) or DMEM-Ham´sF12 medium (black line). 
(One representative experi-
ment of at least 3 is shown.)
Considering cluster formation of mCD40B grown in different culture media only slight differences 
were found. Treatment with DMEM medium resulted in the highest density of clusters, which is 
also supported by the highest proliferation rates (figure 24A). Aside from this the use of IMDM 
and DMEM-Ham´s F12 media induced formation of cell clusters which were to some extent frayed 
and dissociated (figures 24B and C, respectively).
Figure 24:  Cluster formation of 
mCD40B cells is dependent on selec-
tion of cell culture medium
Photographs were taken at a 5x magnifica-
tion. B-cell cluster formation is depend-
ent on cell culture medium: cultivation 
in DMEM medium (A), IMDM medium 
(B) and DMEM-Ham´s F12 medium (C). 
(One representative picture of at least 
3 independent cultures is shown.)
60RESULTS
Comparing mCD40B cultures grown in different culture media no significant differences were 
found by flow cytometric analysis. After 14 days of cultivation on tmuCD40L HeLa cells with DMEM 
medium CD19+ CD3- B cells with an average purity of 94.9 ± 3.6 % were generated. By treatment 
with IMDM or DMEM-Ham´s F12 media the B cell proportion was diminished to 93.2 ± 2.8 % and 
92.6 ± 2.7 %, respectively. One representative test series of at least 3 is shown in figure 25 A-G.
Figure 25:  Purity of 
mCD40B cells is de-
pendent on selection of 
cell culture medium 
FACS analysis of the pro-
portion of CD19+ CD3- B 
cells in mCD40B cultures 
grown in different cell cul-
ture media on day 0, day 7 
and day 14 of culture: cul-
tivation in DMEM medium 
(25A-C), IMDM medium 
(25D-E) or DMEM-Ham´s 
F12 medium(25F-G). 
(One representative experiment out of 3 is shown.) 
Evaluation of the activation status showed that there were no significant differences in expres-
sion of MHC molecules I-Ab and H-2Db as well as CD80 and CD86. Only cultivation in IMDM tended 
to result in lower expression levels. One representative test series of at least 3 is shown in figures 
26 - 28. 
Due to increased growth rate as well as slightly augmented purity and activation DMEM medium 
was chosen for further mCD40B cultures. 
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Figure 27:  Activation 
status of mCD40B in 
IMDM medium
Figure 26:  Activation 
status of mCD40B in 
DMEM medium
Phenotypical FACS analysis 
was performed assessing 
the expression of MHC 
molecules Class-I (H-2Db) 
and Class-II (I-Ab) and the 
expression of co-stimula-
tory molecules CD80, CD86 
on CD19+ CD3- mCD40B 
cells cultivated in different 
cell culture media on day 
0, day 7 and day 14 of cell 
culture: DMEM - (26A-D) 
IMDM - (27A-D) DMEM-
Ham´s F12 - (28A-D).
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Figure 28:  Activation 
status of mCD40B in 
DMEM-Ham´s F12 
medium
Histograms shaded in dark gray represent the isotype controls; 
lines in light grey stand for specific antibody staining on day 0, 
line in dark grey on day 7 and black lines represent day 14. 
(One representative experiment out of 3 is shown.)
3.1.2.   Optimized system for generation of CD40-activated B cells 
from C57BL/6 mice
The assessment of the key components to generate effective mCD40B culture conditions resulted 
in following strategy (Liebig et al., 2010 218):
Splenocytes from C57BL/6 mice (8-12 weeks of age) are enriched by density gradient centrifuga-
tion with specific mouse Pancoll. Purified lymphocytes are co-cultivated with adherent irradiated 
murine CD40L expressing feeder cells (tmuCD40L HeLa) providing the CD40 stimulus. The murine 
CD40B culture is performed on 6-well plates in DMEM-Medium supplemented with fresh IL-4 
[1 U/mL], ß-ME [100 µM/mL] and Cyclosporin A (CsA) [0.63 µg/mL]. Every 3 - 4 days the cell sus-
pension is transferred onto fresh irradiated CD40L expressing feeder cells, and cell culture me-
dium and additives are replenished meanwhile (see illustration 29). Until day 14 of culture cell 
cluster formation is induced resulting in typical round CD40B cell cluster due to homotypic aggre-
gation (figure 30A, B).  During time course CD3+ T-cell population is diminished from an average 
30 % to less than 5 % compared to the proliferating CD19+ B-cell population that steadily increases 
to more than 95 % until day 14 of culture representing an average 3.7 fold increase (figure 30C). 
Under these conditions the so-termed “murine CD40-activated B cells” (mCD40B) continuously 
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30A B
up-regulate activation marker CD80, CD86 and MHC molecules I-Ab and H-2Db compared to im-
mature splenocytic B cells (figure 30D). 
Figure 29:  Illustration of the optimized cell culture system for generation of highly activated 
proliferating murine CD40-activated B cells
This optimized cell culture system was established to generate highly activated prolif-
erating murine CD40B cells within 14 days. In brief, splenic lymphocytes from C57BL/6 
mice are enriched and plated onto irradiated tmuCD40L HeLa in DMEM-Medium sup-
plemented with fresh IL-4, ß-ME and CsA. After 3-4 days of co-cultivation feeder cells and 
growth stimuli are replenished leading to an accumulation of murine CD40B cells.
Figure 30:  Characterisation of second generation activated murine CD40B cells 
lymphocyte enrichment
C57BL/6 (8-12 wk)
CD40L stimulus29
mCD40B culture:
start w/ lymphocytes
[1.25x106 cells/mL]
tmuCD40L HeLa:
γ-irradiated (78 Gy) 
[0.4x106 cells/well] 
optimal mCD40B conditions:
DMEM   + IL-4 [1 U/mL]
                 + ß-ME [100 µM/mL] 
                 + CsA [0.63 µg/mL] 
harvest mCD40B
spleen removal repeat mCD40B cultivation:
every 3-4 days w/
 [0.75x106 cells/mL] 
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Photographs were taken at a 5x magnification using a light optical microscope fitted with 
a digital camera. (A) No B-cell clusters on day 0 when splenocytes are plated onto adherent 
muCD40L HeLa compared to (B) formation of typical round clusters after 14 days of culture. 
(One representative photograph of at least 15 independent CD40B-cultures is shown.) 
(C) Using the trypan blue ex-
clusion test the number of 
viable mCD40B cells was de-
termined every re-cultivation 
event and at each point of 
time the relative growth was 
assessed normalising the 
relative growth to the percent-
age of CD3+ and CD19+ cells 
in the culture determined by 
flow cytometric analysis. 
(The growth curve represents 
the relative growth normal-
ised to the fraction of B cells 
and T cells of at least 19 inde-
pendently grown cultures.)
(D) Activation status of 
mCD40B grown in optimal cul-
ture condition was document-
ed by analysing the expression 
of MHC molecules Class-I (H-
2Db) and Class-II (I-Ab) and the 
expression of co-stimulatory 
molecules CD80 and CD86 
on day 0, day 7 and day 14. 
(Mean values of fluorescence 
intensity gated on viable 
CD19+ cells ± SD of at least 
9 experiments is shown.)
For all further experiments mCD40B were generated according to this optimized system, other-
wise marked differently. Every mCD40B culture was routinely checked for proliferation, purity, 
activation status and cluster formation as well. Exclusively cultures comprising highly-activated, 
≥ 90 % pure CD19+ B cells were used. 
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3.2. Characterisation of the immune-stimulatory capacity of 
murine CD40-activated B cells “in vitro”
To study the antigen-presenting function of the above described murine CD40-activated B cells 
their ability to stimulate a proliferative response to allogeneic CD3+ T cells in vitro was initially 
investigated. Here T cell activation is induced via signalling through binding of the T-cell receptor 
to allo-antigens in context of MHC on antigen-presenting cells. For complete activation of T cells 
additional co-stimulatory signals are required which are supplied by interaction of CD28 on T cells 
as well as CD80 (B7-1) and CD86 (B7-2) on APCs (Galvin et. al, 1992 219). This fact is utilized in the 
mixed lymphocyte reaction (MLR) assay (Steinman et al., 1978 220) where the in vitro prolifera-
tion of > 90 % pure negatively selected CD3+ T cells (figure 31A) from BALB/c wild type mice (MHC 
haplotype d) in response to stimulation by mCD40B from C57BL/6 wild type mice (MHC haplotype 
b) was determined. 
Since dendritic cells have long been viewed as the most potent APC due to their ability to induce 
primary immune responses in vivo (Inaba et al., 1990 221) bone marrow-derived DC served as 
alternative source of antigen-presenting cells and as positive control in the MLR. Therefore CD34+ 
bone marrow cells from hind limbs of C57BL/6 wild type mice (MHC haplotype b) were isolated 
(figure 31B) and differentiated in endotoxin-tested medium containing GM-CSF growth factor 
[500 U/mL] (Lutz et al., 1999 222). Mature DCs were generated to assure activation of T cells in the 
MLR and 2 different maturation stimuli namely lipopolysaccharide (LPS), a cell wall component 
of gram-negative bacteria or anti-CD40 antibody were tested to cover the heterogeneity of DC 
subsets (herein after referred to as DC LPS and DC aCD40Ab, respectively). Myeloid-derived DC 
phenotype was controlled by determination of the CD11b+ CD11c+ MHC-IIhigh (I-Ab) population 
(figure 31C and H, respectively). After 24h maturation with LPS [10 ng/mL] or anti-CD40 antibody 
[1 µg/mL] the expression of co-stimulatory molecules CD80, CD86 and CD83 on DC LPS and DC 
aCD40Ab was monitored by flow cytometry (figures 31 D-G and I-L, respectively). 
Figure 31:  Phenotypical analysis of T cells and DC subsets 
induced in allogeneic MLR
(A) T cells for MLR were purified by negative selec-
tion for CD3+ T cells from BALB/c mice and used 
when FACS analysis resulted in purity > 90 %. 
(One representative T-cell enrichment of at least 12 is shown.)
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(B) Myeloid DCs were generated from 75-80 % pure, posi-
tively selected CD34+ bone marrow progenitor cells through 
stimulation with GM-CSF [500 U/mL] for 7 days. 
(One representative CD34+ cell-enrichment of at least 26 is shown.)
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(C-G and H-L) mDC LPS and mDC aCD40Ab were finally matured 
for 24h using LPS [10 ng/mL] or aCD40 antibody [1 µg/mL], re-
spectively. Maturation status was controlled by FACS analysis of 
expression of co-stimulatory molecules CD80, CD86, and CD83 
on > 90 % pure CD11c+ CD11b+ MHC-IIhigh (I-Ab) cell population. 
(One representative DC maturation of at least 26 is shown.)
The phenotype of mCD40B cultivated for 14 days or for 7 days (herein after referred to as mCD40B 
d14 or mCD40B d7, respectively) was routinely checked as well (data not shown).
To measure the dynamics of the T-cell response T cells were labelled with the fluorescent prolifera-
tion marker 5, 6-carboxyﬂuorescein diacetate succinimidyl ester (CFSE) and cultivated together 
with DC LPS, DC aCD40Ab, mCD40B d14 or mCD40B d7 at various APC-to-T cell ratios (0:1, 3:1, 1:1, 
1:10, 1:20, 1:50, 1:100) in triplicates in 96 well plates for 5 days. CFSE segregates equally between 
daughter cells upon cell division, resulting in the sequential halving of cellular fluorescence inten-
sity with each successive generation. When analyzed by flow cytometry, this sequential halving 
of fluorescence is visualized as distinct peaks in the histogram (figure 32A-J). Furthermore, the 
expression of the activation marker CD25 on divided T cells as a function of mitotic number was 
monitored as well (figure 33A-J). 
Neither CD3+CD4+ nor CD3+CD8+ T cell population proliferated or showed up-regulation of CD25 
expression when T cells were cultivated without APC (negative control, figures 32 and 33 A and B, 
respectively). Notably, T cell proliferation occurred not only when DC LPS (figure 32C, D) or DC aCD-
40Ab (32E, F) were used as APC, but also when mCD40B d14 (32G, H) or mCD40B d7 (32I, J) were 
used at a 1-to-1 ratio to stimulate allogeneic T cells. Additionally, stimulation of T cell division by 
either source of APC was accompanied by an up-regulation of CD25 expression (figure 33C-J).
I-Ab
ce
ll 
co
u
n
t
K
CD86
ce
ll 
co
u
n
t
L
68RESULTS
Figure 32:  Proliferation 
of allogeneic T cells in 
MLR at APC-to-T cell ra-
tio 1-to-1
Typical sequential halv-
ing of CFSE fluorescence 
intensity with each gen-
eration is detected by flow 
cytometric analysis. 
(A, B) Negative control: 
CD3+ CD4+ and CD3+ CD8+ 
T cells were cultivated 
without stimulating APC.
(C and D, E and F, G and 
H, I and J) Cultivation of 
CD3+ CD4+ and CD3+ CD8+ 
T-cells with DC LPS, DC 
aCD40Ab, mCD40B d14 or 
mCD40B d7 as stimulating 
APC in MLR, respectively. 
(One representative ex-
periment of 8 is shown.)
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Figure 33:  CD25 expres-
sion of proliferated allo-
geneic T cells in MLR at 
ratio 1-to-1
Sequential halving of CFSE 
fluorescence intensity which 
is accompanied by up-reg-
ulation of CD25 expression 
on CD3+CD4+ and CD3+CD8+ 
T-cell populations is docu-
mented by FACS analysis.
 (A, B) Negative control: T 
cells were cultivated with-
out stimulating APC.
(C and D, E and F, G and 
H, I and J) Cultivation of 
CD3+ CD4+ and CD3+ CD8+ 
T-cells with DC LPS, DC 
aCD40Ab, mCD40B d14 or 
mCD40B d7 as stimulating 
APC in MLR, respectively.
(One representative ex-
periment of 8 is shown.)
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Furthermore, by performing 8 independent allogeneic MLRs it was observed that mCD40B were 
able to stimulate CD3+ T cells to proliferate as measured by decrease in CFSE-fluorescence inten-
sity (figure 34A-D). Comparing different mCD40B and DC stimulator subtypes at various ratios it 
was noticed that mCD40B subtypes performed best using bigger APC-to-T cell ratios (1:1 to 1:10 
for CD3+CD4+ T cells and 3:1 to 1:1 for CD3+CD8+ T cells) compared with DC subtypes performing 
best at lower ratios (1:10 to 1:20 for CD3+CD4+ and 1:1 to 1:10 for CD3+CD8+ T cells). As there were 
significant differences in the percentage of proliferated T cells at different ratios in favour of both 
DC subtypes DC LPS as well as DC aCD40Ab were used as reference APCs in further in vivo experi-
ments. Comparing mCD40B d14 and mCD40B d7 significant differences were seen in stimulating 
proliferation of CD3+CD4+ T cells at ratios 3-to-1 and 1-to-1 when mCD40B d7 were used as APC. In 
contrast CD3+CD8+ T cell proliferation was induced significantly stronger when mCD40B d14 were 
used as APC at ratios 3-to-1 and 1-to-1. 
For the induction of a sufficient and long-lasting immune response by antigen-presenting cells 
the action of CD4+ helper T cells as well as CD8+ cytotoxic T cells is needed. Since there was no clear 
result in favour of one mCD40B subtype mCD40B d14 and mCD40B d7 were used in the following 
experiments to characterize their antigen-presentation capacity in vivo.
Figure 34:  Statistical 
analysis of T-cell prolifera-
tion of eight independent 
allogeneic MLRs
CD3+CD4+ T-cell proliferation at 
various ratios in allogeneic MLR 
with either DC LPS and DC aCD-
40Ab (A) or with mCD40B d14 
and mCD40B d7 (C) as APCs. 
CD3+CD8+ T-cell proliferation at 
various ratios in allogeneic MLR 
with either DC LPS and DC aCD-
40Ab (B) or with mCD40B d14 
and mCD40B d7 (D) as APCs.
(Mean values of the percentage of proliferated T-cells ± SD 
of 8 independent MLR experiments is shown. Significant dif-
ferences calculated with paired Student´s t-test are marked 
by an asterisk. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001)
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3.3. Characterisation of the immunologic activity of mCD40B 
“in vivo” - Establishment of a murine vaccination model
In order to analyze whether highly activated, > 90 % pure mCD40B are potent antigen-presenting 
cells in vivo their systemic effects concerning safety were addressed in the first part - in the second 
part the efficacy regarding the elicited immune response was investigated for the first time. 
3.3.1.   Analysis of secondary immunological effects of adoptive 
mCD40B cell transfer
In cancer immunotherapy the adoptive transfer of tumour-reactive T cells directed against self-
derived tumour-antigen can induce severe adverse effects like auto-immunity. In fact rarely, but 
also in vaccinations with dendritic cells toxicities like immunologic injection site reactions or au-
toimmune disorders arising from humoral or cellular immune responses of the individual to his 
own tissue constituents have been observed. To assess whether the administration of mCD40B 
in vivo would be safe or would lead to any toxic side effects C57BL/6 mice were challenged with 
pure mCD40B suspended in PBS buffer in three different routes (intraperitoneal, intravenous and 
subcutaneous) to allow the distribution into all systemic lymphoid organs and tissues. In various 
murine tumour models mice are repeatedly vaccinated with 2 x 10e4 to 2 x 10e6 dendritic cells 
for up to four weeks to induce sufficient anti-tumour immunity (Balkow et al., 2009 223; Galea-
Lauri et al., 2004 224; Eggert et al., 2002 225). Therefore to address long-term toxicity of mCD40B 
administration high doses [1 x 10e6 cells/injection] of mCD40B were injected two times a week 
for five weeks. Furthermore acute toxicity was assessed by injecting mice once with very high 
mCD40B doses [1 x 10e7 cells/injection]. Matched groups of mice received PBS buffer only in three 
different routes serving as negative control. After five weeks of further observation mice were 
sacrificed and no changes in behaviour, weight and survival of mCD40B treated mice compared to 
PBS injected control mice were detected (figure 35A and B). 
35A
Figure 35:  No difference in 
weight and survival of mice 
treated with > 90 % pure 
mCD40B
Per group five C57BL/6 mice were 
challenged with either mCD40B 
or PBS alone as negative control 
in three different routes (intra-
peritoneal - ip, intravenous - iv or 
subcutaneous - sc) and weight (A) 
and survival (B) were documented. 
(Mean values ± SD of 4 independ-
ent experiments with five C57BL/6 
mice per group are shown.)
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For histo-pathological analysis clinical relevant organs (heart, lung, liver, kidney and spleen) were 
removed and paraffin-embedded sections prepared by hematoxylin and eosin (H&E) staining (fig-
ure 36A-E). Classification of histological sections was done by an experienced pathologist look-
ing for lymphocytic infiltrations, structural tissue injury and other indications for inflammation. 
Therefore three non-consecutive sections of each organ were completely screened, lymphocytic 
infiltrates were counted and a semi-quantitative analysis was performed (figure 36F) revealing 
normal histology in all organs analyzed. Comparing mCD40B treated mice with PBS injected 
control mice there were no significant differences. However there were lymphocytic infiltrations 
found in lung sections accompanied by discrete chronic bronchitis and in some liver sections in 
mCD40B treated animals and the PBS injected control group as well.  Therefore these results were 
not attributed to administration of mCD40B cells but were the result of suboptimal animal hous-
ing caused by dusty air - probably due to non-filtered, non-ventilated caging systems and fine 
granulation beddings.  
Figure 36:  Normal histology of organs after 
mCD40B administration 
Histo-pathological analysis of H&E stained sec-
tions of heart (A), lung (B), liver (C), spleen (D) 
and kidney (E) exhibited normal histology. 
(Organ sections of five mCD40B treated and 
PBS injected C57BL/6 mice per group (injec-
tion routes iv, ip or sc) were completely screened 
and 4 independent experiments performed.)
 
(A) Heart: Heart muscle over-
layed by thin epicardial tissue.
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(Representative photographs of mice treated 
with 1 x 10e7 mCD40B cells injected intrave-
nously taken at 100x magnification are shown.)
(E) Kidney: Renal cortex tissue. Regu-
lar glomerular and tubular structures.
(D) Spleen: Regular structured splenic tissue 
with prominent secundar follicle and a fine 
capsule. White pulp (WP) and red pulp (RP).
(C) Liver: Liver tissue with fine cen-
tral veins and regular portal fields.
(B) Lung: Well developed lung tissue. In the cen-
tre two bronchioli lined with regular respira-
tory epithelium. Discrete chronic bronchitis.
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(F) Semi-quantitative analysis was performed by screening three non-consecutive histologi-
cal sections of each organ for lymphocytic infiltrations and counting them. Mean values of 
4 independent experiments were calculated and assigned to one of three categories: 
o  no infiltrate, +  few lymphocytic infiltrates (1 ≤ x ≤ 3) ++  several lymphocytic infiltrates (4 ≤ x ≤ 8). 
Furthermore secondary lymphoid organs were screened for rejection reactions by assessment 
of the lymphocyte subsets involved in adaptive immune reactions. Therefore mesenteric and in-
guinal lymph nodes as well as spleen were dissected, single cell suspensions prepared and com-
position of B220+ B cells, CD3+ T cells as well as CD3+CD4+ helper T cell and CD3+CD8+ cytotoxic T 
cell populations determined by FACS analysis (for figure 37A-H see also next page).  Comparing 
mCD40B treated mice and PBS injected control group (injection routes iv, ip or sc) no significant 
differences in the composition of the four cell populations were detected, neither in the spleen, 
nor in the lymph nodes in four experiments performed independently. 
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Figure 37:  No secondary immunological effects after mCD40B administration
Assessment of lymphocyte composition of B220+ B cells (A and B), CD3+ T cells (C and D), CD4+ helper 
T cells (E and F) and CD8+ cytotoxic T cells (G and H) in mesenteric and inguinal lymph nodes and 
spleen of mCD40B treated mice and PBS injected control mice (injection routes iv, ip or sc). 
(Mean values ± SD of 4 independent experiments with five C57BL/6 mice per group are shown.)
To summarize, histo-pathological assessment of behaviour, weight, survival, clinical relevant or-
gans and secondary lymphoid organs after administration of mCD40B revealed no differences 
compared to PBS injected control group. After showing the safety and lack of toxicity of the ad-
ministration of high doses of mCD40B in C57BL/6 mice we next developed the mCD40B vaccina-
tion schedule. 
3.3.2.   Characterization of mCD40B as cellular adjuvant - Induction 
of immunity 
As professional APCs dendritic cells are able to take up antigen, thus become activated and mi-
grate to secondary lymphoid organs were they present antigens to T cells (Inaba et al., 1990 221). 
By using mCD40B cells as cellular adjuvant it was tested whether those cells are basically able to 
efficiently present antigen to T cells in order to induce specific immune responses in adaptive im-
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munotherapy. Therefore mCD40B cells were loaded with peptide by peptide-pulsing, which is a 
common technique to deliver antigens to APCs (Inaba et al., 1990 221; Zitvogel et al., 1996 120). 
Several parameters were systematically analysed to set up an efficient vaccination schedule with 
mCD40B, namely route of administration (iv, ip or sc), cell dose [1 x 10e5, 1 x 10e6, 1 x 10e7 
cells/injection], vaccination intervals (day 0, day 7, day 14) and formulation (mCD40B d7 or 
mCD40B d14 and mCD40B γ-irradiated with 26 Gy). Peptide-pulsed DC which were injected sub-
cutaneously served as a gold standard to which mCD40Bs were compared (Balkow et al., 2009 223; 
Galea et al., 2004 224; Eggert et al., 2002 225). As positive control specific peptide was emulsified 
in incomplete Freund’s adjuvant (IFA), because IFA is considered to be one of the most effective 
adjuvants and administered subcutaneously into the right flank once. Herein adjuvant activity is 
a result of sustained release of antigen from the oily deposit (depot effect), and stimulation of a 
local innate immune response leading to enhanced adaptive immunity. An essential component 
of this response is an intense inflammatory reaction at the site of antigen deposition resulting 
from an influx of leukocytes and their interaction with antigen (Hossain et al., 2001 226; Shibaki 
et al., 2002 227).  
The efficacy of different mCD40B cell-based peptide vaccine formulations in inducing specific im-
mune responses was tested by the functional analysis of antigen-specific T cells: 1) the in vivo 
cytolytic activity of antigen-specific CD8+ cytotoxic T cells and 2) the magnitude of the CD8+ T cell 
response by production of intracellular IFN-γ. Therefore two assays were established: 1) the in vivo 
cytotoxicity assay and 2) the intracellular cytokine staining for IFN-γ in CD8+ cytotoxic T cells. 
To basically test peptide-antigen presentation by mCD40B in vivo for the first time the H-2Db re-
stricted (MHC-I) synthetic peptide [amino acid sequence KAVYNFATM] derived from murine path-
ogenic lymphocytic choriomeningitis virus (LCMV) glycoprotein 33-41 (GP33) was used to load 
mCD40B with (Gairin et al., 1995 228; Stemmer et al., 1999 229). For vaccination mCD40B d14 
were either pulsed with 10 µM LCMV peptide (mCD40B d14+) or left untreated (mCD40B d14-) and 
1 x 10e6 cells were administered intraperitoneally into C57BL/6 mice twice at a 7 day interval in 
the style of DC vaccinations. To assess the functionality of LCMV-specific CD8+ T cells the in vivo cy-
totoxicity assay was performed (figure 38A, next page). To this end immunized mice were injected 
with CFSE-stained splenocytes from naïve mice loaded with LCMV peptide. Unloaded splenocytes 
stained with a lower CFSE concentration served as reference. Specific killing of peptide-loaded 
CFSEhigh target cell fraction was determined by flow cytometric analysis calculating the ratio of the 
frequencies of CFSE-labelled splenocytes loaded with LCMV peptide and unloaded splenocytes 
(One representative gating for CFSE-positive target cells is displayed in figure 38B). With induction 
of LCMV-specific immune response cytotoxic potential is demonstrated by decrease of percentage 
of the CFSEhigh fraction (Representative data for identification of CFSEhigh (right gate) and CFSElow 
(left gate) target cell fraction is shown in figures 38C-G).
No specific lysis was detected when mice were vaccinated with PBS alone (NC). While only low 
levels of specific lysis were detected in mice vaccinated with peptide alone (pep only) or mCD40B 
d14-, the LCMV-specific lysis was significantly increased to 33 % in mice vaccinated with mCD40B 
d14+. Similarly in mice vaccinated with IFA plus peptide (PC) specific lysis rose to 30 %. (Combined 
data of 7 independent experiments with 2 mice per group is shown in figure 38H.)
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Figure 38:  Vaccination with mCD40B LCMV induces antigen-specific cytotoxicity of 
        CD8+ T cells
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(A) C57BL/6 mice were vaccinated with 1 x 10e6 mCD40B d14 pulsed with LCMV peptide (mCD40B 
d14+) or left unpulsed (mCD40B d14-) at a 7 day interval. Vaccination with IFA plus peptide served 
as positive control, administration of PBS alone (NC) or peptide alone (pep only) served as nega-
tive controls. 4 days after the second immunization 1 x 10e7 target cells labelled with differ-
ent amounts of CFSE were administered intraperitoneally into vaccinated mice. Specific lysis by 
CD8+ cytotoxic T cells in vivo was determined by flow cytometry calculating the ratio of the fre-
quencies of CFSE-labelled splenocytes loaded with LCMV peptide and unloaded splenocytes.  
In (B-G) representative FACS data from one of 7 vaccination experiments is shown. (B) Typi-
cal gating on CFSE-stained target cell fraction. Further gating of target cells on peptide-pulsed 
CFSEhigh (right gate) and unpulsed CFSElow fraction (left gate) of mice vaccinated with (C) PBS 
alone (NC), (D) mCD40B d14-, (E) peptide alone (pep only), (F) mCD40B d14+ or (G) IFA (PC). 
(H) Bar chart of mean values ± SD of specific lysis combining data of 7 independent vaccina-
tion experiments with two C57BL/6 mice per group are shown. Significant differences calculated 
with paired Student´s t-test are marked by an asterisk. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001
For establishment of the intracellular cytokine staining for IFN-γ in CD8+ cytotoxic T cells identical 
vaccinations as described above were performed in C57BL/6 mice using the same LCMV-peptide. 
To determine the frequencies of CD8+ IFN-γ+ T cells vaccinated mice were sacrificed, spleens re-
moved and purified lymphocytes re-stimulated with 10 µM LCMV-peptide to induce production 
of intracellular IFN-γ by specific antigen-experienced CD8+ cytotoxic T cells. During re-stimulation 
lymphocytes were treated with BD Golgi-Stop™ containing monensin to block cytokine transport 
outside the cell. As a consequence IFN-γ accumulates in the Golgi-complex and detection by flow 
cytometry is facilitated (figure 39).
Figure 39:  Illustration of vaccination schedule and intracellular cytokine staining procedure
When vaccinating C57BL/6 mice with LCMV-peptide levels of intracellular accumulated IFN-γ 
were generally low (< 2 %) and production of IFN-γ was independent from treatment of mice, 
likely due to intra-individual differences (data not shown) in this wild-type line. Therefore the TCR-
transgenic OT-I line was used in further vaccination experiments to detect intracellular IFN-γ. In 
OT-I mice T-cell levels are strongly skewed towards CD8+ cytotoxic T cells so it is facilitated to fol-
low their fate during immune responses. Furthermore these T cells express a single T-cell receptor 
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257-264 
[SIINFEKL] derived from hen eggs 
ovalbumin (Hogquist et al., 1994 230) representing a well studied foreign model-antigen. 
For that reasons in order to find the optimal mCD40B formulation inducing specific immune re-
sponses in vivo vaccination parameters were systematically analyzed by performing the cytotox-
icity assay in C57BL/6 mice and the intracellular cytokine staining for IFN-γ produced by CD8+ 
cytotoxic T cells in OT-I mice both treated with foreign peptide OVA vaccine formulations. 
Before using in vaccination experiments OT-I mice were routinely monitored for expression of 
TCR-chain Vβ5 on CD3
+CD8+ T cells (figure 40). All mice checked expressed TCR-chain Vβ5 in more 
than 90 % of all CD3+CD8+ T cells.
Figure 40:  Vβ5 expression by CD3+CD8+ T 
cells in OT-I mice
Splenocytes from OT-I mice were monitored for 
expression of transgenic TCR-chain Vβ5 by flow 
cytometric analysis using Vβ5-PE antibody. 
(One representative FACS analysis is shown.)
For vaccination experiments in OT-I mice generation of mCD40B and DC originated from OT-I 
line (herein after referred to as mCD40B OT-I and DC OT-I, respectively) was performed accord-
ing C57BL/6 protocol without any changes. Thereby growth, phenotype and purity of mCD40B 
OT-I were comparable to that of mCD40B C57/BL6. Formation of typical round cell clusters was 
observed and an average 4.1 fold increase in growth of 10 independently performed mCD40B 
cultures was documented when B cells originated from OT-I mice (figure 41A,B). Cultivation ac-
cording optimal mCD40B C57BL/6 culture protocol led to a similar purity (A) and activation profile 
(B-E) as determined by expression of MHC molecules Class-I (H-2Db) and Class-II (I-Ab) and the 
expression of co-stimulatory molecules CD80, CD86 on CD19+ CD3- mCD40B OT-I compared to 
mCD40B C57BL/6 (figure 42 A-E).
Figure 41:  Cluster formation (A) and proliferation (B) of mCD40B cells originated from OT-I 
splenocytes
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(A) Photographs were taken at a 5x magnification using a light op-
tical microscope fitted with a digital camera. 
(One representative picture of at least 10 independent mCD40B OT-I cultures is shown.)
(B) The number of viable mCD40B cells was determined every 3-4 days us-
ing the trypan blue exclusion test. Until day 14 of culture the relative growth was as-
sessed by calculating the relative increase between two passages. 
(Representative data of 10 independently performed mCD40B OT-I cultures is shown.)
Figure 42:  Purity (A) and activation status (B-E) of mCD40B cells originated from OT-I 
splenocytes
FACS analysis of the proportion of CD19+ CD3- B cells in mCD40B cultures grown from OT-I spleno-
cytes according optimal mCD40B C57BL/6 culture protocol displaying purity (A) and activation 
profile (B-E) as determined by expression of MHC molecules Class-I (H-2Db) and Class-II (I-Ab) 
and the expression of co-stimulatory molecules CD80, CD86 on CD19+ CD3- mCD40B OT-I. 
(One representative FACS analysis of at least 10 is shown.) 
Likewise phenotype of DC generated from ≥  80 % pure CD34+ bone marrow progenitor cells of OT-I 
mice (figure 43A) was similar to that of DC C57BL/6 monitored by determination of the CD11b+ 
CD11c+ MHC-IIhigh (I-Ab) population. After 24h maturation with LPS [10 ng / mL] or anti-CD40 anti-
body [1 µg/mL] the expression of co-stimulatory molecules CD80, CD86 and CD83 on DC LPS and 
DC aCD40Ab was up-regulated as monitored by flow cytometry. (One representative analysis of 
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at least 10 DC LPS and DC aCD40Ab cultures originated from OT-I mice is shown in figure 43 B-F 
and G-K, respectively.)
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Figure 43:  Phenotypical analysis of DC subsets originated from OT-I CD34+ bone marrow
(A) Myeloid DCs were generated from 80-85 % pure, positively selected CD34+ bone marrow pro-
genitor cells from OT-I mice through stimulation with GM-CSF [500 U/mL] for 7 days. 
(B-F and G-K) mDC LPS and mDC aCD40Ab from OT-I mice were finally matured for 24 
hours using LPS [10 ng/mL] or aCD40 antibody [1 µg/mL], respectively. Maturation sta-
tus was controlled by FACS analysis of expression of co-stimulatory molecules CD80, 
CD86, and CD83 on > 90 % pure CD11c+CD11b+MHC-IIhigh (I-Ab) cell population.
(One representative FACS analysis of DC OT-I from at least 10 is shown.)
Starting with identification of the optimal mCD40B formulation vaccinations with OVA peptide 
were performed comparing mCD40B d14 and mCD40B d7. Furthermore sub-lethally irradiated 
(26Gy) mCD40B were tested to thereby see whether their antigen-presenting function would be 
diminished.
Similar to LCMV vaccinations no specific lysis was detected when mice were vaccinated with PBS 
alone (NC). While only low levels of specific lysis were detected in mice vaccinated with peptide 
alone (pep only) or mCD40B d14- (green bars), the OVA-specific lysis was significantly elevated 
from 71 ± 28 % when 1 x 10e6 mCD40B d7+ (dark blue) were used to 84 ± 13 % using 1 x 10e6 
mCD40B d14+ (blue) while irradiation of mCD40B d14+ diminished specific lysis rate to 76 ± 22 % 
(grey bar), all injected ip. Similarly in mice vaccinated with IFA plus peptide (PC) specific lysis rose 
to 74 ± 24 %. (Mean values of 7 independent experiments with 2 mice per group ± SD. Bar graph 
shows combined data in figure 44A.) Furthermore specific lysis rates in successful vaccinated 
C57BL/6 mice were increased compared to LCMV vaccinations revealing strong immunogenicity 
of the foreign OVA peptide.
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Figure 44:  Vaccination with mCD40B OVA induces antigen-specific cytotoxicity dependent 
from adjuvant formulation
C57BL/6 mice were vaccinated with 1x10e6 mCD40B d7, mCD40B d14 or sub-lethally irradiated mCD40B 
pulsed with 10 µM OVA peptide (mCD40B d14+) or left unpulsed (mCD40B d14-) all injected ip at a 7 day 
interval. Vaccination with IFA plus peptide served as positive control, administration of PBS alone (NC) or 
peptide alone (pep only) display further negative controls. 4 days after the second immunization 1 x 10e7 
target cells labelled with different amounts of CFSE were administered intraperitoneally into vaccinated 
mice. Specific lysis by CD8+ cytotoxic T cells in vivo was determined by flow cytometry calculating the ra-
tio of the frequencies of CFSE-labelled splenocytes loaded with OVA peptide and unloaded splenocytes.  
Bar chart of mean values ± SD of specific lysis combining data of 7 independent vaccination ex-
periments with two C57BL/6 mice per group are shown. Significant differences calculated 
with paired Student´s t-test are marked by an asterisk. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001
Performing vaccinations in OT-I mice elevated levels of intracellular IFN-γ+ CD8+ cytotoxic T cells 
were detected dependent on treatment of mice as determined by flow cytometric analysis. In OT-I 
mice vaccinated with PBS alone (NC) or 1 x 10e6 mCD40B d14 left unpulsed (mCD40B d14-) basal 
IFN-γ levels were detected in CD8+ cytotoxic T cells. In contrast, when mice were vaccinated with 
IFA plus peptide (PC) or mCD40B d14 pulsed with peptide (mCD40B d14+) IFN-γ levels of antigen-
specific CD8+ cytotoxic T cells were increased from basal levels of 1.1 ± 0.7 % or 0.6 ± 0.5 % to 
16.2 ± 3.2 % or 5.0 ± 1.8 %, respectively, but only when purified lymphocytes were re-stimulated 
with OVA peptide. (Mean values of 7 independent experiments with 2 mice per group ± SD.) There-
fore IFN-γ production was specifically attributed to response by antigen-experienced CD8+ cyto-
toxic T cells showing that those T cells were functionally competent. (One representative gating 
for IFN-γ+ CD8+ cytotoxic T cells is displayed in figure 45A-H.)
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Figure 45:  Vaccination with mCD40B OVA induces intracellular IFN-γ production by specific 
antigen-experienced CD8+ T cells
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OT-I mice were vaccinated with 1 x 10e6 mCD40B d14 pulsed with OVA peptide (mCD40B d14+) or 
left unpulsed (mCD40B d14-) at a 7 day interval. Vaccination with IFA plus peptide represents the 
positive control, administration of PBS alone (NC) displays the negative control. Production of intra-
cellular IFN-γ by specific antigen-experienced CD8+ cytotoxic T cells was detected by flow cytom-
etry after re-stimulating purified lymphocytes of vaccinated animals with the same peptide. 
 (A-H) IFN-γ levels of un-stimulated CD8+ T cells (left column) vs. IFN-γ levels of CD8+ T cells 
from vaccinated mice re-stimulated with 10 µM OVA peptide in vitro (right column). 
(One representative gating for IFN-γ+CD8+ cytotoxic T cells out of at least 
17 independently performed experiments is displayed.) 
In order to identify the optimal mCD40B formulation by the second approach vaccinations with 
mCD40B d14, mCD40B d7 and sub-lethally irradiated (26 Gy) mCD40B d14, all injected ip were 
performed in TCR-transgenic OT-I mice with OVA peptide comparing specifically induced IFN-γ 
production of antigen-experienced CD8+ cytotoxic T cells. Levels of IFN-γ were significantly el-
evated from basal levels of < 2 % (green bars) to 6.5 ± 2.1 % (dark blue) or 5.5 ± 3.8 % (blue) when 
vaccinations were performed with mCD40B d7+ or mCD40B d14+, respectively. In contrast, irradi-
ated mCD40B d14 pulsed with OVA peptide (grey bar) did not lead to elevated levels of CD8+ IFN-γ+ 
T cells. (Mean values of 7 independent experiments with 2 mice per group ± SD. Bar graph shows 
combined data in figure 46).
Figure 46:  Vaccination with mCD40B OVA induces intracellular IFN-γ production by specific 
antigen-experienced CD8+ T cells dependent from adjuvant formulation
OT-I mice were vaccinated with 1x10e6 mCD40B d7, mCD40B d14 or sub-lethally irradiated 
mCD40B pulsed with OVA peptide (mCD40B d14+) or left unpulsed (mCD40B d14-) all inject-
ed ip at a 7 day interval. Vaccination with IFA plus peptide served as positive control, admin-
istration of PBS alone (NC) or peptide alone (pep only) display further negative controls. 
Mean values of frequencies of IFN-γ+ CD8+ T cells re-stimulated with OVA peptide were normalized to cor-
responding un-stimulated sample of the same animal. Bar chart of mean values ± SD combining data of 
7 independent vaccination experiments with two OT-I mice per group are shown. Significant differences 
calculated with paired Student´s t-test are marked by an asterisk. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001
87RESULTS
020
40
60
80
100
%
 s
p
ec
if
ic
 ly
si
s
NC
CD40B d14- [e6] ip
pep only
CD40B d14+ [e6] ip
CD40B d14+ [e6] sc
CD40B d14+ [e6] iv
PC
*
**
***********
47A 
0
5
10
15
20
%
 C
D
8+
 IF
N
g+
 T
 c
el
ls
NC
CD40B d14- [e6] ip
pep only
CD40B d14+ [e6] ip
CD40B d14+ [e6] sc
CD40B d14+ [e6] iv
PC
********
B 
A comparison of OVA-specific T cell reactions in response to the different mCD40B formulations as 
assessed by in vivo cytotoxicity assay and production of intracellular IFN-γ did not clearly favour 
one particular formulation. Irrespective of the duration of CD40-activation the T cell response in-
duced with mCD40B d7 and mCD40B d14 was significantly increased compared to NC, pep only or 
mCD40B left unpulsed. Whereas irradiated mCD40B d14 significantly raised levels of specific lysis 
there was no effect measured by IFN-γ production. Comparing mCD40B d7 and mCD40B d14 there 
was no significant difference detected by both methods. As cultivation of mCD40B for 14 days 
resulted in higher amounts of cells generated this formulation was used in further experiments.
Second, the impact of injection route of mCD40B introduced in vaccination experiments to induce 
specific immune response was examined by both methods (figure 47A and B). Therefore 1 x 10e6 
mCD40B d14+ were injected ip (blue), sc (purple) or iv (magenta) and specific lysis or production 
of intracellular IFN-γ were measured as described before. Whereas vaccination in all three routes 
were able to significantly increase levels of specific lysis of target cells there was no significant 
effect on IFN-γ production detectable when mCD40B were administered iv. Given that intraperi-
toneal mCD40B injection had a significant benefit over other routes in specific induction of im-
munity as determined by specific lysis of target cell testing of further vaccination parameters was 
compared  to mCD40B d14+ injected ip. 
Figure 47:  Vaccinations with mCD40B OVA d14 induces antigen-specific T cell responses 
dependent from injection route
C57BL/6 mice (A) or OT-I mice (B) were vaccinated with 1x10e6 mCD40B d14 pulsed with OVA peptide 
(mCD40B d14+) injected ip, sc or iv at a 7 day interval (blue, purple or magenta bar, respectively). Vaccina-
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tion with IFA plus peptide served as positive control (red bar), administration of PBS alone (NC), mCD40B 
left unpulsed (mCD40B d14-) or peptide alone (pep only) display further negative controls (green bars). 
(A) 4 days after the second immunization 1 x 10e7 target cells labelled with different amounts 
of CFSE were administered intraperitoneally into vaccinated mice. Specific lysis by CD8+ cy-
totoxic T cells in vivo was determined by flow cytometry calculating the ratio of the frequen-
cies of CFSE-labelled splenocytes loaded with OVA peptide and unloaded splenocytes.  
(B) Production of intracellular IFN-γ by specific antigen-experienced CD8+ cytotoxic T cells was de-
tected by flow cytometry after re-stimulating purified lymphocytes of vaccinated animals with 
the same peptide. Mean values of frequencies of IFN-γ+CD8+ T cells re-stimulated with OVA 
peptide were normalized to corresponding un-stimulated sample of the same animal. 
Bar charts of mean values ± SD of specific lysis (A) and frequency of CD8+ IFN-γ+ T cells (B) combining data 
of 4 independent vaccination experiments with three mice per group are shown. Significant differences 
calculated with paired Student´s t-test are marked by an asterisk. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001
Third, the effect of varying cell doses of mCD40B inserted in vaccinations was studied with both 
assays. Hence 1 x 10e5, 1 x 10e6 and 1 x 10e7 mCD40B d14+ were administered ip at a 7 day inter-
val and read out assays performed as described before (figure 48A and B). Thereby a dose depend-
ent effect of vaccinations with mCD40B was identified as increasing cell doses from 1 x 10e5 to 
1 x 10e6 or 1 x 10e7 significantly raised levels of specific lysis of target cells from 26.4 ± 8.7 % (light 
blue) to 83.7 ± 13.4 % (blue) or 96.0 ± 3.4 % (dark blue), respectively. (Mean values of 3 independ-
ent experiments with 3 mice per group ± SD).
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Figure 48:  Vaccinations with mCD40B OVA d14 induce antigen-specific T cell responses 
dose dependently
C57BL/6 mice (A) or OT-I mice (B) were vaccinated with 1 x 10e5, 1 x 10e6 or 1 x 10e7 
mCD40B d14 pulsed with OVA peptide (mCD40B d14+) injected ip at a 7 day interval (light 
blue, blue or dark blue bar, respectively). Vaccination with IFA plus peptide served as posi-
tive control (red bar), administration of PBS alone (NC), mCD40B left unpulsed (mCD40B 
d14-) or peptide alone (pep only) display further negative controls (green bars). 
(A) 4 days after the second immunization 1 x 10e7 target cells labelled with different amounts 
of CFSE were administered intraperitoneally into vaccinated mice. Specific lysis by CD8+ cy-
totoxic T cells in vivo was determined by flow cytometry calculating the ratio of the frequen-
cies of CFSE-labelled splenocytes loaded with OVA peptide and unloaded splenocytes.  
(B) Production of intracellular IFN-γ by specific antigen-experienced CD8+ cytotoxic T cells was de-
tected by flow cytometry after re-stimulating purified lymphocytes of vaccinated animals with 
the same peptide. Mean values of frequencies of IFN-γ+CD8+ T cells re-stimulated with OVA 
peptide were normalized to corresponding un-stimulated sample of the same animal. 
Bar charts of mean values ± SD of specific lysis (A) and frequency of CD8+IFN-γ+ T cells (B) combining data 
of 3 independent vaccination experiments with three mice per group are shown. Significant differences 
calculated with paired Student´s t-test are marked by an asterisk. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001
Fourth, the effect of varying mCD40B vaccination schedules was analysed with both assays. Fur-
thermore DC LPS or DC aCD40Ab were pulsed with OVA peptide and included into vaccination ex-
periments to see whether mCD40B used under optimal conditions would be able to keep up with 
the widely recognised antigen-presentation function of DC. And so mCD40B d14+ were adminis-
tered ip at a 7 day interval with one or two booster vaccinations and read out assays performed as 
described before. According to literature 1 x 10e6 DCOVA were administered sc in additional experi-
ments (figure 49A and B). In doing so the levels of specific lysis were increased from 83.7 ± 13.4 % 
(blue) to 99.8 ± 0.3 % (light grey) when the booster vaccination was repeated. However this effect 
could not be confirmed by detection of IFN-γ production. Vaccination with DC LPS or DC aCD40Ab 
raised levels of specific lysis to 72.2 ± 13.5 % (orange) or 95.3 ± 6.8 % (yellow), respectively. Again 
this result could not be verified by analysis of IFN-γ production. (Mean values of 3 independent 
experiments with 3 mice per group ± SD).
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Figure 49:  Repetitive vaccinations with mCD40B OVA d14 induce strong antigen-specific T 
cell responses 
C57BL/6 mice (A) or OT-I mice (B) were treated with 1 x 10e6 mCD40B d14 pulsed with OVA peptide 
(mCD40B d14+) injected ip at a 7 day interval in a primary and booster vaccination or in one primary and 
two booster vaccinations (blue or light grey bar, respectively). Vaccinations with 1 x 10e6  
DC LPS or DC aCD40Ab pulsed with peptide were injected sc. Vaccination with IFA plus  
peptide served as positive control (red bar), administration of PBS alone (NC), mCD40B left  
unpulsed (mCD40B d14-) or peptide alone (pep only) display further negative controls (green bars). 
(A) 4 days after the second immunization 1 x 10e7 target cells labelled with different amounts 
of CFSE were administered intraperitoneally into vaccinated mice. Specific lysis by CD8+ cy-
totoxic T cells in vivo was determined by flow cytometry calculating the ratio of the frequen-
cies of CFSE-labelled splenocytes loaded with OVA peptide and unloaded splenocytes.  
(B) Production of intracellular IFN-γ by specific antigen-experienced CD8+ cytotoxic T cells was de-
tected by flow cytometry after re-stimulating purified lymphocytes of vaccinated animals with 
the same peptide. Mean values of frequencies of IFN-γ+CD8+ T cells re-stimulated with OVA 
peptide were normalized to corresponding un-stimulated sample of the same animal. 
Bar charts show mean values ± SD of specific lysis (A) and frequency of CD8+IFN-γ+ T cells (B). Combined 
data of 3 independent vaccination experiments with three mice per group is shown. Significant differ-
ences calculated with paired Student´s t-test are marked by an asterisk. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001
By analysing mCD40B formulation, injection route, cell dose and vaccination schedule with specif-
ic lysis of target cells and production of intracellular IFN-γ through antigen-specific CD8+ cytotoxic 
T cells the following optimal vaccination algorithm for induction of a specific immune response 
against foreign model antigen OVA was developed. Formulation of mCD40B was set at mCD40B+ 
d14 given that specific immune responses detected by elevated lysis of target cells and increased 
IFN-γ production by CD8+ cytotoxic T cells were induced and high amounts of cellular vaccine 
could be generated. Furthermore intraperitoneal injection of 1x107 mCD40B cells yielded in clear, 
significant benefit over other routes and doses. Finally repeated booster vaccinations elevated 
levels of specific lysis of target cells and were chosen for application in the most effective mCD40B 
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vaccination schedule. In figure 50 the chosen one schedule is clearly represented. This schedule 
was finally applied in first mCD40B vaccination experiments to study their ability to induce anti-
tumour immunity.
Figure 50:  Illustration of an effective mCD40B vaccination schedule
Induction of specific immune responses is optimally gained by vaccinating C57BL/6 
mice or OT-I mice with 1 x 10e7 mCD40B d14 pulsed with peptide (mCD40B+) in-
jected ip at a 7 day interval in one primary and two booster vaccinations.
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3.4. mCD40B as cellular adjuvant against B16 melanoma
In order to evaluate the protective effect of mCD40B anti-tumour vaccination the B16 melanoma 
a well established and widely used mouse tumour model was chosen. In the 80s the B16 cell line 
was established originating in spontaneously arising melanoma in C57BL/6 mice by Dr. I.J. Fidler 
and colleagues. B16 melanoma cells can be cultivated in vitro. After subcutaneous injection of B16 
melanoma cells into a syngeneic animal (H-Db) again a solid tumour can develop. Fidler et al. es-
tablished several sub-lines with different metastasizing potential. Thus the parental cell line B16.
F1 is able to form lung metastases upon intravenous tail vein injection. Furthermore the number 
of metastases was increased upon isolation of those tumour cells from lung-metastases and re-
injection into syngeneic mice, a technique which is called passaging. By repeating passaging for 
several times the variant tumour line B16.F10 with higher survival and growth potential was es-
tablished (Fidler et al., 1973 231; Fidler et al., 1976 232).  
Human melanomas express different tumour-associated antigens which are potential targets for 
novel designs for therapeutic cancer vaccines. Melanoma-associated antigens include melano-
somal proteins (tyrosinase, tyrosinase-related proteins 1 and 2 (TRP-1/2) and gp100) and tumour-
specific antigens comprising the MAGE, BAGE and GAGE class of antigens. These antigens are non-
mutated self-peptides, thus not representing strong immunogens or tumour-rejections antigens. 
Therefore to efficiently induce T cells specific for self-epitopes it is important ensure high expres-
sion of these epitopes on the cell surface of antigen-presenting cells. Pulsing professional APC 
with exogenously peptides is aiming at this issue (Kawakami et al., 1998 233). B16 melanoma 
cells express some non-mutated, melanoma-associated antigens (TRP-2 and gp100) analogue to 
antigens in human melanoma (Schreurs et al., 1997 234; Schreurs et al., 2000 235). So we chose 
the TRP-2 peptide [amino acid sequence SVYDFFVWL] to pulse mCD40B cells with representing a 
model of tumour immunotherapy closely mimicking cancer therapy in melanoma patients (Bloom 
et al., 1997 236).
To examine the effect of peptide-loaded mCD40B in a preventive vaccination approach the treat-
ment regimen started with a first vaccination (Prime) followed by two further vaccinations (1st 
and 2nd Boost) of C57BL/6 mice in 7 day interval (figure 51A). One week after the last injection B16 
tumour was inoculated by sc injection of 1 x 10e6 B16.F10 melanoma cells into the right flank and 
tumour volume was determined daily until day 13 after inoculation by measuring tumour diam-
eter [mm3] using a vernier calliper.
 In groups of mice receiving 1 x 10e6 mCD40B d14 tumour growth was significantly decelerated 
compared to PBS-injected control mice only when mCD40B d14 had been pulsed with TRP-2 pep-
tide [10 µM]. This growth slow-down was observed from onset of tumour growth on at day seven 
after tumour challenge. Raising mCD40B dose from 1 x 10e6 to 1 x 10e7 cells per injection did 
not show an enhancement of vaccine efficacy but growth rate was also significantly decreased 
compared to PBS control group. In groups of mice receiving preventive treatment with 1 x 10e6 
dendritic cells loaded with the same peptide matured with LPS or anti-CD40 antibody a deceler-
ating effect on tumour growth was even stronger with two mice treated with DC LPS remaining 
tumour free until termination on day 13 post tumour inoculation (figure 51B).
93RESULTS
***
**
***
*
B 
***
***
**
*
***
**
**
51A
day 0 day 7 day 14 day 21
anti-Tumour
Immune Response
Prime 1st Boost 2nd Boost
B16 tumour 
challenge
preventive B16 vaccination
C57BL/6
Figure 51:  Preventive vaccination using mCD40B TRP-2 d14 induces growth deceleration 
of B16 melanoma 
(A) Preventive vaccination schedule performing three subsequent vaccinations ad-
ministered in a seven day interval followed by B16.F10 tumour inoculation (1 x 10e6) 
sc into the right flank of C57BL/6 mice one week after the last injection. 
(B) Volume of subcutaneous B16 melanoma in groups of C57BL/6 mice treated by ip injec-
tion of 1 x 10e6 or 1 x 10e7 mCD40B d14 pulsed with TRP-2 peptide (mCD40B d14+) (blue 
and dark blue line, respectively). Alternatively mice were vaccinated with 1 x 10e6 DC LPS or 
DC aCD40Ab pulsed with peptide injected sc into the left flank (orange and yellow line, re-
spectively). Administration of PBS alone (NC) or 1 x 10e6 mCD40B left unpulsed (mCD40B 
d14-) injected ip served as negative controls (green and light green line, respectively).
Tumour growth was assessed daily by multiplying the largest tumour diameters of three dimen-
sions [mm3]. Line plot shows mean values ± SD of tumour volume of indicated treatment groups 
from two independent vaccination experiments with 3 mice per group. Significant differences cal-
culated with paired Student´s t-test are marked by an asterisk. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001
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In conclusion first anti-tumour vaccination experiments with TRP-2 peptide-pulsed mCD40B show 
that specific immune response is induced thereby leading to a significant reduction in tumour 
growth. Whether this noticeable but weak effect can be increased to a level of complete tumour 
remission needs to be further evaluated. 
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4. DISCUSSION
4.1. A murine system for the generation of immune-
stimulatory B cells
Fundamental for this work was the development of effective cultivation conditions in order to 
generate murine CD40-activated B cells that fulfil the prerequisites to operate as antigen-present-
ing cells. 
CD40 stimulation in the presence of IL-4 has shown to efficiently stimulate human B lymphocytes 
to proliferate and differentiate. However, varying effects on responses of B lymphocytes have 
shown to be induced by different sources of CD40 stimulus, namely soluble agonists or mem-
brane-associated cellular forms of the CD40L differing in the degree of cross-linking and density 
(Kehry M.R. and Castle B.E., 1994 237; Néron et al., 2011 205). A higher degree of cross-linking and 
multimerization of CD40L has been shown to be associated with increased B-cell proliferation 
reflecting different modes of B and T-cell interaction. To provide strongly stimulating conditions 
in our model naïve B cells were activated with membrane-bound CD40L expressed by adherent 
feeder cells additionally facilitating removal of residual feeder cells from B-cell culture. Induction 
of proliferation and up-regulation of co-stimulatory as well as MHC-molecules on mCD40B cell 
cultures confirmed sufficient CD40 triggering in our model (see figures 6B, 7D-G).
The effect of CD40 stimulation on B cell proliferation and differentiation has been shown to be 
synergistically enhanced by IL-4 addition due to up-regulation of CD40 expression upon IL-4 treat-
ment (Vallé et al., 1989 238; Maliszewski et al., 1993 239). This effect was in line with our results 
comparing proliferation rates of mCD40B cultures in the presence or absence of IL-4 reaching a 
plateau between 1 and 2 U/mL in a dose-dependent-manner (see figures 6B and 8). However, a 
transfection of IL-4 into feeder cells resulting in membrane-bound IL-4 has been suggested for fur-
ther improvement of expansion of human CD40-activated B cells by others and an analogous ap-
proach would be worthwhile to be tested in the murine expansion system (Park et al., 2007 240). 
Notably, we were not able to expand murine CD40-activated B cells for longer than three weeks 
(data not shown). This stands in great contrast to reports of expansion durations for human CD40-
activated B-cell cultures from several months to a few years as reported by several groups (Jung 
et al., 2001 241; O´Nions J. and Allday M.J., 2004 242; Wiesner et al., 2008 243). Furthermore, 
Ahmadi T. mentioned expansion of murine CD40-activated B cells by activation with human 
CD40L-transfected L cells for several weeks, but did not show them in his paper. However, the 
proliferation rates he depicted were equal to the ones we found (Ahmadi et al., 2008 208). After 
all, sufficient cell numbers were produced in our system with 30-50 x 10e6 primary B cells being 
obtained from a single murine spleen.  Moreover, the duration of the expansion period was long 
enough in order to evaluate up-regulation of co-stimulatory molecules and immune-stimulatory 
capacity of mCD40B cells. 
To date several in vitro models mimicking CD40 activation have been established using soluble 
and membrane-bound forms of CD40 ligand. Besides qualitative and quantitative optimization of 
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the adjuvant applied there is no CD40-activating reagent which is suitable for application in hu-
man clinical trials at present. Therefore, omission of allogeneic and xenogeneic components from 
cell culture represents an open gap to be filled through the development of a human GMP-grade 
soluble recombinant forms of CD40L and serum-free culture conditions (Neron et al., 2011 244). 
Nevertheless, murine CD40Bs expanded in our system did not induce any overt side effects after 
systemic application to mice, therefore their administrations was considered as safe (see figures 
35, 36, 37). Per se this model significantly facilitates the immunological characterisation of the 
murine CD40-activated B cells.
4.2. Antigen-presentation and T-cell activation by CD40-
activated B cells
There is solid evidence that B cells act as professional antigen-presenting cells given that they 
are able to internalize antigens, process and present them via MHC-II to T cells, which upon cog-
nate antigen-recognition build up an “immunological synapse” (Cassell D.J. and Schwartz R.H., 
1994 49; Grakoui et al., 1999 39). Proper activation of T cells according the “two-signal model” 
of lymphocyte activation drives the generation of potent effector T cells culminating in efficient 
immune responses (Bretscher P.A., 1999 6). Furthermore CD40-CD40L interaction between APCs 
and CD4+ T cells has been shown to be required for sufficient induction of anti-tumour immunity 
(Mackey et al., 1998 187; Diehl et al., 1999 188). Therefore triggering CD40 on APCs has been in-
vestigated as possibility to bypass CD4+ T cell function. Several studies have addressed different 
aspects of CD40-activated B cell´s antigen-presenting function mostly in vitro, and there is contro-
versial data showing induction of tolerogenic or immunogenic T-cell responses with certain B-cell 
activation stimuli (Parekh et al., 2003 245; Tu et al., 2008 209; Dumont et al., 2008 246; Zheng et 
al., 2009 210; Zheng et al., 2010 211). 
In vitro induction of T-cell responses in allogeneic MLRs require TCR signalling through binding 
of alloantigen-MHC complex and T-cell activation through co-stimulation by APCs. In our model 
murine CD40-activated B cells rapidly up-regulated and maintained expression of CD80 and CD86 
and MHC-molecules needed for antigen presentation (see figure 30D). As this immune-phenotype 
was regarded potent in co-stimulating T cells, it was not astonishing that murine CD40-activated 
B cells of either subset induced significant proliferative responses to both CD4+ and CD8+ T cells in 
allogeneic MLR. Moreover, both mCD40B subsets were superior in inducing CD4+ over CD8+ T cell 
proliferation, possibly being a result of high peak expression of MHC-II molecule I-Ab. Finally, at 
low APC-to-T cell ratios mCD40B day 7 and mCD40B day 14 were significantly better in inducing 
CD4+ and CD8+ T cell proliferation, respectively. Whether this observation can be translated into a 
meaning of biological relevance e.g. that the duration of CD40-activation has a significant impact 
on T cell tropism needs to be further examined. 
Little is known about the antigen-presenting capacity of CD40-activated B cells in vivo, however 
their utilization as cellular vaccine for the immunotherapy of cancer has been proposed. For the 
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purpose of assessing the applicability of mCD40B in vivo we studied whether antigen-loaded 
CD40-activated B cells are able to induce antigen-specific T-cell responses in vivo. 
Previous studies have suggested a variety of methods for loading of human CD40-activated B cells 
with viral or tumour-derived antigens, such as direct antigen-pulsing with peptides or tumour-
lysates, gene delivery by retroviral transduction and DNA/RNA transfection, or fusions of CD40Bs 
and tumour cells (Schultze et al., 1997 113; Kondo et al., 2002 196; Lapointe et al., 2003 195; 
Coughlin 2004 200; Fujiwara et al., 2005 197; Klier et al., 2010 247). Additionally, few reports on 
human peptide-pulsed CD40Bs have already shown efficient induction of primary and secondary 
antigen-specific CD4+ and CD8+ T cells in vitro (Schultze et al., 1997 113; von Bergwelt-Baildon 
et al., 2002 199; Lapointe et al., 2003 195; Zentz et al., 2007 248). Still, little is known about the 
presentation of MHC-I restricted antigens by CD40-activated B cells so far. By performing peptide 
pulsing with either viral peptide LCMV or foreign model-antigen OVA antigen delivery to mCD40B 
was ensured as antigen is loaded directly onto MHC-I molecules and the antigen-processing ma-
chinery can be omitted.
In accordance with the study of Ritchie D.S. who used membrane fractions from insect cells con-
taining muCD40L injected i.v., we could show that LCMV-pulsed mCD40B induce in vivo cytotoxic-
ity after ip injection and that this killing of target cells was antigen specific (Ritchie et al., 2004 214 
and figure 38H). Furthermore, using model peptide OVA for mCD40B-based induction of immu-
nity we found that induction of CTL response in vivo is dependent on injection route (ip > iv > sc), 
cell dose (10e7 > 10e6 > 10e5) and number of vaccination repetitions (2 > 1 booster vaccinations). 
However, our results contradict Lee J.´s to some extent. He reported that OVA-transfected B cells 
activated via anti-CD40 antibody (HM40-3) and CpG induced only weak CTL responses in vitro and 
failed to prime CD8+ T cells after i.p. injection in vivo (Lee et al., 2008 249). Furthermore Guo S. also 
published recently, that OVA-peptide pulsed B cells activated with the same HM40-3 antibody in-
jected i.v. were weak inducers of CD8+ T cell responses as determined by IFN-γ secretion and that 
they failed to induce in vivo cytotoxicity similar to OVA-nucleofected murine CD40B cells. On the 
other hand he demonstrated that in his model OVA-transgenic but not irradiated OVA-transgenic 
mCD40Bs were as efficient as OVA-transgenic DC in inducing T cell responses in vivo (Guo et al., 
2010 212). Conversely, we could show that OVA-pulsed mCD40B cells were competent in inducing 
specific lysis of target cells when using our cultivation system. 
How can those differing results be obtained? First, contrary to Lee J. and Guo S. we used CD40L 
feeder cells to stimulate B cells with, probably resulting in a stronger CD40 stimulus due to higher 
cross-linking capacity of membrane-bound CD40 (Fanslow et al., 1994 206; Néron et al., 2005 
207). Comparing the immune-phenotype of both mCD40B subsets as follows, the expression of 
MHC and co-stimulatory molecules is largely up-regulated in our system whereas Lee J. and Guo 
S. do not achieve the same elevated expression levels with their anti-CD40 antibody treatment. 
Second, we could show that the in vivo induction of the CTL response is dependent on injection 
route and dose of antigen-loaded CD40-activated B cell. Whereas Lee J. immunizes his mice with a 
low dose of 4 x 10e5 cells i.p. Gou S. applies 1-2 x 10e6 cells injected iv, which is likely to addition-
ally account for the poor results. 
Furthermore, in his model using transgenic mice with mutant MHC-I molecule H-2Db Ritchie D.S. 
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could show that antigen-presentation by mCD40B was partly dependent on cross-presentation 
of antigen by other endogenous APCs (Ritchie et al., 2004 214). This would explain why using ir-
radiated mCD40B resulted in specific killing of target cell in our hands similar to non-irradiated 
mCD40B. Upon sufficient CD40-stimulation and following stable expression of their immune-
phenotype mCD40B might directly present antigen and deliver antigen to endogenous APC as 
well, with the latter mechanism being prevalent upon irradiation.
In order to clarify the mechanism the induced immune response was functionally characterised 
by the amount of IFN-γ secretion and the cytolytic activity of antigen-specific CD8+ cytotoxic T 
cells. Another question that remains to be answered is why different results were obtained for 
equal parameters (e.g. injection route iv) applying both techniques as a read-out of APC function. 
First, the techniques used to assess vaccinations with OVA-pulsed mCD40B were applied to differ-
ent mouse models. At the beginning of our studies we were not able to detect IFN-γ production of 
antigen-specific CD8+ T cells from immunized wild-type mice upon peptide re-stimulation in vitro. 
Therefore we switched to use TCR-transgenic OT-I mice analogous to Gou S. and then detected 
up to 10.2 % (± 3.17) CD8+ IFN+ T cells upon mCD40B vaccinations whereas in vivo cytotoxicity 
still was performed in wild-type mice. Second, IFN-γ production is initiated very early upon cross-
linking of the T cell receptor complex whereas cytolysis of target cells occurs later during immune 
response (Ullman et al., 1990 250). Therefore minimal IFN-γ secretion may not exclude functional 
T cell response, but rather show time progression and thus we set higher value to results on cy-
tolysis of target cells.
4.3. Induction of anti-tumour immunity by vaccination with 
mCD40B
The particular focus of this thesis was to develop a murine model to study B cells as APCs in vivo 
and test their applicability in a realistic tumour model. Hence, this work provides the first murine 
model to study CD40 ligand activated B cells as APC in vivo which allowed us the induction of tu-
mour regression of the strongly immunogenic B16.F10 melanoma by mCD40Bs pulsed with the 
naturally expressed tumour-antigen TRP-2.
The identification of TAAs, the inherent nature of the host´s immune system to respond to TAAs 
and the ability to ex vivo generate and manipulate APCs in order to present TAAs has stimulated 
the concept of anti-tumour vaccination. In order to elicit effective anti-tumour-immunity the vac-
cination approach must overcome inhibitory mechanisms such as tumour-mediated immune eva-
sion by secretion of immunosuppressive cytokines and induction of tolerance through toleriza-
tion of T cells by insufficient costimulation. Thereby, recognition and destruction of the tumour by 
the immune system is prevented. 
In a study on tumour-mediated immune suppression of CD40-activated B cells we demonstrated 
that phenotype, migratory potential and antigen presenting function of human CD40-activated 
B cells is resistant to PGE-2, IL-10, TGF-β and VEGF (Shimabukuro-Vornhagen et al., PLoS One in 
revision) whereas DCs are thereby inhibited in differentiation and antigen presenting function 
(Steinbrink et al, 1999 251; Gabrilovich et al., 2004 252). This resistance of activated B cells against 
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immune-suppressive cytokines might reflect situations in autoimmune disease where B cells 
function as APCs in vivo - on the one hand their treatment being difficult, on the other hand B-cell 
depletion by monoclonal antibodies being that efficient.
Furthermore, both CD40-activated B cells and immature DCs have been shown to induce Treg in 
mice and human (Reichardt et al., 2007 253; Zheng et al., 2010 211; Steinman et al., 2003 136). 
But whether or not B cells act as stimulatory or tolerogenic cells has been suggested to depend on 
the strength of B cell activation (Shimabukuro-Vornhagen et al., 2009 254). 
When using mCD40B stimulated with murine CD40L-expressing feeder cells, pulsed with TAA Trp-
2 according the optimal vaccination schedule to induce protective immunity against B16 melano-
ma we found that tumour growth was significantly reduced (figure 51). However unexpectedly, 
when increasing the cell dose from 1 x 10e6 to 1 x 10e7 mCD40B per vaccination no further re-
duction of tumour growth was observed. Therefore the window of immunogenicity might be met 
with a certain cell dose underlining the need for studying the APC functions of CD40B in vivo.
Ritchie D.S. demonstrated that using mCD40B pulsed with viral peptide in a preventive setting 
against model-tumour cells expressing the corresponding epitope, reduction of tumour growth 
is only provided upon stimulation with CD40L-membrane fractions, but not upon activation of B 
cells with IL-4 or LPS (Ritchie et al., 2004 214). 
On the contrary, despite significant CTL induction in vivo Lee J. showed that therapeutic vaccina-
tion with 4 x 10e5 mCD40B injected ip, activated with anti-CD40 antibody and transfected with 
RNA encoding for TAA TRP-2 and co-stimulatory molecules, did not prevent from B16 melanoma 
growth (Lee et al., 2008 249). Furthermore, using B cells activated with anti-CD40 antibody and/or 
CpG, Guo S. reported on the failure of 1 x 10e5 OVA-peptide pulsed mCD40B injected iv to reduce 
EG-7 tumour growth in a therapeutic setting as well, whereas vaccination with OVA-transfected 
mCD40B protected similar to OVA-transgenic DCs against tumour growth (Guo et al., 2010 212).  
Even though our data and Ritchie´s study appear to be contradictory to Lee´s and Guo´s work at 
first sight, one can draw several conclusions from those pieces of data. First, there is evidence that 
murine CD40-activated B cells are capable of efficiently transporting antigens from the periphery 
to lymphoid organs and interact with T cells in vitro and in vivo, thus eliciting specific T cell re-
sponses regulated by the nature and strength of stimulus inserted. Whereas “innate” stimulation 
of B cells with LPS will lead to induction of Treg, insufficient T cell co-stimulation will lead to T 
cell anergy or apoptosis. Upon cognate interaction of activated antigen-loaded B cells and T cells 
specific T cells are expanded and activated via a combination of direct T-cell stimulation and cross-
presentation of antigen by local APCs. Due to the migratory potential of mCD40Bs this happens 
upon i.v. and i.p. injection in lymph nodes and spleen, and to a lesser extent upon sc injection as 
well. Dependent on the stimulus used to activate B cells different ways of antigen-loading may 
lead to functional antigen-presentation. Whereas weak B cell activation would require internal 
antigen-processing for efficient and durable antigen-presentation to T cells, it would be sufficient 
for properly activated B cells to present exogenous peptide upon external loading. Furthermore, 
mCD40B vaccination might induce both cellular and humoral immune responses thereby improv-
ing immunity against tumour antigens.  
101DISCUSSION
4.4. Comparison of mCD40B to mDC as APC
In order to investigate whether mCD40B are comparable to DCs in eliciting T cell responses the 
APC capacity of two subsets of each group with highly activated phenotype were introduced to 
MLR. Herein, the protein expression levels of co-stimulatory molecules of mCD40B subsets were 
comparable to that of matured DCs (figures 30D and 31C-L). However, the comparison of mDC 
and mCD40B subsets revealing that mDC were superior to mCD40B in increasing the number of 
T cells did not meet our expectation (figures 34A-D). Hence, closer examination differences be-
tween mCD40B and mDC contributing to T-cell activation in allogeneic MLR is required. 
Morphological factors that might be relevant are cell size as well as number and size of dendrites. 
To this end, APC cell sizes were assessed by flow cytometric analysis of their forward scatter area, 
which is approximately proportional to size. We found that DCs introduced in MLR were about 
1.5 times bigger than mCD40Bs at least partly accounting for their differential capacity to stimu-
late T-cell proliferation in vitro (data not shown).
Biochemical differences of mCD40B and mDC affecting MLR might be turnover, expression levels 
and density of MHC, co-stimulatory and co-inhibitory molecules as well as up-take, processing 
and presentation of self-proteins as allo-antigens. Furthermore a differential impact of irradiation 
on mCD40B and mDC might explain for this discrepancy as sub-lethal irradiation would enable 
further cell proliferation leading to antigen loss due to rapid turnover. Also Guo´s study demon-
strating that OVA-transfected mCD40B or mDC but not OVA-peptide pulsed mCD40B were able 
to induce reduction of EG-7 tumour growth confirms that prevention from antigen loss by stable 
transfection may achieve a beneficial result. 
There is only very limited data available on the ability of activated B cells to induce anti-tumour 
immunity in vivo. In particular, there are only few studies that directly compared B cells with DCs 
in the ability to induce an anti-tumour immune response.
Due to their efficient APC capacity DCs have been most frequently used in cellular immunotherapy 
for the generation of tumour-specific immune responses. In a systemic review of clinical trials us-
ing DC vaccination a proof of this concept was provided showing an association between induced 
cellular immune response and clinical benefit rate (Draube et al., 2011 144). Essential parameters 
accounting for outcome of DC-based cancer vaccination have been revealed, namely adequate cell 
number, appropriate DC subset at proper stage of differentiation and the injection route support-
ing migration of DCs to secondary lymphoid organs. Thus, despite proven safety and feasibility 
DC-based cancer vaccination is limited. In order to evaluate CD40-activated B cells as alternative 
source of APC we systemically investigated several vaccination parameters and compared them 
to DCs. Performing mCD40B vaccinations we also found a positive association between elevation 
of mCD40B cell numbers as well as vaccination repetitions and functional T cell response (figures 
48A and 48A). In contrast to DCs CD40B cells stimulated in vitro show enormous proliferating ca-
pacity and large amounts can be obtained from few mL of peripheral blood (Wiesner et al.,2008 
243; Schultze et al., 1997 113). Therefore cell number would not represent a major challenge in 
CD40B-based immunotherapy - not even in immune-compromised patients. 
Antigen-presentation to T cells and following induction of an immune response requires physi-
cally interaction of lymphocytes in secondary lymphoid organs. Previously, we could show that 
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CD40-activated B cells do not only express certain chemokines and receptors allowing them to 
transmigrate the walls of high endothelial venules (HEV) and attract T cells, but also that they 
localize in spleen and lymph nodes upon i.v. and s.c. injection (von Bergwelt-Baildon et al., 2006 
213 and Klein-Gonzáles, unpublished data). On the contrary DCs lack CD62L (L-selectin) required 
for entering the draining lymph node across the HEV and only few DC administered i.v., s.c. or 
intradermally reach the draining lymph nodes (Ridolf et al., 2004 145; Quillien et al., 2005 146). 
Furthermore, when injected iv DCs accumulate in the spleen and non-lymphoid tissues, but not in 
the lymph node (Robert et al., 2003 255). In order to meet the migration requirements of mCD40B 
for in vivo CTL induction different injection routes were performed and analyzed. We were able 
to identify several key parameters which influence the induction of T-cell responses by mCD40B. 
Vaccine formulation, cell dose, the injection route, as well as the vaccination schedule all had a 
significant impact on the strength of the elicited T-cell response.
In line with Park´s data on LPS-activated B cells loaded with antigen by RNA-transfection we found 
that s.c. administration of peptide-pulsed mCD40B had significant lower effect on CTL response 
induction in the spleen than DCs (Park et al., 2008 256; figures 47A and 49A). Furthermore upon 
iv injection mCD40B also induced significant CTL responses in the spleen as expected from in vivo 
migration experiments performed by us and others (Klein-Gonzáles, unpublished data and Ah-
madi et al., 2007 208). This was not surprising as B lymphocytes travel through peripheral blood 
and lymphoid tissues finally entering the follicles to form germinal centres. On the other side 
DCs reside in peripheral tissues and organs induced to migrate through the afferent lymphatic 
vessels to the regional lymph node upon antigen up-take. To our knowledge there is only one 
report on i.p. vaccination of mice with OVA-transfected B cells activated with CpG and anti-CD40 
antibody showing absent induction of CTL response by in vitro europium release (Lee et al., 2008 
249). However, insufficient activation stimulus may again account for this negative result. In our 
model ip injections of peptide-pulsed mCD40B were significantly better over other routes and 
rates of target cell lysis indeed comparable to DC vaccinations (figures 47A and 49A). Interestingly, 
the level of induced anti-tumour immunity on day 13 post tumour inoculation was significantly 
higher when using mDC compared to mCD40B, although either treatment regimen was found to 
be similar in inducing CTL responses (figure 49A). Differential regulation of cellular and humoral 
immune responses improving immunity against tumour antigens by both cell types might lead to 
these varying results.  
4.5. Concluding remarks
When we compare our data to other studies using CD40-activated B cells we learn that in order to 
generate B cells with effective APC function adequate CD40 signalling has to be provided. To date 
membrane-bound forms stimulating via CD40 exceed over soluble forms probably due to differ-
ential cross-linking and signal transduction. Several soluble human CD40 ligands in trimeric and 
hexameric composition and agonistic antibodies have been tested by us and others and to date 
there is no GMP-grade construct with equal potential to induce activation and proliferation. This 
step indispensable for testing CD40-activated B cells in Phase I trial is worked on in cooperation 
with Miltenyi Biotech Company.
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5. FUTURE PROSPECTS
At the moment this model for the generation of murine CD40-activated B cells capable of inducing 
anti-tumour immunity is used to further evaluate the mechanisms by which antigen-presenting 
B cells confer or inhibit effective anti-tumour responses. In order to determine the window of im-
munogenicity the quality and the quantity of the elicited anti-tumour response will be analyzed 
in more detail. Therefore the capacity of mCD40B to regulate T-cell differentiation will be char-
acterised phenotypically for composition of B cell subsets and for their cytokine profiles driving 
either T
h
1 (IFN-γ) or T
h
2 (IL-4) skewed CD4+ or CD8+ T cell responses in vivo. Furthermore we will 
clarify whether sub-optimal B cell activation leads to induction of inhibitory B cell subsets, such 
as B cells producing neutralizing antibody or regulatory B cells with CD19hi CD1dhi CD5+ pheno-
type secreting immune-suppressive cytokines (IL-10). We will test whether by adaption of the B 
cell subset therapeutic and preventive immunity against tumour antigens can be improved and 
whether a tumour antigen-specific T-cell memory can be generated to meet the requirements for 
full anti-tumour immunity.
Second, CD40-activated B cells have been used to present antigens to CD4+ and CD8+ T cells. How-
ever, antigen processing mechanisms in CD40B cells are still unclear. By use of antigen processing 
inhibitors of endocytosis (NaN
3
 and 2-deoxy-d-glucose), endosomal acidification (Chloroquine), 
proteases (E-64d) and synthesis of new MHC II molecules (BrefeldinA), we want to clarify how 
CD40Bs can take-up, process and present antigen by the MHC-class II pathway and to what extent 
other mechanisms like trogocytosis and cross-presentation on MHC class I molecules are relevant. 
Third, specific B cells act as antigen-presenting cells due to their ability of BCR-mediated endocy-
tosis of whole protein antigen. Utilizing the B cell receptor-mediated enhanced antigen-uptake 
and processing the interaction with T cells and their activation may be improved. Therefore the 
CD40B approach will be applied to clonal B cell populations with a tumour-antigen-specific B-cell 
receptor to test whether those B cells represent a more effective alternative to previous CD40B 
vaccines.
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